NAME	ORIGINAL SIZE	AFTER RESTRICTING TO DATASET	STATUS	
NAKAMURA_CANCER_MICROENVIRONMENT_UP	26	12		
NAKAMURA_CANCER_MICROENVIRONMENT_DN	46	38		
WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP	21	19		
WEST_ADRENOCORTICAL_TUMOR_MARKERS_DN	20	15		
WINTER_HYPOXIA_UP	92	69		
WINTER_HYPOXIA_DN	52	37		
PARENT_MTOR_SIGNALING_UP	567	443		
PARENT_MTOR_SIGNALING_DN	46	30		
PYEON_HPV_POSITIVE_TUMORS_UP	98	60		
PYEON_HPV_POSITIVE_TUMORS_DN	10	7		
NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP	285	212		
NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN	634	427		
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP	205	171		
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN	136	105		
LU_TUMOR_VASCULATURE_UP	29	20		
LU_TUMOR_VASCULATURE_DN	13	9		
KORKOLA_EMBRYONAL_CARCINOMA_UP	41	31		
KORKOLA_EMBRYONAL_CARCINOMA_DN	13	9		
KORKOLA_TERATOMA_UP	16	13		
KORKOLA_YOLK_SAC_TUMOR_UP	20	16		
KORKOLA_CHORIOCARCINOMA_UP	6	5		
KORKOLA_CHORIOCARCINOMA_DN	11	8		
KORKOLA_SEMINOMA_UP	44	32		
KORKOLA_SEMINOMA_DN	13	8		
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_UP	108	84		
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN	92	79		
HOLLMANN_APOPTOSIS_VIA_CD40_UP	201	164		
HOLLMANN_APOPTOSIS_VIA_CD40_DN	267	194		
LIU_PROSTATE_CANCER_UP	96	70		
LIU_PROSTATE_CANCER_DN	481	354		
LIU_SOX4_TARGETS_UP	137	105		
LIU_SOX4_TARGETS_DN	309	242		
ONKEN_UVEAL_MELANOMA_UP	783		Rejected!	
ONKEN_UVEAL_MELANOMA_DN	526	426		
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP	206	145		
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN	169	130		
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP	351	277		
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN	84	69		
DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_UP	59	45		
DAVICIONI_PAX_FOXO1_SIGNATURE_IN_ARMS_DN	20	16		
FOURNIER_ACINAR_DEVELOPMENT_EARLY_UP	21	17		
FOURNIER_ACINAR_DEVELOPMENT_EARLY_DN	6	5		
FOURNIER_ACINAR_DEVELOPMENT_LATE_UP	11	8		
FOURNIER_ACINAR_DEVELOPMENT_LATE_DN	21	20		
NAM_FXYD5_TARGETS_DN	18	15		
FRASOR_TAMOXIFEN_RESPONSE_UP	51	37		
FRASOR_TAMOXIFEN_RESPONSE_DN	11	10		
KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP	129	91		
KIM_RESPONSE_TO_TSA_AND_DECITABINE_DN	13	10		
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP	294	219		
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN	349	182		
WATANABE_COLON_CANCER_MSI_VS_MSS_UP	29	19		
WATANABE_COLON_CANCER_MSI_VS_MSS_DN	81	53		
KOBAYASHI_EGFR_SIGNALING_6HR_UP	7	6		
KOBAYASHI_EGFR_SIGNALING_6HR_DN	18	16		
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP	151	126		
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_DN	52	39		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_UP	25	20		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN	493	338		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_UP	30	24		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_MYELOID_DN	38	30		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP	39	28		
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN	66	52		
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP	146	108		
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN	391	260		
ZERBINI_RESPONSE_TO_SULINDAC_UP	9	5		
ZERBINI_RESPONSE_TO_SULINDAC_DN	6		Rejected!	
IGARASHI_ATF4_TARGETS_UP	6		Rejected!	
IGARASHI_ATF4_TARGETS_DN	90	72		
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_UP	183	140		
ZHONG_RESPONSE_TO_AZACITIDINE_AND_TSA_DN	70	46		
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_UP	332	245		
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN	182	137		
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP	255	207		
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN	68	54		
DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_UP	64	48		
DAVICIONI_RHABDOMYOSARCOMA_PAX_FOXO1_FUSION_DN	15	12		
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP	408	268		
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN	175	98		
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP	68	46		
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_DN	7	6		
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP	44	30		
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN	198	131		
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP	73	51		
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN	69	44		
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_UP	21	12		
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_DN	7	5		
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP	69	55		
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_DN	91	66		
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP	94	70		
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN	74	60		
CHANDRAN_METASTASIS_TOP50_UP	38	28		
CHANDRAN_METASTASIS_TOP50_DN	45	42		
WILCOX_RESPONSE_TO_PROGESTERONE_UP	152	102		
WILCOX_RESPONSE_TO_PROGESTERONE_DN	66	49		
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_UP	579	427		
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN	463	315		
GARY_CD5_TARGETS_UP	473	390		
GARY_CD5_TARGETS_DN	431	343		
ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP	485	308		
ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN	384	256		
SAMOLS_TARGETS_OF_KHSV_MIRNAS_UP	8	6		
SAMOLS_TARGETS_OF_KHSV_MIRNAS_DN	62	43		
HOOI_ST7_TARGETS_UP	94	58		
HOOI_ST7_TARGETS_DN	123	78		
PRAMOONJAGO_SOX4_TARGETS_UP	52	44		
PRAMOONJAGO_SOX4_TARGETS_DN	51	43		
PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP	82	66		
PUIFFE_INVASION_INHIBITED_BY_ASCITES_DN	145	109		
PIEPOLI_LGI1_TARGETS_UP	15	11		
PIEPOLI_LGI1_TARGETS_DN	14	7		
THUM_SYSTOLIC_HEART_FAILURE_UP	423	327		
THUM_SYSTOLIC_HEART_FAILURE_DN	244	163		
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP	177	131		
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN	663		Rejected!	
CORRE_MULTIPLE_MYELOMA_UP	74	53		
CORRE_MULTIPLE_MYELOMA_DN	62	49		
HUTTMANN_B_CLL_POOR_SURVIVAL_UP	276	213		
HUTTMANN_B_CLL_POOR_SURVIVAL_DN	60	47		
DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_UP	1382		Rejected!	
DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN	116	93		
CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP	39	29		
CASORELLI_APL_SECONDARY_VS_DE_NOVO_DN	9	9		
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP	368	276		
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN	320	227		
LIU_CMYB_TARGETS_UP	165	131		
LIU_CMYB_TARGETS_DN	7	6		
LIU_VMYB_TARGETS_UP	127	105		
LIU_TARGETS_OF_VMYB_VS_CMYB_UP	20	12		
LIU_TARGETS_OF_VMYB_VS_CMYB_DN	43	32		
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP	380	262		
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN	455	343		
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	450	323		
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	460	370		
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	121	80		
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN	50	39		
DOANE_BREAST_CANCER_CLASSES_UP	72	47		
DOANE_BREAST_CANCER_CLASSES_DN	34	28		
DOANE_RESPONSE_TO_ANDROGEN_UP	184	129		
DOANE_RESPONSE_TO_ANDROGEN_DN	241	199		
DOANE_BREAST_CANCER_ESR1_UP	112	82		
DOANE_BREAST_CANCER_ESR1_DN	48	34		
WANG_RESPONSE_TO_ANDROGEN_UP	29	23		
WANG_RESPONSE_TO_FORSKOLIN_UP	23	18		
WANG_RESPONSE_TO_FORSKOLIN_DN	9	8		
TIMOFEEVA_GROWTH_STRESS_VIA_STAT1_DN	16	14		
LAIHO_COLORECTAL_CANCER_SERRATED_UP	112	94		
LAIHO_COLORECTAL_CANCER_SERRATED_DN	86	61		
BORCZUK_MALIGNANT_MESOTHELIOMA_UP	305	255		
BORCZUK_MALIGNANT_MESOTHELIOMA_DN	104	62		
ROY_WOUND_BLOOD_VESSEL_UP	50	41		
ROY_WOUND_BLOOD_VESSEL_DN	22	13		
GRABARCZYK_BCL11B_TARGETS_UP	81	57		
GRABARCZYK_BCL11B_TARGETS_DN	57	41		
NEWMAN_ERCC6_TARGETS_UP	26	16		
NEWMAN_ERCC6_TARGETS_DN	39	24		
HORIUCHI_WTAP_TARGETS_UP	306	226		
HORIUCHI_WTAP_TARGETS_DN	310	253		
GAL_LEUKEMIC_STEM_CELL_UP	133	100		
GAL_LEUKEMIC_STEM_CELL_DN	244	175		
CHOI_ATL_CHRONIC_VS_ACUTE_DN	18	17		
BASAKI_YBX1_TARGETS_UP	290	222		
BASAKI_YBX1_TARGETS_DN	384	279		
NOJIMA_SFRP2_TARGETS_UP	31	26		
NOJIMA_SFRP2_TARGETS_DN	25	22		
WIKMAN_ASBESTOS_LUNG_CANCER_UP	17	13		
WIKMAN_ASBESTOS_LUNG_CANCER_DN	28	23		
RODRIGUES_DCC_TARGETS_UP	5		Rejected!	
RODRIGUES_DCC_TARGETS_DN	121	106		
RODRIGUES_NTN1_TARGETS_UP	17	12		
RODRIGUES_NTN1_TARGETS_DN	158	128		
WANG_LMO4_TARGETS_UP	372	259		
WANG_LMO4_TARGETS_DN	352	256		
WANG_CLIM2_TARGETS_UP	269	171		
WANG_CLIM2_TARGETS_DN	186	135		
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP	175	133		
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN	138	78		
VECCHI_GASTRIC_CANCER_EARLY_UP	430	309		
VECCHI_GASTRIC_CANCER_EARLY_DN	367	243		
BARRIER_COLON_CANCER_RECURRENCE_UP	42	36		
BARRIER_COLON_CANCER_RECURRENCE_DN	20	15		
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_UP	158	129		
SMIRNOV_CIRCULATING_ENDOTHELIOCYTES_IN_CANCER_DN	5	5		
SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP	84	57		
JAEGER_METASTASIS_UP	44	34		
JAEGER_METASTASIS_DN	258	165		
OSMAN_BLADDER_CANCER_UP	404	322		
OSMAN_BLADDER_CANCER_DN	406	284		
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_UP	78	58		
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN	335	231		
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_UP	119	83		
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN	180	120		
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_UP	233	187		
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN_GEL_DN	275	198		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_UP	32	21		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_DN	23	13		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP	79	63		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN	53	38		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_UP	17	15		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_RED_DN	25	21		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_UP	28	21		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_MAGENTA_DN	12	11		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_LIGHTYELLOW_UP	11	10		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_LIGHTYELLOW_DN	11	8		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_UP	23	18		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREEN_DN	25	21		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP	136	92		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN	61	44		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP	35	29		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_DN	11	8		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_UP	18	15		
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN	74	40		
RUNNE_GENDER_EFFECT_UP	9		Rejected!	
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_UP	85	60		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_6HR_DN	41	36		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP	182	121		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN	31	21		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP	157	109		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN	205	136		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP	194	125		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_DN	142	96		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP	175	120		
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN	143	88		
LOPEZ_MESOTELIOMA_SURVIVAL_TIME_UP	14	12		
LOPEZ_MESOTELIOMA_SURVIVAL_TIME_DN	7	7		
BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_UP	30	23		
BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN	33	25		
BILBAN_B_CLL_LPL_UP	63	50		
BILBAN_B_CLL_LPL_DN	42	32		
HOEBEKE_LYMPHOID_STEM_CELL_UP	95	73		
HOEBEKE_LYMPHOID_STEM_CELL_DN	86	74		
PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP	33	21		
PEPPER_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN	21	14		
AKL_HTLV1_INFECTION_UP	27	21		
AKL_HTLV1_INFECTION_DN	68	52		
RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP	78	55		
RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN	362	315		
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_UP	276	208		
MULLIGHAN_NPM1_MUTATED_SIGNATURE_1_DN	126	91		
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_UP	139	104		
MULLIGHAN_NPM1_MUTATED_SIGNATURE_2_DN	77	57		
MULLIGHAN_MLL_SIGNATURE_1_UP	380	297		
MULLIGHAN_MLL_SIGNATURE_1_DN	242	185		
MULLIGHAN_MLL_SIGNATURE_2_UP	418	320		
MULLIGHAN_MLL_SIGNATURE_2_DN	281	217		
MULLIGHAN_NPM1_SIGNATURE_3_UP	341	261		
MULLIGHAN_NPM1_SIGNATURE_3_DN	162	121		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_GRANULOCYTE_UP	15	13		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_GRANULOCYTE_DN	7	6		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP	185	144		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN	187	151		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_UP	55	45		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_DN	17	12		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP	204	163		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN	54	40		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP	157	123		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_DN	16	11		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_MONOCYTE_UP	21	19		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINED_IN_MONOCYTE_DN	8	6		
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_SUSTAINDED_IN_ERYTHROCYTE_UP	44	37		
LOPEZ_MESOTHELIOMA_SURVIVAL_WORST_VS_BEST_UP	14	11		
LOPEZ_MESOTHELIOMA_SURVIVAL_WORST_VS_BEST_DN	7	6		
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP	52	42		
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN	43	38		
DITTMER_PTHLH_TARGETS_UP	112	96		
DITTMER_PTHLH_TARGETS_DN	73	64		
UDAYAKUMAR_MED1_TARGETS_UP	135	113		
UDAYAKUMAR_MED1_TARGETS_DN	240	194		
ODONNELL_TFRC_TARGETS_UP	456	261		
ODONNELL_TFRC_TARGETS_DN	139	90		
ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP	83	60		
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN	45	33		
SENESE_HDAC1_TARGETS_UP	457	339		
SENESE_HDAC1_TARGETS_DN	260	177		
SENESE_HDAC1_AND_HDAC2_TARGETS_UP	238	168		
SENESE_HDAC1_AND_HDAC2_TARGETS_DN	232	168		
SENESE_HDAC2_TARGETS_UP	114	91		
SENESE_HDAC2_TARGETS_DN	133	93		
SENESE_HDAC3_TARGETS_UP	501	389		
SENESE_HDAC3_TARGETS_DN	536	373		
LEE_NEURAL_CREST_STEM_CELL_UP	146	104		
LEE_NEURAL_CREST_STEM_CELL_DN	118	84		
HUMMEL_BURKITTS_LYMPHOMA_UP	43	33		
HUMMEL_BURKITTS_LYMPHOMA_DN	15	13		
TIEN_INTESTINE_PROBIOTICS_2HR_UP	27	24		
TIEN_INTESTINE_PROBIOTICS_2HR_DN	88	70		
TIEN_INTESTINE_PROBIOTICS_6HR_UP	55	47		
TIEN_INTESTINE_PROBIOTICS_6HR_DN	167	134		
TIEN_INTESTINE_PROBIOTICS_24HR_UP	557	460		
TIEN_INTESTINE_PROBIOTICS_24HR_DN	214	180		
ZHOU_INFLAMMATORY_RESPONSE_FIMA_UP	544	322		
ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN	284	187		
ZHOU_INFLAMMATORY_RESPONSE_LPS_UP	431	252		
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP	1278		Rejected!	
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN	329	238		
SABATES_COLORECTAL_ADENOMA_SIZE_UP	23	14		
SABATES_COLORECTAL_ADENOMA_SIZE_DN	14	8		
SABATES_COLORECTAL_ADENOMA_UP	141	80		
SABATES_COLORECTAL_ADENOMA_DN	291	172		
SCIBETTA_KDM5B_TARGETS_UP	19	13		
SCIBETTA_KDM5B_TARGETS_DN	81	60		
NAGASHIMA_NRG1_SIGNALING_UP	176	142		
NAGASHIMA_NRG1_SIGNALING_DN	58	38		
NAGASHIMA_EGF_SIGNALING_UP	58	48		
KIM_WT1_TARGETS_UP	214	173		
KIM_WT1_TARGETS_DN	459	362		
KIM_WT1_TARGETS_8HR_UP	164	140		
KIM_WT1_TARGETS_8HR_DN	129	90		
KIM_WT1_TARGETS_12HR_UP	162	125		
KIM_WT1_TARGETS_12HR_DN	209	167		
ELVIDGE_HYPOXIA_UP	171	135		
ELVIDGE_HYPOXIA_DN	146	119		
ELVIDGE_HYPOXIA_BY_DMOG_UP	130	105		
ELVIDGE_HYPOXIA_BY_DMOG_DN	59	49		
ELVIDGE_HIF1A_TARGETS_UP	67	54		
ELVIDGE_HIF1A_TARGETS_DN	91	74		
ELVIDGE_HIF2A_TARGETS_UP	6		Rejected!	
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_UP	41	34		
ELVIDGE_HIF1A_AND_HIF2A_TARGETS_DN	104	80		
JAATINEN_HEMATOPOIETIC_STEM_CELL_UP	316	224		
JAATINEN_HEMATOPOIETIC_STEM_CELL_DN	226	158		
MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_UP	20	15		
MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_DN	12	9		
GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_UP	23	14		
GRAHAM_CML_QUIESCENT_VS_CML_DIVIDING_DN	11		Rejected!	
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_UP	87	70		
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN	47	28		
GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_UP	57	39		
GRAHAM_CML_QUIESCENT_VS_NORMAL_DIVIDING_DN	12	6		
GRAHAM_CML_DIVIDING_VS_NORMAL_DIVIDING_UP	13	6		
GRAHAM_CML_DIVIDING_VS_NORMAL_DIVIDING_DN	10	6		
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP	181	149		
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN	95	62		
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP	66	50		
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN	87	72		
BIDUS_METASTASIS_UP	214	160		
BIDUS_METASTASIS_DN	161	117		
WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP	265	201		
WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN	199	148		
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_UP	137	112		
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN	67	53		
MAYBURD_RESPONSE_TO_L663536_UP	29	23		
MAYBURD_RESPONSE_TO_L663536_DN	56	42		
WATANABE_ULCERATIVE_COLITIS_WITH_CANCER_UP	18	16		
WATANABE_ULCERATIVE_COLITIS_WITH_CANCER_DN	14	10		
DODD_NASOPHARYNGEAL_CARCINOMA_UP	1821		Rejected!	
DODD_NASOPHARYNGEAL_CARCINOMA_DN	1375		Rejected!	
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP	633	493		
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN	805		Rejected!	
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP	722		Rejected!	
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_DN	537	390		
RODRIGUES_THYROID_CARCINOMA_UP	16	12		
RODRIGUES_THYROID_CARCINOMA_DN	77	56		
GOZGIT_ESR1_TARGETS_UP	149	103		
GOZGIT_ESR1_TARGETS_DN	781	498		
HAHTOLA_SEZARY_SYNDROM_UP	98	76		
HAHTOLA_SEZARY_SYNDROM_DN	42	29		
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP	177	142		
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_DN	27	22		
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_UP	64	55		
HAHTOLA_MYCOSIS_FUNGOIDES_CD4_DN	116	99		
HAHTOLA_MYCOSIS_FUNGOIDES_UP	19	13		
HAHTOLA_MYCOSIS_FUNGOIDES_DN	16	12		
PROVENZANI_METASTASIS_UP	194	155		
PROVENZANI_METASTASIS_DN	136	109		
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP	35	25		
LIU_CDX2_TARGETS_UP	36	25		
LIU_CDX2_TARGETS_DN	8		Rejected!	
COLDREN_GEFITINIB_RESISTANCE_UP	85	62		
COLDREN_GEFITINIB_RESISTANCE_DN	230	160		
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP	128	116		
KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_DN	64	64		
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP	117	108		
KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN	75	72		
PASTURAL_RIZ1_TARGETS_UP	11	6		
PASTURAL_RIZ1_TARGETS_DN	5		Rejected!	
CHOW_RASSF1_TARGETS_UP	27	22		
CHOW_RASSF1_TARGETS_DN	29	23		
ENK_UV_RESPONSE_EPIDERMIS_UP	293	234		
ENK_UV_RESPONSE_EPIDERMIS_DN	508	428		
ENK_UV_RESPONSE_KERATINOCYTE_UP	530	429		
ENK_UV_RESPONSE_KERATINOCYTE_DN	485	406		
LANDIS_BREAST_CANCER_PROGRESSION_UP	44	40		
LANDIS_BREAST_CANCER_PROGRESSION_DN	70	67		
GESERICK_TERT_TARGETS_DN	21	20		
YEMELYANOV_GR_TARGETS_DN	10	10		
LAU_APOPTOSIS_CDKN2A_UP	55	51		
LAU_APOPTOSIS_CDKN2A_DN	5	5		
DELYS_THYROID_CANCER_UP	443	357		
DELYS_THYROID_CANCER_DN	232	187		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_UP	58	43		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_DN	51	46		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_UP	126	104		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN	142	132		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_UP	120	97		
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN	153	134		
CASTELLANO_HRAS_TARGETS_UP	5		Rejected!	
CASTELLANO_HRAS_TARGETS_DN	6	5		
CASTELLANO_HRAS_AND_NRAS_TARGETS_UP	6		Rejected!	
CASTELLANO_HRAS_AND_NRAS_TARGETS_DN	8	7		
CASTELLANO_NRAS_TARGETS_UP	68	56		
CASTELLANO_NRAS_TARGETS_DN	14	14		
CHEBOTAEV_GR_TARGETS_UP	77	61		
CHEBOTAEV_GR_TARGETS_DN	120	90		
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_UP	29	23		
BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN	48	39		
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_UP	8	7		
BERENJENO_TRANSFORMED_BY_RHOA_REVERSIBLY_DN	29	28		
LINDGREN_BLADDER_CANCER_CLUSTER_1_UP	121	87		
LINDGREN_BLADDER_CANCER_CLUSTER_1_DN	378	306		
LINDGREN_BLADDER_CANCER_CLUSTER_2A_UP	8	8		
LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN	141	105		
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP	329	254		
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN	229	167		
KOINUMA_COLON_CANCER_MSI_UP	16	12		
KOINUMA_COLON_CANCER_MSI_DN	8	7		
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP	34	31		
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN	23	19		
NADERI_BREAST_CANCER_PROGNOSIS_UP	50	33		
NADERI_BREAST_CANCER_PROGNOSIS_DN	18	15		
MARKEY_RB1_CHRONIC_LOF_UP	115	99		
MARKEY_RB1_CHRONIC_LOF_DN	118	92		
MARKEY_RB1_ACUTE_LOF_UP	215	179		
MARKEY_RB1_ACUTE_LOF_DN	228	189		
CHIN_BREAST_CANCER_COPY_NUMBER_UP	27	19		
CHIN_BREAST_CANCER_COPY_NUMBER_DN	16	12		
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP	552	415		
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN	234	192		
VANHARANTA_UTERINE_FIBROID_UP	45	40		
VANHARANTA_UTERINE_FIBROID_DN	67	53		
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP	67	55		
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_DN	36	33		
LANDIS_ERBB2_BREAST_TUMORS_65_UP	22	20		
LANDIS_ERBB2_BREAST_TUMORS_65_DN	37	34		
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP	20	17		
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN	55	49		
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP	239	189		
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN	172	124		
ODONNELL_METASTASIS_UP	82	49		
ODONNELL_METASTASIS_DN	24	18		
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP	211	158		
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN	84	64		
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	1142		Rejected!	
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN	1781		Rejected!	
GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	612	495		
GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN	770		Rejected!	
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP	191	144		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN	90	63		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_UP	26	17		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_B_DN	8	7		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP	170	141		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_DN	19	14		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP	38	27		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_DN	9	6		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP	97	71		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_DN	22	18		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP	185	145		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN	33	26		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_UP	238	159		
GAUSSMANN_MLL_AF4_FUSION_TARGETS_G_DN	35	27		
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_UP	19	17		
BERENJENO_TRANSFORMED_BY_RHOA_FOREVER_DN	31	30		
CAIRO_PML_TARGETS_BOUND_BY_MYC_UP	23	21		
CAIRO_PML_TARGETS_BOUND_BY_MYC_DN	14	13		
OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_UP	117	103		
OUELLET_OVARIAN_CANCER_INVASIVE_VS_LMP_DN	11	10		
LANDIS_ERBB2_BREAST_TUMORS_324_UP	150	125		
LANDIS_ERBB2_BREAST_TUMORS_324_DN	149	137		
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_UP	32	23		
BARRIER_CANCER_RELAPSE_NORMAL_SAMPLE_DN	31	23		
BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_UP	16	12		
BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_DN	13	6		
BARIS_THYROID_CANCER_UP	23	21		
BARIS_THYROID_CANCER_DN	59	57		
BERENJENO_TRANSFORMED_BY_RHOA_UP	536	447		
BERENJENO_TRANSFORMED_BY_RHOA_DN	394	333		
TAKADA_GASTRIC_CANCER_COPY_NUMBER_UP	7	7		
TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN	29	20		
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_UP	26	22		
WANG_BARRETTS_ESOPHAGUS_AND_ESOPHAGUS_CANCER_DN	37	27		
KERLEY_RESPONSE_TO_CISPLATIN_UP	44	35		
KERLEY_RESPONSE_TO_CISPLATIN_DN	5		Rejected!	
MISSIAGLIA_REGULATED_BY_METHYLATION_UP	126	98		
MISSIAGLIA_REGULATED_BY_METHYLATION_DN	122	100		
TANG_SENESCENCE_TP53_TARGETS_UP	33	25		
TANG_SENESCENCE_TP53_TARGETS_DN	57	46		
WANG_BARRETTS_ESOPHAGUS_UP	51	36		
WANG_BARRETTS_ESOPHAGUS_DN	25	20		
WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP	121	101		
WANG_ESOPHAGUS_CANCER_VS_NORMAL_DN	101	91		
WANG_ESOPHAGUS_CANCER_PROGRESSION_UP	9	6		
SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_UP	15	10		
SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN	18	12		
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP	63	34		
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN	26	13		
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP	58	47		
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_DN	21	14		
MCBRYAN_PUBERTAL_BREAST_3_4WK_UP	214	171		
MCBRYAN_PUBERTAL_BREAST_3_4WK_DN	39	30		
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP	271	215		
MCBRYAN_PUBERTAL_BREAST_4_5WK_DN	196	159		
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP	116	92		
MCBRYAN_PUBERTAL_BREAST_5_6WK_DN	137	111		
MCBRYAN_PUBERTAL_BREAST_6_7WK_UP	197	164		
MCBRYAN_PUBERTAL_BREAST_6_7WK_DN	79	59		
VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP	16	14		
VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN	16	10		
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_UP	52	34		
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_DN	19	16		
LUI_THYROID_CANCER_PAX8_PPARG_UP	44	36		
LUI_THYROID_CANCER_PAX8_PPARG_DN	45	38		
HAMAI_APOPTOSIS_VIA_TRAIL_UP	584	446		
HAMAI_APOPTOSIS_VIA_TRAIL_DN	186	131		
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_UP	69	64		
OUELLET_CULTURED_OVARIAN_CANCER_INVASIVE_VS_LMP_DN	35	18		
HUMMERICH_BENIGN_SKIN_TUMOR_UP	18	11		
HUMMERICH_BENIGN_SKIN_TUMOR_DN	18	11		
MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP	169	153		
MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN	62	54		
HUMMERICH_MALIGNANT_SKIN_TUMOR_UP	16	12		
HUMMERICH_MALIGNANT_SKIN_TUMOR_DN	18	11		
LUCAS_HNF4A_TARGETS_UP	58	47		
LUCAS_HNF4A_TARGETS_DN	8		Rejected!	
ZIRN_TRETINOIN_RESPONSE_WT1_UP	23	19		
ZIRN_TRETINOIN_RESPONSE_WT1_DN	6		Rejected!	
ZIRN_TRETINOIN_RESPONSE_UP	21	17		
ZIRN_TRETINOIN_RESPONSE_DN	6	5		
STREICHER_LSM1_TARGETS_UP	44	38		
STREICHER_LSM1_TARGETS_DN	19	15		
BUSA_SAM68_TARGETS_UP	7	7		
BUSA_SAM68_TARGETS_DN	6	5		
KAN_RESPONSE_TO_ARSENIC_TRIOXIDE	123	90		
LANG_MYB_FAMILY_TARGETS	29	28		
MCBRYAN_TERMINAL_END_BUD_UP	12	11		
MCBRYAN_TERMINAL_END_BUD_DN	7	6		
NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_UP	29	28		
NUNODA_RESPONSE_TO_DASATINIB_IMATINIB_DN	13	12		
DARWICHE_SKIN_TUMOR_PROMOTER_UP	142	95		
DARWICHE_SKIN_TUMOR_PROMOTER_DN	185	122		
DARWICHE_PAPILLOMA_RISK_LOW_UP	162	107		
DARWICHE_PAPILLOMA_RISK_LOW_DN	165	110		
DARWICHE_PAPILLOMA_RISK_HIGH_UP	147	96		
DARWICHE_PAPILLOMA_RISK_HIGH_DN	180	121		
DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP	146	97		
DARWICHE_SQUAMOUS_CELL_CARCINOMA_DN	181	120		
MAHADEVAN_IMATINIB_RESISTANCE_UP	23	15		
MAHADEVAN_IMATINIB_RESISTANCE_DN	20	14		
TOMIDA_METASTASIS_UP	26	18		
TOMIDA_METASTASIS_DN	18	16		
SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN	13	7		
OZANNE_AP1_TARGETS_UP	18	13		
OZANNE_AP1_TARGETS_DN	5		Rejected!	
HWANG_PROSTATE_CANCER_MARKERS	28	22		
CORRADETTI_MTOR_PATHWAY_REGULATORS_DN	6	5		
HU_ANGIOGENESIS_UP	21	19		
HU_ANGIOGENESIS_DN	37	29		
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_UP	60	51		
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_DN	45	41		
DARWICHE_PAPILLOMA_PROGRESSION_RISK	74	52		
SHIRAISHI_PLZF_TARGETS_UP	10	8		
SHIRAISHI_PLZF_TARGETS_DN	9	6		
MOTAMED_RESPONSE_TO_ANDROGEN_UP	6		Rejected!	
MOTAMED_RESPONSE_TO_ANDROGEN_DN	6	5		
RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_SMAD4_UP	7	7		
RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_SMAD4_DN	8	8		
RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_UP	6	5		
RAMJAUN_APOPTOSIS_BY_TGFB1_VIA_MAPK1_DN	8	8		
OLSSON_E2F3_TARGETS_UP	28	20		
OLSSON_E2F3_TARGETS_DN	49	39		
MARKS_HDAC_TARGETS_UP	23	18		
MARKS_HDAC_TARGETS_DN	15	12		
CHOI_ATL_ACUTE_STAGE	6		Rejected!	
CHOI_ATL_STAGE_PREDICTOR	44	31		
WONG_ENDMETRIUM_CANCER_UP	25	12		
WONG_ENDMETRIUM_CANCER_DN	82	63		
WONG_ENDOMETRIAL_CANCER_LATE	10	6		
ABDULRAHMAN_KIDNEY_CANCER_VHL_UP	5		Rejected!	
ABDULRAHMAN_KIDNEY_CANCER_VHL_DN	14	13		
KONG_E2F1_TARGETS	10	9		
KONG_E2F3_TARGETS	97	79		
TANAKA_METHYLATED_IN_ESOPHAGEAL_CARCINOMA	103	62		
EGUCHI_CELL_CYCLE_RB1_TARGETS	23	21		
CROSBY_E2F4_TARGETS	6	5		
MARKS_ACETYLATED_NON_HISTONE_PROTEINS	15	12		
IVANOV_MUTATED_IN_COLON_CANCER	13	10		
TAKAYAMA_BOUND_BY_AR	10	7		
RIZ_ERYTHROID_DIFFERENTIATION	77	67		
RIZ_ERYTHROID_DIFFERENTIATION_CCNE1	40	34		
RIZ_ERYTHROID_DIFFERENTIATION_HBZ	41	28		
CHASSOT_SKIN_WOUND	10	10		
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP	181	139		
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN	800		Rejected!	
MUELLER_METHYLATED_IN_GLIOBLASTOMA	40	28		
RIZ_ERYTHROID_DIFFERENTIATION_HEMGN	31	24		
RIZ_ERYTHROID_DIFFERENTIATION_APOBEC2	27	19		
RIZ_ERYTHROID_DIFFERENTIATION_6HR	40	24		
RIZ_ERYTHROID_DIFFERENTIATION_12HR	43	38		
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_UP	207	146		
PEREZ_TP53_TARGETS	1174		Rejected!	
PEREZ_TP63_TARGETS	355	255		
PEREZ_TP53_AND_TP63_TARGETS	205	158		
WAKASUGI_HAVE_ZNF143_BINDING_SITES	58	53		
RODRIGUES_NTN1_AND_DCC_TARGETS	35	26		
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_UP	28	21		
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN	88	67		
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP	64	57		
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_DN	84	60		
TURJANSKI_MAPK1_AND_MAPK2_TARGETS	12	10		
TURJANSKI_MAPK8_AND_MAPK9_TARGETS	8	7		
TURJANSKI_MAPK7_TARGETS	8	8		
TURJANSKI_MAPK11_TARGETS	5	5		
TURJANSKI_MAPK14_TARGETS	10	8		
MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH	15	14		
MAHADEVAN_RESPONSE_TO_MP470_DN	19	17		
MAHADEVAN_RESPONSE_TO_MP470_UP	20	10		
APPIERTO_RESPONSE_TO_FENRETINIDE_UP	38	32		
APPIERTO_RESPONSE_TO_FENRETINIDE_DN	51	39		
NAGY_TFTC_COMPONENTS_HUMAN	19	14		
NAGY_STAGA_COMPONENTS_HUMAN	15	10		
NAGY_PCAF_COMPONENTS_HUMAN	9	6		
BAKER_HEMATOPOESIS_STAT1_TARGETS	10	10		
BAKER_HEMATOPOIESIS_STAT3_TARGETS	16	14		
BAKER_HEMATOPOESIS_STAT5_TARGETS	7	7		
SEIDEN_MET_SIGNALING	19	18		
AUNG_GASTRIC_CANCER	54	39		
SANCHEZ_MDM2_TARGETS	15	10		
BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER	22	22		
NAKAMURA_LUNG_CANCER	8	6		
GALLUZZI_PERMEABILIZE_MITOCHONDRIA	43	39		
HAEGERSTRAND_RESPONSE_TO_IMATINIB	9	9		
MATHEW_FANCONI_ANEMIA_GENES	11	11		
MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER	55	39		
GILMORE_CORE_NFKB_PATHWAY	14	14		
SCHEIDEREIT_IKK_TARGETS	18	15		
DUTTA_APOPTOSIS_VIA_NFKB	33	26		
DEBOSSCHER_NFKB_TARGETS_REPRESSED_BY_GLUCOCORTICOIDS	24	15		
ROVERSI_GLIOMA_COPY_NUMBER_DN	54	41		
SEIDEN_ONCOGENESIS_BY_MET	88	71		
HUMMERICH_SKIN_CANCER_PROGRESSION_UP	88	75		
HUMMERICH_SKIN_CANCER_PROGRESSION_DN	100	87		
CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN	32	20		
KLEIN_TARGETS_OF_BCR_ABL1_FUSION	45	39		
ROVERSI_GLIOMA_LOH_REGIONS	44	31		
ROVERSI_GLIOMA_COPY_NUMBER_UP	100	70		
RASHI_RESPONSE_TO_IONIZING_RADIATION_1	45	35		
RASHI_RESPONSE_TO_IONIZING_RADIATION_2	127	111		
RASHI_RESPONSE_TO_IONIZING_RADIATION_3	48	40		
RASHI_RESPONSE_TO_IONIZING_RADIATION_4	61	42		
RASHI_RESPONSE_TO_IONIZING_RADIATION_5	147	116		
RASHI_RESPONSE_TO_IONIZING_RADIATION_6	84	69		
RASHI_NFKB1_TARGETS	19	18		
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM	31	24		
AIGNER_ZEB1_TARGETS	35	27		
SUZUKI_AMPLIFIED_IN_ORAL_CANCER	16	10		
HESSON_TUMOR_SUPPRESSOR_CLUSTER_3P21_3	7	5		
MARTIN_INTERACT_WITH_HDAC	44	40		
LASTOWSKA_COAMPLIFIED_WITH_MYCN	43	30		
IWANAGA_E2F1_TARGETS_NOT_INDUCED_BY_SERUM	6	5		
LI_LUNG_CANCER	41	36		
LI_AMPLIFIED_IN_LUNG_CANCER	178	154		
LINDGREN_BLADDER_CANCER_CLUSTER_2B	392	318		
LINDGREN_BLADDER_CANCER_HIGH_RECURRENCE	49	41		
LINDGREN_BLADDER_CANCER_WITH_LOH_IN_CHR9Q	116	90		
NAKAMURA_ALVEOLAR_EPITHELIUM	5	5		
NAKAMURA_BRONCHIAL_AND_BRONCHIOLAR_EPITHELIA	7		Rejected!	
NAKAMURA_LUNG_CANCER_DIFFERENTIATION_MARKERS	14	8		
GALLUZZI_PREVENT_MITOCHONDIAL_PERMEABILIZATION	22	20		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_17	25	15		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_24	14	12		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_25	15	7		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_7	8	6		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_27	15	9		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_15	13	9		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_29	11	5		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_9	8	7		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_16	14	8		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_14	6		Rejected!	
EBAUER_TARGETS_OF_PAX3_FOXO1_FUSION_DN	48	30		
EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION	50	40		
SCHAVOLT_TARGETS_OF_TP53_AND_TP63	16	12		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_8	18	11		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_23	24	17		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_11	5		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_2	5		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_21	9		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_30	9		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_3	5		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_6	6		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_12	11	10		
MATTIOLI_MGUS_VS_PCL	116	80		
MATTIOLI_MGUS_VS_MULTIPLE_MYELOMA	16	11		
FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL	326	246		
FARMER_BREAST_CANCER_APOCRINE_VS_BASAL	330	251		
FARMER_BREAST_CANCER_BASAL_VS_LULMINAL	330	250		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_5	7		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_18	8		Rejected!	
LUI_THYROID_CANCER_CLUSTER_1	51	43		
LUI_THYROID_CANCER_CLUSTER_2	42	32		
LUI_THYROID_CANCER_CLUSTER_3	28	23		
LUI_THYROID_CANCER_CLUSTER_4	16	7		
LUI_THYROID_CANCER_CLUSTER_5	13	10		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_22	13	10		
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_1	7		Rejected!	
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_13	10		Rejected!	
GRASEMANN_RETINOBLASTOMA_WITH_6P_AMPLIFICATION	14	12		
LUI_TARGETS_OF_PAX8_PPARG_FUSION	34	27		
SCHLOSSER_SERUM_RESPONSE_UP	134	103		
SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC	108	81		
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY	32	30		
SCHLOSSER_MYC_TARGETS_REPRESSED_BY_SERUM	159	126		
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN	47	44		
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP	47	43		
SCHLOSSER_SERUM_RESPONSE_DN	712		Rejected!	
MATTIOLI_MULTIPLE_MYELOMA_SUBGROUPS	16	10		
MATTIOLI_MULTIPLE_MYELOMA_WITH_14Q32_TRANSLOCATIONS	36	31		
FARMER_BREAST_CANCER_CLUSTER_1	44	31		
FARMER_BREAST_CANCER_CLUSTER_8	7		Rejected!	
FARMER_BREAST_CANCER_CLUSTER_7	20	13		
FARMER_BREAST_CANCER_CLUSTER_6	16	12		
FARMER_BREAST_CANCER_CLUSTER_5	19	18		
FARMER_BREAST_CANCER_CLUSTER_4	16	14		
FARMER_BREAST_CANCER_CLUSTER_2	33	28		
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER	140	121		
SCHEIDEREIT_IKK_INTERACTING_PROTEINS	58	51		
JAERVINEN_AMPLIFIED_IN_LARYNGEAL_CANCER	40	31		
HEIDENBLAD_AMPLIFIED_IN_SOFT_TISSUE_CANCER	13	11		
HEIDENBLAD_AMPLIFIED_IN_BONE_CANCER	7	5		
OHASHI_AURKA_TARGETS	6	5		
OHASHI_AURKB_TARGETS	10	8		
KOBAYASHI_RESPONSE_TO_ROMIDEPSIN	19	13		
LA_MEN1_TARGETS	24	20		
KOMMAGANI_TP63_GAMMA_TARGETS	9	8		
LUND_SILENCED_BY_METHYLATION	16	16		
HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2	18	16		
PATTERSON_DOCETAXEL_RESISTANCE	29	23		
BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX	17	14		
BOWIE_RESPONSE_TO_TAMOXIFEN	18	14		
AIYAR_COBRA1_TARGETS_UP	39	30		
AIYAR_COBRA1_TARGETS_DN	29	19		
LI_CISPLATIN_RESISTANCE_DN	35	21		
LI_CISPLATIN_RESISTANCE_UP	28	20		
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_UP	23	15		
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_4NM_DN	7	7		
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP	36	23		
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN	38	29		
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP	81	60		
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_DN	25	21		
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP	64	52		
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN	19	13		
XU_HGF_SIGNALING_NOT_VIA_AKT1_6HR	26	23		
XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR	19	16		
XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP	35	31		
XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN	20	15		
XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_UP	14	11		
XU_HGF_TARGETS_INDUCED_BY_AKT1_48HR_DN	27	15		
XU_HGF_TARGETS_REPRESSED_BY_AKT1_UP	10	8		
XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN	95	59		
XU_AKT1_TARGETS_6HR	27	22		
XU_AKT1_TARGETS_48HR	9	7		
SHI_SPARC_TARGETS_UP	24	21		
SHI_SPARC_TARGETS_DN	13	11		
WAESCH_ANAPHASE_PROMOTING_COMPLEX	12	12		
AGARWAL_AKT_PATHWAY_TARGETS	10	8		
NEBEN_AML_WITH_FLT3_OR_NRAS_UP	8	6		
NEBEN_AML_WITH_FLT3_OR_NRAS_DN	12	11		
DIRMEIER_LMP1_RESPONSE_EARLY	66	60		
EINAV_INTERFERON_SIGNATURE_IN_CANCER	27	20		
AMUNDSON_DNA_DAMAGE_RESPONSE_TP53	16	14		
SNIJDERS_AMPLIFIED_IN_HEAD_AND_NECK_TUMORS	37	33		
NAISHIRO_CTNNB1_TARGETS_WITH_LEF1_MOTIF	8	6		
WHITE_NEUROBLASTOMA_WITH_1P36.3_DELETION	21	19		
BEGUM_TARGETS_OF_PAX3_FOXO1_FUSION_AND_PAX3	7	7		
SILIGAN_BOUND_BY_EWS_FLT1_FUSION	47	33		
DAUER_STAT3_TARGETS_UP	49	42		
DAUER_STAT3_TARGETS_DN	50	40		
PATIL_LIVER_CANCER	747		Rejected!	
KORKOLA_EMBRYONAL_CARCINOMA	13		Rejected!	
KORKOLA_TERATOMA	39	34		
KORKOLA_YOLK_SAC_TUMOR	62	39		
KORKOLA_CHORIOCARCINOMA	6		Rejected!	
WANG_METHYLATED_IN_BREAST_CANCER	35	28		
HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER	31	21		
TERAMOTO_OPN_TARGETS_CLUSTER_1	13	10		
TERAMOTO_OPN_TARGETS_CLUSTER_3	5		Rejected!	
TERAMOTO_OPN_TARGETS_CLUSTER_4	13	11		
TERAMOTO_OPN_TARGETS_CLUSTER_5	7	5		
TERAMOTO_OPN_TARGETS_CLUSTER_6	27	24		
TERAMOTO_OPN_TARGETS_CLUSTER_7	19	16		
TERAMOTO_OPN_TARGETS_CLUSTER_8	8	6		
SCHRAMM_INHBA_TARGETS_UP	7	6		
SCHRAMM_INHBA_TARGETS_DN	24	23		
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP	73	53		
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_DN	30	23		
YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN	87	59		
YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_UP	25	16		
KANG_GIST_WITH_PDGFRA_UP	50	43		
KANG_GIST_WITH_PDGFRA_DN	5		Rejected!	
MEINHOLD_OVARIAN_CANCER_LOW_GRADE_UP	19	14		
MEINHOLD_OVARIAN_CANCER_LOW_GRADE_DN	20	19		
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_UP	28	25		
DACOSTA_ERCC3_ALLELE_XPCS_VS_TTD_DN	36	27		
DACOSTA_LOW_DOSE_UV_RESPONSE_VIA_ERCC3_XPCS_UP	18	12		
DACOSTA_LOW_DOSE_UV_RESPONSE_VIA_ERCC3_XPCS_DN	9	8		
DACOSTA_UV_RESPONSE_VIA_ERCC3_UP	309	249		
DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	855		Rejected!	
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	483	384		
DIRMEIER_LMP1_RESPONSE_LATE_UP	57	50		
DIRMEIER_LMP1_RESPONSE_LATE_DN	32	27		
HEIDENBLAD_AMPLICON_8Q24_UP	40	28		
HEIDENBLAD_AMPLICON_8Q24_DN	46	37		
HEIDENBLAD_AMPLICON_12P11_12_UP	33	28		
HEIDENBLAD_AMPLICON_12P11_12_DN	30	15		
AMUNDSON_GENOTOXIC_SIGNATURE	105	87		
AMUNDSON_RESPONSE_TO_ARSENITE	217	171		
FUNG_IL2_SIGNALING_2	12	7		
FUNG_IL2_SIGNALING_1	11	8		
FUNG_IL2_TARGETS_WITH_STAT5_BINDING_SITES_T1	9		Rejected!	
FUNG_IL2_TARGETS_WITH_STAT5_BINDING_SITES	7	6		
SASAKI_TARGETS_OF_TP73_AND_TP63	11	6		
YANAGIHARA_ESX1_TARGETS	30	26		
WEINMANN_ADAPTATION_TO_HYPOXIA_UP	29	24		
WEINMANN_ADAPTATION_TO_HYPOXIA_DN	41	32		
TSUNODA_CISPLATIN_RESISTANCE_UP	15	12		
TSUNODA_CISPLATIN_RESISTANCE_DN	51	37		
MAINA_HYPOXIA_VHL_TARGETS_UP	6		Rejected!	
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_UP	176	127		
MARTORIATI_MDM4_TARGETS_NEUROEPITHELIUM_DN	164	100		
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP	227	161		
MARTORIATI_MDM4_TARGETS_FETAL_LIVER_DN	514	430		
LI_WILMS_TUMOR_ANAPLASTIC_UP	19	15		
LI_WILMS_TUMOR_ANAPLASTIC_DN	5		Rejected!	
BORLAK_LIVER_CANCER_EGF_UP	57	49		
MANN_RESPONSE_TO_AMIFOSTINE_UP	20	20		
MANN_RESPONSE_TO_AMIFOSTINE_DN	10	8		
YAN_ESCAPE_FROM_ANOIKIS	24	19		
DARWICHE_PAPILLOMA_RISK_HIGH_VS_LOW_UP	6	6		
DARWICHE_PAPILLOMA_RISK_HIGH_VS_LOW_DN	32	24		
OXFORD_RALA_TARGETS_UP	9	7		
OXFORD_RALA_TARGETS_DN	10	8		
OXFORD_RALB_TARGETS_DN	9	7		
OXFORD_RALB_TARGETS_UP	8	7		
OXFORD_RALA_AND_RALB_TARGETS_UP	10	7		
OXFORD_RALA_AND_RALB_TARGETS_DN	9	9		
OXFORD_RALA_OR_RALB_TARGETS_UP	48	42		
OXFORD_RALA_OR_RALB_TARGETS_DN	24	17		
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP	83	57		
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN	114	71		
WOOD_EBV_EBNA1_TARGETS_UP	110	93		
WOOD_EBV_EBNA1_TARGETS_DN	47	37		
MOHANKUMAR_TLX1_TARGETS_UP	414	324		
MOHANKUMAR_TLX1_TARGETS_DN	193	108		
DAIRKEE_TERT_TARGETS_UP	380	280		
DAIRKEE_TERT_TARGETS_DN	124	82		
DAWSON_METHYLATED_IN_LYMPHOMA_TCL1	59	37		
MURATA_VIRULENCE_OF_H_PILORI	24	19		
WANG_HCP_PROSTATE_CANCER	111	81		
JOHANSSON_BRAIN_CANCER_EARLY_VS_LATE_UP	7	7		
JOHANSSON_BRAIN_CANCER_EARLY_VS_LATE_DN	45	44		
WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_UP	8	6		
WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_DN	6	5		
MAINA_VHL_TARGETS_UP	10	7		
MAINA_VHL_TARGETS_DN	18	14		
GRUETZMANN_PANCREATIC_CANCER_UP	358	302		
GRUETZMANN_PANCREATIC_CANCER_DN	203	163		
JAZAG_TGFB1_SIGNALING_UP	108	80		
JAZAG_TGFB1_SIGNALING_DN	35	26		
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_UP	108	87		
JAZAG_TGFB1_SIGNALING_VIA_SMAD4_DN	66	49		
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP	30	26		
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_DN	51	47		
SIMBULAN_UV_RESPONSE_NORMAL_UP	9	6		
SIMBULAN_UV_RESPONSE_NORMAL_DN	33	26		
SIMBULAN_UV_RESPONSE_IMMORTALIZED_DN	31	30		
CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP	21	19		
CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN	38	33		
INAMURA_LUNG_CANCER_SCC_UP	14	10		
INAMURA_LUNG_CANCER_SCC_DN	14	11		
INAMURA_LUNG_CANCER_SCC_SUBTYPES_UP	14	10		
INAMURA_LUNG_CANCER_SCC_SUBTYPES_DN	5		Rejected!	
WATTEL_AUTONOMOUS_THYROID_ADENOMA_UP	73	50		
WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN	55	38		
SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION	50	45		
KIM_MYC_AMPLIFICATION_TARGETS_UP	201	149		
KIM_MYC_AMPLIFICATION_TARGETS_DN	97	63		
KIM_MYCN_AMPLIFICATION_TARGETS_UP	92	70		
KIM_MYCN_AMPLIFICATION_TARGETS_DN	103	79		
KIM_MYCL1_AMPLIFICATION_TARGETS_UP	13	6		
KIM_MYCL1_AMPLIFICATION_TARGETS_DN	20	17		
TSAI_RESPONSE_TO_IONIZING_RADIATION	149	124		
YANG_BREAST_CANCER_ESR1_UP	36	28		
YANG_BREAST_CANCER_ESR1_DN	25	23		
YANG_BREAST_CANCER_ESR1_LASER_UP	34	22		
YANG_BREAST_CANCER_ESR1_LASER_DN	50	42		
YANG_BREAST_CANCER_ESR1_BULK_UP	27	17		
YANG_BREAST_CANCER_ESR1_BULK_DN	23	18		
WANG_RESPONSE_TO_BEXAROTENE_UP	34	28		
WANG_RESPONSE_TO_BEXAROTENE_DN	29	24		
STANHILL_HRAS_TRANSFROMATION_UP	8	8		
REN_MIF_TARGETS_DN	5		Rejected!	
SEMBA_FHIT_TARGETS_UP	11	8		
SEMBA_FHIT_TARGETS_DN	10	9		
SHANK_TAL1_TARGETS_DN	10	8		
HASINA_NOL7_TARGETS_UP	13	9		
HASINA_NOL7_TARGETS_DN	13	10		
KONDO_HYPOXIA	8		Rejected!	
HOWLIN_PUBERTAL_MAMMARY_GLAND	69	58		
KREPPEL_CD99_TARGETS_UP	6	5		
KREPPEL_CD99_TARGETS_DN	8	7		
HATADA_METHYLATED_IN_LUNG_CANCER_UP	390	227		
HATADA_METHYLATED_IN_LUNG_CANCER_DN	38	12		
CALVET_IRINOTECAN_SENSITIVE_VS_RESISTANT_UP	5	5		
CALVET_IRINOTECAN_SENSITIVE_VS_RESISTANT_DN	5		Rejected!	
CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_UP	5	5		
CALVET_IRINOTECAN_SENSITIVE_VS_REVERTED_DN	5		Rejected!	
FURUKAWA_DUSP6_TARGETS_PCI35_UP	74	43		
FURUKAWA_DUSP6_TARGETS_PCI35_DN	74	59		
WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_UP	14	10		
WANG_RESPONSE_TO_PACLITAXEL_VIA_MAPK8_DN	5	5		
KARAKAS_TGFB1_SIGNALING	18	14		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1	229	182		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2	153	126		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3	70	60		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4	261	211		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5	94	61		
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6	46	31		
LIEN_BREAST_CARCINOMA_METAPLASTIC	35	32		
SCHMAHL_PDGF_SIGNALING	9	7		
TOMLINS_PROSTATE_CANCER_UP	40	34		
TOMLINS_PROSTATE_CANCER_DN	40	35		
TOMLINS_METASTASIS_UP	14	12		
TOMLINS_METASTASIS_DN	20	17		
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_UP	44	30		
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_LARGE_VS_TINY_DN	45	34		
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_UP	38	31		
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS_HUGE_DN	33	25		
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_UP	14	10		
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_2FC_DN	21	16		
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP	479	406		
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN	584		Rejected!	
HUI_MAPK14_TARGETS_UP	21	19		
DIERICK_SEROTONIN_FUNCTION_GENES	6	5		
THEODOROU_MAMMARY_TUMORIGENESIS	31	18		
BALLIF_DEVELOPMENTAL_DISABILITY_P16_P12_DELETION	13	7		
SCHLESINGER_METHYLATED_IN_COLON_CANCER	10	7		
JIANG_CORE_DUPLICON_GENES	13		Rejected!	
PUJANA_BREAST_CANCER_LIT_INT_NETWORK	101	92		
PUJANA_XPRSS_INT_NETWORK	168	145		
PUJANA_BRCA1_PCC_NETWORK	1652		Rejected!	
PUJANA_BRCA2_PCC_NETWORK	423	350		
PUJANA_ATM_PCC_NETWORK	1442		Rejected!	
PUJANA_CHEK2_PCC_NETWORK	779		Rejected!	
PUJANA_BRCA_CENTERED_NETWORK	117	106		
SCHLESINGER_H3K27ME3_IN_NORMAL_AND_METHYLATED_IN_CANCER	28	14		
SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER	88	65		
GOERING_BLOOD_HDL_CHOLESTEROL_QTL_CIS	13	10		
GOERING_BLOOD_HDL_CHOLESTEROL_QTL_TRANS	14	7		
KHETCHOUMIAN_TRIM24_TARGETS_UP	47	44		
KHETCHOUMIAN_TRIM24_TARGETS_DN	8	8		
OHM_METHYLATED_IN_ADULT_CANCERS	27	25		
OHM_EMBRYONIC_CARCINOMA_UP	6	5		
OHM_EMBRYONIC_CARCINOMA_DN	8	7		
ALCALA_APOPTOSIS	88	73		
OKAWA_NEUROBLASTOMA_1P36_31_DELETION	22	20		
COWLING_MYCN_TARGETS	43	31		
GROSS_HYPOXIA_VIA_HIF1A_ONLY	8	7		
FALVELLA_SMOKERS_WITH_LUNG_CANCER	80	57		
OZEN_MIR125B1_TARGETS	25	21		
GALIE_TUMOR_ANGIOGENESIS	8	8		
GALIE_TUMOR_STEMNESS_GENES	6	6		
KAUFFMANN_MELANOMA_RELAPSE_UP	61	55		
KAUFFMANN_MELANOMA_RELAPSE_DN	6	5		
WILLIAMS_ESR1_TARGETS_UP	26	22		
WILLIAMS_ESR1_TARGETS_DN	6		Rejected!	
WILLIAMS_ESR2_TARGETS_UP	28	23		
WILLIAMS_ESR2_TARGETS_DN	11	10		
GROSS_ELK3_TARGETS_UP	27	26		
GROSS_ELK3_TARGETS_DN	32	26		
GROSS_HYPOXIA_VIA_ELK3_UP	209	179		
GROSS_HYPOXIA_VIA_ELK3_DN	156	131		
GROSS_HIF1A_TARGETS_UP	8	5		
GROSS_HIF1A_TARGETS_DN	25	20		
GROSS_HYPOXIA_VIA_HIF1A_UP	77	64		
GROSS_HYPOXIA_VIA_HIF1A_DN	110	89		
GROSS_HYPOXIA_VIA_ELK3_ONLY_UP	33	30		
GROSS_HYPOXIA_VIA_ELK3_ONLY_DN	44	38		
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP	142	120		
GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_DN	103	86		
NUYTTEN_NIPP1_TARGETS_UP	769		Rejected!	
NUYTTEN_NIPP1_TARGETS_DN	848		Rejected!	
NUYTTEN_EZH2_TARGETS_UP	1037		Rejected!	
NUYTTEN_EZH2_TARGETS_DN	1024		Rejected!	
INGRAM_SHH_TARGETS_UP	127	101		
INGRAM_SHH_TARGETS_DN	64	46		
MANTOVANI_NFKB_TARGETS_UP	43	36		
MANTOVANI_NFKB_TARGETS_DN	11	6		
MANTOVANI_VIRAL_GPCR_SIGNALING_UP	86	66		
MANTOVANI_VIRAL_GPCR_SIGNALING_DN	49	34		
BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_UP	811		Rejected!	
BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN	637	474		
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP	167	125		
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_DN	98	74		
NAKAYAMA_FRA2_TARGETS	43	37		
LOPEZ_MBD_TARGETS	957		Rejected!	
LOPEZ_MBD_TARGETS_IMPRINTED_AND_X_LINKED	17	14		
ROPERO_HDAC2_TARGETS	114	69		
GOUYER_TUMOR_INVASIVENESS	9	5		
LIU_LIVER_CANCER	38	25		
LIU_BREAST_CANCER	30	20		
LIU_NASOPHARYNGEAL_CARCINOMA	70	54		
LIU_COMMON_CANCER_GENES	79	53		
LOCKWOOD_AMPLIFIED_IN_LUNG_CANCER	214	170		
FREDERICK_PRKCI_TARGETS	10	7		
RAHMAN_TP53_TARGETS_PHOSPHORYLATED	21	18		
WEI_MIR34A_TARGETS	148	119		
WEI_MYCN_TARGETS_WITH_E_BOX	795		Rejected!	
LIAO_HAVE_SOX4_BINDING_SITES	40	37		
LIAO_METASTASIS	539	405		
HASEGAWA_TUMORIGENESIS_BY_RET_C634R	11	6		
TONG_INTERACT_WITH_PTTG1	57	38		
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_UP	9	8		
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN	22	22		
SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_UP	11	6		
SCIAN_INVERSED_TARGETS_OF_TP53_AND_TP73_DN	31	25		
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_UP	21	11		
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_DN	26	24		
SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_UP	13	12		
SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_DN	17	14		
GOUYER_TATI_TARGETS_UP	10	9		
GOUYER_TATI_TARGETS_DN	17	16		
CAFFAREL_RESPONSE_TO_THC_UP	33	26		
CAFFAREL_RESPONSE_TO_THC_DN	31	20		
CAFFAREL_RESPONSE_TO_THC_8HR_5_UP	16	11		
CAFFAREL_RESPONSE_TO_THC_8HR_5_DN	11	9		
CAFFAREL_RESPONSE_TO_THC_8HR_3_UP	5		Rejected!	
CAFFAREL_RESPONSE_TO_THC_8HR_3_DN	10	9		
CAFFAREL_RESPONSE_TO_THC_24HR_3_UP	8	6		
CAFFAREL_RESPONSE_TO_THC_24HR_3_DN	13	12		
CAFFAREL_RESPONSE_TO_THC_24HR_5_UP	34	27		
CAFFAREL_RESPONSE_TO_THC_24HR_5_DN	59	43		
RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_UP	5	5		
RANKIN_ANGIOGENIC_TARGETS_OF_VHL_HIF2A_DN	8	7		
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_UP	25	21		
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN	46	41		
SUH_COEXPRESSED_WITH_ID1_AND_ID2_UP	19	17		
WOTTON_RUNX_TARGETS_UP	21	16		
WOTTON_RUNX_TARGETS_DN	29	21		
FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP	10	10		
FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_DN	8	5		
FUJIWARA_PARK2_IN_LIVER_CANCER_UP	8	8		
FUJIWARA_PARK2_IN_LIVER_CANCER_DN	5	5		
GARCIA_TARGETS_OF_FLI1_AND_DAX1_UP	57	42		
GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN	176	128		
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_UP	236	174		
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN	382	274		
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_UP	109	75		
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN	110	72		
RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_UP	121	97		
RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN	15	10		
RICKMAN_METASTASIS_UP	344	230		
RICKMAN_METASTASIS_DN	261	203		
FRIDMAN_SENESCENCE_UP	77	68		
FRIDMAN_SENESCENCE_DN	13	12		
FRIDMAN_IMMORTALIZATION_DN	34	29		
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP	176	130		
SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN	514	406		
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP	116	94		
SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN	57	44		
SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP	487	344		
SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN	428	314		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX1_UP	15	12		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX1_DN	10	7		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX2_UP	6	5		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX2_DN	7	6		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_UP	11	8		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	32	26		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX5_UP	11	8		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX5_DN	8	7		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_UP	8	8		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX6_DN	5		Rejected!	
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_UP	21	16		
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_DN	45	38		
KOYAMA_SEMA3B_TARGETS_UP	292	195		
KOYAMA_SEMA3B_TARGETS_DN	411	296		
COURTOIS_SENESCENCE_TRIGGERS	6	6		
RICKMAN_HEAD_AND_NECK_CANCER_A	100	57		
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX3	5		Rejected!	
RICKMAN_HEAD_AND_NECK_CANCER_B	48	22		
RICKMAN_HEAD_AND_NECK_CANCER_C	113	49		
RICKMAN_HEAD_AND_NECK_CANCER_D	37	15		
RICKMAN_HEAD_AND_NECK_CANCER_E	89	45		
RICKMAN_HEAD_AND_NECK_CANCER_F	54	32		
WU_CELL_MIGRATION	184	145		
TAGHAVI_NEOPLASTIC_TRANSFORMATION	12	10		
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_UP	35	25		
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN	28	24		
BALDWIN_PRKCI_TARGETS_UP	35	33		
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP	69	66		
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN	206	183		
HE_PTEN_TARGETS_UP	16	15		
HE_PTEN_TARGETS_DN	7	5		
AMIT_DELAYED_EARLY_GENES	18	17		
DEN_INTERACT_WITH_LCA5	26	25		
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_UP	283	234		
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN	165	134		
BENPORATH_ES_1	379	278		
BENPORATH_ES_2	40	21		
BENPORATH_NANOG_TARGETS	988		Rejected!	
BENPORATH_OCT4_TARGETS	290	223		
BENPORATH_SOX2_TARGETS	734		Rejected!	
BENPORATH_NOS_TARGETS	179	131		
BENPORATH_SUZ12_TARGETS	1038		Rejected!	
BENPORATH_EED_TARGETS	1062		Rejected!	
BENPORATH_ES_WITH_H3K27ME3	1118		Rejected!	
BENPORATH_PRC2_TARGETS	652	338		
BENPORATH_MYC_TARGETS_WITH_EBOX	230	198		
BENPORATH_MYC_MAX_TARGETS	775		Rejected!	
BENPORATH_CYCLING_GENES	648		Rejected!	
BENPORATH_PROLIFERATION	147	119		
PETRETTO_CARDIAC_HYPERTROPHY	34	30		
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP	195	148		
STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN	517	382		
STARK_HYPPOCAMPUS_22Q11_DELETION_UP	53	37		
STARK_HYPPOCAMPUS_22Q11_DELETION_DN	20	14		
STARK_BRAIN_22Q11_DELETION	13	6		
BENPORATH_ES_CORE_NINE	9	8		
BENPORATH_ES_CORE_NINE_CORRELATED	100	87		
PETRETTO_BLOOD_PRESSURE_UP	12	9		
PETRETTO_BLOOD_PRESSURE_DN	7	5		
PETRETTO_HEART_MASS_QTL_CIS_UP	28	20		
PETRETTO_HEART_MASS_QTL_CIS_DN	24	16		
PETRETTO_LEFT_VENTRICLE_MASS_QTL_CIS_UP	6		Rejected!	
PETRETTO_LEFT_VENTRICLE_MASS_QTL_CIS_DN	7		Rejected!	
AMIT_EGF_RESPONSE_20_HELA	11	9		
AMIT_EGF_RESPONSE_40_HELA	42	35		
AMIT_EGF_RESPONSE_60_HELA	46	39		
AMIT_EGF_RESPONSE_120_HELA	69	55		
AMIT_EGF_RESPONSE_240_HELA	60	50		
AMIT_EGF_RESPONSE_480_HELA	164	135		
AMIT_EGF_RESPONSE_20_MCF10A	14	13		
AMIT_EGF_RESPONSE_40_MCF10A	19	17		
AMIT_EGF_RESPONSE_60_MCF10A	39	32		
AMIT_EGF_RESPONSE_120_MCF10A	43	37		
AMIT_EGF_RESPONSE_240_MCF10A	20	16		
AMIT_EGF_RESPONSE_480_MCF10A	43	34		
AMIT_SERUM_RESPONSE_20_MCF10A	21	18		
AMIT_SERUM_RESPONSE_40_MCF10A	32	27		
AMIT_SERUM_RESPONSE_60_MCF10A	57	47		
AMIT_SERUM_RESPONSE_120_MCF10A	65	51		
AMIT_SERUM_RESPONSE_240_MCF10A	57	48		
AMIT_SERUM_RESPONSE_480_MCF10A	39	25		
GEORGES_CELL_CYCLE_MIR192_TARGETS	62	56		
GEORGES_TARGETS_OF_MIR192_AND_MIR215	893		Rejected!	
SHEN_SMARCA2_TARGETS_UP	424	332		
SHEN_SMARCA2_TARGETS_DN	357	185		
LIN_SILENCED_BY_TUMOR_MICROENVIRONMENT	108	68		
SAKAI_TUMOR_INFILTRATING_MONOCYTES_DN	81	68		
SAKAI_TUMOR_INFILTRATING_MONOCYTES_UP	27	25		
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN	36	23		
JEON_SMAD6_TARGETS_UP	24	21		
JEON_SMAD6_TARGETS_DN	19	18		
WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT	66	48		
SUNG_METASTASIS_STROMA_UP	110	86		
SUNG_METASTASIS_STROMA_DN	54	37		
SHIN_B_CELL_LYMPHOMA_CLUSTER_1	13	9		
SHIN_B_CELL_LYMPHOMA_CLUSTER_2	30	27		
SHIN_B_CELL_LYMPHOMA_CLUSTER_3	28	26		
SHIN_B_CELL_LYMPHOMA_CLUSTER_5	18	10		
SHIN_B_CELL_LYMPHOMA_CLUSTER_6	11	7		
SHIN_B_CELL_LYMPHOMA_CLUSTER_7	27	27		
SHIN_B_CELL_LYMPHOMA_CLUSTER_8	36	34		
SHIN_B_CELL_LYMPHOMA_CLUSTER_9	19	16		
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP	223	167		
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_DN	103	76		
MORI_PRE_BI_LYMPHOCYTE_UP	80	68		
MORI_PRE_BI_LYMPHOCYTE_DN	77	66		
MORI_LARGE_PRE_BII_LYMPHOCYTE_UP	86	75		
MORI_LARGE_PRE_BII_LYMPHOCYTE_DN	58	46		
MORI_SMALL_PRE_BII_LYMPHOCYTE_UP	86	73		
MORI_SMALL_PRE_BII_LYMPHOCYTE_DN	76	69		
MORI_IMMATURE_B_LYMPHOCYTE_UP	53	45		
MORI_IMMATURE_B_LYMPHOCYTE_DN	90	78		
MORI_MATURE_B_LYMPHOCYTE_UP	90	70		
MORI_MATURE_B_LYMPHOCYTE_DN	75	67		
MORI_PLASMA_CELL_UP	51	38		
MORI_PLASMA_CELL_DN	33	28		
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP	110	81		
MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_DN	17	16		
COLLIS_PRKDC_SUBSTRATES	20	18		
COLLIS_PRKDC_REGULATORS	15	15		
TOMIDA_LUNG_CANCER_POOR_SURVIVAL	5	5		
LEE_TARGETS_OF_PTCH1_AND_SUFU_UP	53	44		
LEE_TARGETS_OF_PTCH1_AND_SUFU_DN	83	61		
KAUFFMANN_DNA_REPAIR_GENES	230	202		
KAUFFMANN_DNA_REPLICATION_GENES	147	117		
NIKOLSKY_BREAST_CANCER_1Q21_AMPLICON	38	31		
NIKOLSKY_BREAST_CANCER_1Q32_AMPLICON	13	9		
NIKOLSKY_BREAST_CANCER_5P15_AMPLICON	26	17		
NIKOLSKY_BREAST_CANCER_6P24_P22_AMPLICON	21	16		
NIKOLSKY_BREAST_CANCER_7P22_AMPLICON	38	23		
NIKOLSKY_BREAST_CANCER_7P15_AMPLICON	11	6		
NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON	76	44		
NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON	57	41		
NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON	132	88		
NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON	157	96		
NIKOLSKY_BREAST_CANCER_10Q22_AMPLICON	9	5		
NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON	158	101		
NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON	46	35		
NIKOLSKY_BREAST_CANCER_12Q24_AMPLICON	15	13		
NIKOLSKY_BREAST_CANCER_14Q22_AMPLICON	14	10		
NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON	22	15		
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON	120	75		
NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON	53	31		
NIKOLSKY_BREAST_CANCER_17P11_AMPLICON	10	6		
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON	133	78		
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON	335	241		
NIKOLSKY_BREAST_CANCER_19P13_AMPLICON	5		Rejected!	
NIKOLSKY_BREAST_CANCER_19Q13.1_AMPLICON	22		Rejected!	
NIKOLSKY_BREAST_CANCER_19Q13.4_AMPLICON	7		Rejected!	
NIKOLSKY_BREAST_CANCER_20P13_AMPLICON	8	6		
NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON	31	20		
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON	149	79		
NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON	16	12		
NIKOLSKY_BREAST_CANCER_22Q13_AMPLICON	17	13		
NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER	94	63		
WHITEHURST_PACLITAXEL_SENSITIVITY	39	27		
STEGMEIER_PRE-MITOTIC_CELL_CYCLE_REGULATORS	11	10		
TESAR_ALK_TARGETS_HUMAN_ES_4D_DN	6		Rejected!	
TESAR_ALK_TARGETS_HUMAN_ES_5D_UP	5		Rejected!	
TESAR_ALK_TARGETS_HUMAN_ES_5D_DN	7		Rejected!	
JI_METASTASIS_REPRESSED_BY_STK11	27	20		
GOTTWEIN_TARGETS_OF_KSHV_MIR_K12_11	63	47		
CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS	50	38		
TCGA_GLIOBLASTOMA_COPY_NUMBER_UP	75	56		
TCGA_GLIOBLASTOMA_COPY_NUMBER_DN	31	25		
DING_LUNG_CANCER_MUTATED_SIGNIFICANTLY	26	24		
DING_LUNG_CANCER_MUTATED_FREQUENTLY	12	11		
DING_LUNG_CANCER_EXPRESSION_BY_COPY_NUMBER	100	90		
ONDER_CDH1_TARGETS_2_UP	256	206		
ONDER_CDH1_TARGETS_2_DN	464	326		
ONDER_CDH1_TARGETS_1_UP	140	101		
ONDER_CDH1_TARGETS_1_DN	169	115		
ONDER_CDH1_TARGETS_3_UP	17	16		
ONDER_CDH1_TARGETS_3_DN	59	25		
ONDER_CDH1_SIGNALING_VIA_CTNNB1	83	63		
ZEILSTRA_CD44_TARGETS_UP	7	6		
ZEILSTRA_CD44_TARGETS_DN	7	7		
CERVERA_SDHB_TARGETS_2	114	83		
ROZANOV_MMP14_TARGETS_SUBSET	33	30		
ROZANOV_MMP14_CORRELATED	11	11		
ROZANOV_MMP14_TARGETS_UP	266	203		
ROZANOV_MMP14_TARGETS_DN	35	23		
LANDEMAINE_LUNG_METASTASIS	21	13		
CERVERA_SDHB_TARGETS_1_UP	118	80		
CERVERA_SDHB_TARGETS_1_DN	38	24		
LE_EGR2_TARGETS_DN	108	91		
ROSS_ACUTE_MYELOID_LEUKEMIA_CBF	82	59		
BYSTRYKH_SCP2_QTL	6		Rejected!	
KENNY_CTNNB1_TARGETS_UP	50	45		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_DN	22	17		
NELSON_RESPONSE_TO_ANDROGEN_DN	19	18		
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_UP	78	67		
BYSTROEM_CORRELATED_WITH_IL5_DN	64	59		
SWEET_KRAS_TARGETS_DN	66	49		
SHEPARD_CRUSH_AND_BURN_MUTANT_UP	197	147		
ROSS_AML_WITH_PML_RARA_FUSION	77	61		
ZUCCHI_METASTASIS_DN	44	34		
LEI_HOXC8_TARGETS_UP	12	11		
PARK_HSC_VS_MULTIPOTENT_PROGENITORS_DN	18	15		
LEE_LIVER_CANCER_CIPROFIBRATE_DN	66	51		
ASTON_MAJOR_DEPRESSIVE_DISORDER_DN	160	124		
STANELLE_E2F1_TARGETS	29	24		
CHESLER_BRAIN_D6MIT150_QTL_CIS	7	6		
SHIPP_DLBCL_CURED_VS_FATAL_DN	45	34		
GRANDVAUX_IFN_RESPONSE_NOT_VIA_IRF3	14	10		
UEDA_CENTRAL_CLOCK	88	73		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_FGF3	8	6		
GOLUB_ALL_VS_AML_UP	24	23		
HOUSTIS_ROS	36	29		
BASSO_B_LYMPHOCYTE_NETWORK	143	118		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS	128	92		
SCHUHMACHER_MYC_TARGETS_DN	7	7		
LEI_HOXC8_TARGETS_DN	17	17		
CHESLER_BRAIN_QTL_CIS	75	51		
ROSS_AML_WITH_CBFB_MYH11_FUSION	52	40		
IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_UP	17	12		
IIZUKA_LIVER_CANCER_PROGRESSION_L1_G1_DN	12	10		
FERRANDO_TAL1_NEIGHBORS	21	16		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS	185	146		
PENG_LEUCINE_DEPRIVATION_UP	142	114		
LEE_LIVER_CANCER_MYC_TGFA_DN	65	52		
IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_DN	25	21		
GOLDRATH_HOMEOSTATIC_PROLIFERATION	171	141		
LAMB_CCND1_TARGETS	19	17		
GNATENKO_PLATELET_SIGNATURE	48	37		
KIM_GERMINAL_CENTER_T_HELPER_UP	66	51		
SHEPARD_BMYB_MORPHOLINO_DN	200	149		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_CIS	65	45		
LEE_LIVER_CANCER_ACOX1_DN	65	54		
PENG_GLUCOSE_DEPRIVATION_UP	48	39		
SMITH_TERT_TARGETS_UP	145	122		
LEE_LIVER_CANCER_MYC_UP	54	51		
MENSSEN_MYC_TARGETS	53	44		
IIZUKA_LIVER_CANCER_PROGRESSION_L0_L1_DN	21	16		
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP	71	66		
DER_IFN_ALPHA_RESPONSE_UP	74	59		
KANNAN_TP53_TARGETS_UP	58	46		
PENG_GLUTAMINE_DEPRIVATION_UP	38	34		
WELCH_GATA1_TARGETS	22	19		
FRASOR_RESPONSE_TO_ESTRADIOL_UP	37	31		
LEE_LIVER_CANCER_MYC_TGFA_UP	61	54		
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN	41	37		
DORSAM_HOXA9_TARGETS_UP	35	30		
DER_IFN_BETA_RESPONSE_DN	8	7		
IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_UP	28	23		
NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_DN	121	101		
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN	58	44		
SHEPARD_BMYB_TARGETS	74	51		
KANNAN_TP53_TARGETS_DN	21	19		
CHANG_POU5F1_TARGETS_UP	15	13		
CHANG_POU5F1_TARGETS_DN	8	8		
SANA_TNF_SIGNALING_DN	90	74		
TARTE_PLASMA_CELL_VS_PLASMABLAST_UP	398	272		
WILLERT_WNT_SIGNALING	24	18		
PENG_LEUCINE_DEPRIVATION_DN	187	164		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_RUNX1	9	8		
KENNY_CTNNB1_TARGETS_DN	52	37		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_LD_MTX_UP	10	8		
WONG_IFNA2_RESISTANCE_UP	16	12		
CHESLER_BRAIN_QTL_TRANS	6	6		
IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_UP	12	9		
BECKER_TAMOXIFEN_RESISTANCE_UP	50	43		
SHEPARD_CRUSH_AND_BURN_MUTANT_DN	185	133		
KIM_GERMINAL_CENTER_T_HELPER_DN	24	16		
RADAEVA_RESPONSE_TO_IFNA1_UP	52	42		
PEART_HDAC_PROLIFERATION_CLUSTER_UP	57	54		
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN	38	30		
KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_DN	41	34		
PARK_HSC_VS_MULTIPOTENT_PROGENITORS_UP	19	15		
YAGI_AML_RELAPSE_PROGNOSIS	35	29		
SHIPP_DLBCL_CURED_VS_FATAL_UP	39	28		
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP	87	73		
LEE_LIVER_CANCER_ACOX1_UP	64	55		
IIZUKA_LIVER_CANCER_PROGRESSION_G2_G3_DN	9	9		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_UP	13	10		
UEDA_PERIFERAL_CLOCK	169	137		
CHESLER_BRAIN_HIGHEST_GENETIC_VARIANCE	37	24		
CHEN_LUNG_CANCER_SURVIVAL	28	22		
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP	62	45		
WIELAND_UP_BY_HBV_INFECTION	101	72		
SHEPARD_BMYB_MORPHOLINO_UP	205	164		
GOLUB_ALL_VS_AML_DN	24	19		
DISTECHE_ESCAPED_FROM_X_INACTIVATION	13	8		
DER_IFN_BETA_RESPONSE_UP	102	82		
MANALO_HYPOXIA_DN	289	233		
CHESLER_BRAIN_HIGHEST_EXPRESSION	40	30		
MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_DN	26	22		
LEE_LIVER_CANCER_MYC_E2F1_DN	64	54		
BYSTROEM_CORRELATED_WITH_IL5_UP	51	44		
ZUCCHI_METASTASIS_UP	43	36		
CHESLER_BRAIN_D6MIT150_QTL_TRANS	9	5		
NELSON_RESPONSE_TO_ANDROGEN_UP	86	73		
LIN_APC_TARGETS	77	62		
VANTVEER_BREAST_CANCER_METASTASIS_DN	121	91		
BROCKE_APOPTOSIS_REVERSED_BY_IL6	144	112		
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN	59	46		
FRASOR_RESPONSE_TO_ESTRADIOL_DN	82	69		
CHEOK_RESPONSE_TO_HD_MTX_DN	24	21		
TENEDINI_MEGAKARYOCYTE_MARKERS	66	58		
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN	309	272		
SMITH_LIVER_CANCER	45	37		
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN	66	55		
ROSS_AML_WITH_MLL_FUSIONS	78	61		
GRANDVAUX_IRF3_TARGETS_UP	15	14		
KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_UP	12	8		
LEE_LIVER_CANCER_MYC_E2F1_UP	56	51		
ASTON_MAJOR_DEPRESSIVE_DISORDER_UP	49	36		
LE_EGR2_TARGETS_UP	108	95		
FERNANDEZ_BOUND_BY_MYC	182	157		
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	151	130		
ROSS_AML_OF_FAB_M7_TYPE	68	62		
MOOTHA_VOXPHOS	87	79		
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN	51	45		
DER_IFN_GAMMA_RESPONSE_DN	11	8		
SANA_RESPONSE_TO_IFNG_UP	78	45		
SANA_TNF_SIGNALING_UP	83	56		
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_UP	47	33		
SCHUHMACHER_MYC_TARGETS_UP	80	69		
SWEET_KRAS_TARGETS_UP	84	71		
CHEOK_RESPONSE_TO_HD_MTX_UP	23	14		
MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_UP	22	17		
OKUMURA_INFLAMMATORY_RESPONSE_LPS	183	132		
SMITH_TERT_TARGETS_DN	87	75		
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN	45	37		
LEE_LIVER_CANCER_DENA_DN	74	57		
SANA_RESPONSE_TO_IFNG_DN	85	74		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_LD_MTX_DN	21	13		
LEE_LIVER_CANCER_MYC_DN	63	49		
LEE_LIVER_CANCER_CIPROFIBRATE_UP	60	54		
IIZUKA_LIVER_CANCER_PROGRESSION_L1_G1_UP	25	17		
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN	43	42		
LU_IL4_SIGNALING	94	76		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS	882		Rejected!	
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_FLI1	9	6		
MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_DN	24	20		
FERRANDO_LYL1_NEIGHBORS	15	15		
PENG_GLUCOSE_DEPRIVATION_DN	169	132		
VANTVEER_BREAST_CANCER_METASTASIS_UP	56	38		
COLLER_MYC_TARGETS_UP	25	22		
MANALO_HYPOXIA_UP	207	170		
REN_BOUND_BY_E2F	61	52		
WONG_IFNA2_RESISTANCE_DN	34	24		
DORSAM_HOXA9_TARGETS_DN	32	30		
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN	546	451		
YE_METASTATIC_LIVER_CANCER	27	20		
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_UP	45	42		
GRANDVAUX_IRF3_TARGETS_DN	19	15		
IIZUKA_LIVER_CANCER_EARLY_RECURRENCE	11	8		
RADAEVA_RESPONSE_TO_IFNA1_DN	10	6		
BECKER_TAMOXIFEN_RESISTANCE_DN	52	39		
PEART_HDAC_PROLIFERATION_CLUSTER_DN	76	68		
NING_CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE_UP	157	132		
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP	51	48		
SASAKI_ADULT_T_CELL_LEUKEMIA	176	146		
PENG_RAPAMYCIN_RESPONSE_DN	245	211		
COLLER_MYC_TARGETS_DN	9	8		
LEE_LIVER_CANCER_E2F1_DN	64	49		
LEE_LIVER_CANCER_DENA_UP	60	53		
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN	25	20		
PENG_RAPAMYCIN_RESPONSE_UP	203	157		
PENG_GLUTAMINE_DEPRIVATION_DN	337	282		
MAGRANGEAS_MULTIPLE_MYELOMA_IGLL_VS_IGLK_UP	42	37		
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP	63	56		
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP	555	448		
GOLDRATH_IMMUNE_MEMORY	65	57		
LEE_LIVER_CANCER_E2F1_UP	62	56		
ROSS_AML_WITH_AML1_ETO_FUSION	76	52		
BHATTACHARYA_EMBRYONIC_STEM_CELL	89	69		
OSAWA_TNF_TARGETS	10	7		
DER_IFN_GAMMA_RESPONSE_UP	71	59		
HASLINGER_B_CLL_WITH_17P13_DELETION	21	18		
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP	79	66		
ZHAN_MULTIPLE_MYELOMA_CD1_UP	45	38		
ABBUD_LIF_SIGNALING_1_DN	26	19		
SANSOM_APC_TARGETS_UP	126	97		
NAKAJIMA_EOSINOPHIL	30	21		
BROWN_MYELOID_CELL_DEVELOPMENT_UP	165	123		
NADLER_OBESITY_UP	61	53		
SANSOM_APC_TARGETS_DN	366	311		
ADDYA_ERYTHROID_DIFFERENTIATION_BY_HEMIN	73	61		
ZHANG_TARGETS_OF_EWSR1_FLI1_FUSION	88	69		
ZHAN_MULTIPLE_MYELOMA_SUBGROUPS	30	29		
SCHURINGA_STAT5A_TARGETS_UP	21	14		
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_UP	78	61		
MA_MYELOID_DIFFERENTIATION_DN	44	39		
GALINDO_IMMUNE_RESPONSE_TO_ENTEROTOXIN	85	73		
VERNELL_RETINOBLASTOMA_PATHWAY_DN	22	14		
HASLINGER_B_CLL_WITH_MUTATED_VH_GENES	18	15		
CROMER_METASTASIS_UP	79	62		
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN	51	40		
GUO_HEX_TARGETS_UP	81	67		
WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_DN	24	21		
ALCALAY_AML_BY_NPM1_LOCALIZATION_UP	140	111		
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP	48	40		
HEDVAT_ELF4_TARGETS_UP	12	7		
XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP	17	14		
STOSSI_RESPONSE_TO_ESTRADIOL	50	37		
YU_MYC_TARGETS_UP	42	34		
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_DN	73	51		
ABBUD_LIF_SIGNALING_2_UP	14	10		
PARK_HSC_MARKERS	44	39		
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP	87	69		
HOFMANN_CELL_LYMPHOMA_DN	39	33		
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_UP	66	54		
MATSUDA_NATURAL_KILLER_DIFFERENTIATION	475	393		
WANG_TARGETS_OF_MLL_CBP_FUSION_UP	44	34		
STONER_ESOPHAGEAL_CARCINOGENESIS_UP	39	28		
STONER_ESOPHAGEAL_CARCINOGENESIS_DN	7	5		
HASLINGER_B_CLL_WITH_13Q14_DELETION	24	17		
HOFMANN_CELL_LYMPHOMA_UP	50	38		
GUO_HEX_TARGETS_DN	65	52		
HSIAO_LIVER_SPECIFIC_GENES	244	191		
GILDEA_METASTASIS	30	22		
ZHAN_MULTIPLE_MYELOMA_SPIKED	22	16		
MUNSHI_MULTIPLE_MYELOMA_DN	11	7		
ASTIER_INTEGRIN_SIGNALING	59	47		
ZHAN_MULTIPLE_MYELOMA_LB_UP	48	30		
HASLINGER_B_CLL_WITH_11Q23_DELETION	23	19		
LEI_MYB_TARGETS	318	257		
BROWN_MYELOID_CELL_DEVELOPMENT_DN	129	101		
ROETH_TERT_TARGETS_DN	8	6		
NEMETH_INFLAMMATORY_RESPONSE_LPS_UP	88	77		
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_DN	163	140		
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN	77	67		
HALMOS_CEBPA_TARGETS_DN	46	39		
NADLER_OBESITY_DN	48	44		
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN	87	76		
WANG_IMMORTALIZED_BY_HOXA9_AND_MEIS1_UP	31	24		
NEMETH_INFLAMMATORY_RESPONSE_LPS_DN	32	28		
GALE_APL_WITH_FLT3_MUTATED_DN	17	12		
ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_UP	89	61		
NADLER_HYPERGLYCEMIA_AT_OBESITY	58	49		
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP	30	24		
ZHAN_MULTIPLE_MYELOMA_PR_UP	45	32		
HALMOS_CEBPA_TARGETS_UP	52	42		
YU_MYC_TARGETS_DN	55	41		
NUMATA_CSF3_SIGNALING_VIA_STAT3	22	18		
ZHAN_MULTIPLE_MYELOMA_UP	64	55		
LENAOUR_DENDRITIC_CELL_MATURATION_UP	114	93		
TAVOR_CEBPA_TARGETS_DN	30	24		
LENAOUR_DENDRITIC_CELL_MATURATION_DN	128	103		
WANG_TARGETS_OF_MLL_CBP_FUSION_DN	45	38		
HADDAD_B_LYMPHOCYTE_PROGENITOR	293	203		
PARK_HSC_AND_MULTIPOTENT_PROGENITORS	50	38		
GREENBAUM_E2A_TARGETS_DN	21	16		
NGUYEN_NOTCH1_TARGETS_UP	29	26		
ZHAN_MULTIPLE_MYELOMA_CD2_UP	45	32		
HASLINGER_B_CLL_WITH_CHROMOSOME_12_TRISOMY	24	20		
ABBUD_LIF_SIGNALING_1_UP	46	41		
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP	26	25		
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_UP	77	65		
GERY_CEBP_TARGETS	126	103		
VERHAAK_AML_WITH_NPM1_MUTATED_UP	183	136		
KANG_IMMORTALIZED_BY_TERT_UP	89	71		
BASSO_CD40_SIGNALING_DN	68	57		
ZHAN_MULTIPLE_MYELOMA_MF_UP	47	36		
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN	162	132		
JAIN_NFKB_SIGNALING	75	65		
ROETH_TERT_TARGETS_UP	14	11		
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_UP	131	111		
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP	182	162		
STAEGE_EWING_FAMILY_TUMOR	33	22		
GALE_APL_WITH_FLT3_MUTATED_UP	56	39		
AFFAR_YY1_TARGETS_UP	214	170		
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN	225	196		
AFFAR_YY1_TARGETS_DN	234	189		
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN	48	39		
VERNELL_RETINOBLASTOMA_PATHWAY_UP	70	61		
ALCALAY_AML_BY_NPM1_LOCALIZATION_DN	184	155		
KANG_IMMORTALIZED_BY_TERT_DN	102	78		
HESS_TARGETS_OF_HOXA9_AND_MEIS1_UP	65	54		
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_DN	19	12		
NGUYEN_NOTCH1_TARGETS_DN	86	73		
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP	412	279		
CHIARETTI_ACUTE_LYMPHOBLASTIC_LEUKEMIA_ZAP70	67	50		
PETROVA_PROX1_TARGETS_DN	64	52		
HOEGERKORP_CD44_TARGETS_DIRECT_DN	14	10		
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS	31	19		
XU_RESPONSE_TO_TRETINOIN_UP	16	14		
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_DN	19	18		
MENSE_HYPOXIA_UP	98	73		
MARCINIAK_ER_STRESS_RESPONSE_VIA_CHOP	25	21		
ZHAN_V2_LATE_DIFFERENTIATION_GENES	45	39		
DORSEY_GAB2_TARGETS	31	25		
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN	63	48		
NAKAJIMA_MAST_CELL	46	33		
LIAN_NEUTROPHIL_GRANULE_CONSTITUENTS	25	16		
ZHAN_MULTIPLE_MYELOMA_MS_UP	48	35		
MA_MYELOID_DIFFERENTIATION_UP	39	36		
RADMACHER_AML_PROGNOSIS	78	63		
CROMER_METASTASIS_DN	81	62		
NOUZOVA_METHYLATED_IN_APL	68	36		
ZHAN_MULTIPLE_MYELOMA_HP_UP	49	36		
XU_RESPONSE_TO_TRETINOIN_DN	13	10		
TAVOR_CEBPA_TARGETS_UP	48	40		
YAGI_AML_SURVIVAL	129	103		
XU_CREBBP_TARGETS_UP	26	22		
VERHAAK_AML_WITH_NPM1_MUTATED_DN	246	185		
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_DN	30	21		
APPEL_IMATINIB_RESPONSE	33	29		
YAGI_AML_FAB_MARKERS	191	158		
ZHAN_MULTIPLE_MYELOMA_CD1_VS_CD2_DN	52	35		
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_DN	172	130		
ABBUD_LIF_SIGNALING_2_DN	7		Rejected!	
XU_CREBBP_TARGETS_DN	44	33		
IGLESIAS_E2F_TARGETS_DN	16	9		
HOEGERKORP_CD44_TARGETS_TEMPORAL_UP	13	9		
SCHURINGA_STAT5A_TARGETS_DN	18	11		
HOEGERKORP_CD44_TARGETS_TEMPORAL_DN	25	18		
IGLESIAS_E2F_TARGETS_UP	151	136		
MUNSHI_MULTIPLE_MYELOMA_UP	81	75		
KAMMINGA_EZH2_TARGETS	41	40		
ZHAN_MULTIPLE_MYELOMA_DN	41	31		
BASSO_CD40_SIGNALING_UP	101	83		
HASLINGER_B_CLL_WITH_6Q21_DELETION	20	13		
HANSON_HRAS_SIGNALING_VIA_NFKB	22	14		
FAELT_B_CLL_WITH_VH3_21_DN	49	42		
GREENBAUM_E2A_TARGETS_UP	33	27		
XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_DN	15	12		
NOUZOVA_TRETINOIN_AND_H4_ACETYLATION	143	97		
BRUNO_HEMATOPOIESIS	66	55		
MOREAUX_B_LYMPHOCYTE_MATURATION_BY_TACI_UP	92	60		
PETROVA_PROX1_TARGETS_UP	28	24		
HOEGERKORP_CD44_TARGETS_DIRECT_UP	27	23		
KUMAR_TARGETS_OF_MLL_AF9_FUSION	405	312		
FAELT_B_CLL_WITH_VH3_21_UP	44	38		
SESTO_RESPONSE_TO_UV_C8	72	66		
KIM_HYPOXIA	25	20		
GENTILE_UV_RESPONSE_CLUSTER_D9	28	17		
LIANG_SILENCED_BY_METHYLATION_2	53	32		
IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR	532	391		
LY_AGING_PREMATURE_DN	30	25		
MARTINEZ_RESPONSE_TO_TRABECTEDIN	50	44		
WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2	36	30		
BROWNE_HCMV_INFECTION_20HR_UP	240	182		
TAKAO_RESPONSE_TO_UVB_RADIATION_UP	86	73		
URS_ADIPOCYTE_DIFFERENTIATION_UP	74	62		
LEE_AGING_NEOCORTEX_DN	80	56		
REN_ALVEOLAR_RHABDOMYOSARCOMA_UP	98	78		
REN_ALVEOLAR_RHABDOMYOSARCOMA_DN	408	380		
TRAYNOR_RETT_SYNDROM_UP	45	32		
MCCLUNG_DELTA_FOSB_TARGETS_8WK	47	40		
BRACHAT_RESPONSE_TO_METHOTREXATE_DN	27	22		
BROWNE_HCMV_INFECTION_16HR_UP	225	181		
MODY_HIPPOCAMPUS_POSTNATAL	63	52		
IYENGAR_RESPONSE_TO_ADIPOCYTE_FACTORS	10	9		
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN	43	34		
BURTON_ADIPOGENESIS_10	30	26		
ABE_VEGFA_TARGETS_2HR	34	23		
SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1A	23	18		
NATSUME_RESPONSE_TO_INTERFERON_BETA_UP	71	57		
BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_UP	390	305		
IVANOVA_HEMATOPOIESIS_MATURE_CELL	293	216		
DAZARD_UV_RESPONSE_CLUSTER_G3	15	11		
SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_UP	42	26		
WEBER_METHYLATED_IN_COLON_CANCER	18	11		
KAAB_FAILED_HEART_ATRIUM_DN	141	118		
SU_PANCREAS	54	30		
RUAN_RESPONSE_TO_TROGLITAZONE_UP	25	23		
WU_HBX_TARGETS_2_DN	16	11		
ZAMORA_NOS2_TARGETS_UP	69	59		
JIANG_AGING_CEREBRAL_CORTEX_UP	36	31		
WEIGEL_OXIDATIVE_STRESS_RESPONSE	35	29		
HEDENFALK_BREAST_CANCER_HEREDITARY_VS_SPORADIC	50	38		
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP	314	236		
BRACHAT_RESPONSE_TO_CISPLATIN	22	15		
IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR	544	398		
LU_AGING_BRAIN_DN	153	120		
RUAN_RESPONSE_TO_TNF_UP	12	10		
WHITESIDE_CISPLATIN_RESISTANCE_UP	11	11		
LEE_CALORIE_RESTRICTION_NEOCORTEX_UP	83	61		
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_DN	64	49		
IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM	302	221		
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_H2O2	39	38		
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR	37	30		
ZHOU_TNF_SIGNALING_4HR	54	46		
MARCHINI_TRABECTEDIN_RESISTANCE_UP	21	17		
GENTILE_UV_LOW_DOSE_UP	27	25		
BLALOCK_ALZHEIMERS_DISEASE_DN	1237		Rejected!	
BROWNE_HCMV_INFECTION_16HR_DN	86	67		
WESTON_VEGFA_TARGETS_6HR	59	53		
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_24HR_UP	14	11		
RAMALHO_STEMNESS_DN	74	60		
ONGUSAHA_TP53_TARGETS	38	33		
GENTILE_UV_RESPONSE_CLUSTER_D4	55	46		
RHODES_CANCER_META_SIGNATURE	64	56		
NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_UP	18	18		
LIAN_LIPA_TARGETS_6M	74	63		
WU_HBX_TARGETS_1_DN	23	20		
NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_DN	20	16		
HARRIS_HYPOXIA	81	64		
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_DN	42	40		
SU_SALIVARY_GLAND	16	6		
BROWNE_HCMV_INFECTION_10HR_DN	56	43		
KAYO_CALORIE_RESTRICTION_MUSCLE_DN	87	65		
HENDRICKS_SMARCA4_TARGETS_UP	56	45		
ZHENG_RESPONSE_TO_ARSENITE_DN	18	16		
MURAKAMI_UV_RESPONSE_6HR_DN	21	15		
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_DN	42	35		
RAMALHO_STEMNESS_UP	206	172		
MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_7	19	11		
MCDOWELL_ACUTE_LUNG_INJURY_UP	45	40		
SESTO_RESPONSE_TO_UV_C4	20	14		
WANG_SMARCE1_TARGETS_DN	371	270		
SU_TESTIS	76	56		
TRAYNOR_RETT_SYNDROM_DN	19	13		
SESTO_RESPONSE_TO_UV_C6	39	34		
MCCLUNG_CREB1_TARGETS_DN	57	41		
RODWELL_AGING_KIDNEY_NO_BLOOD_DN	150	116		
INGRAM_SHH_TARGETS	7	6		
SUZUKI_RESPONSE_TO_TSA_AND_DECITABINE_1B	23	12		
SESTO_RESPONSE_TO_UV_C2	54	40		
KAAB_HEART_ATRIUM_VS_VENTRICLE_UP	249	198		
HU_GENOTOXIC_DAMAGE_24HR	35	29		
NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_UP	19	13		
CUI_TCF21_TARGETS_UP	37	31		
HEDENFALK_BREAST_CANCER_BRACX_UP	20	17		
GEISS_RESPONSE_TO_DSRNA_DN	16	13		
CUI_TCF21_TARGETS_2_DN	830		Rejected!	
VIETOR_IFRD1_TARGETS	23	17		
PAL_PRMT5_TARGETS_UP	203	169		
VARELA_ZMPSTE24_TARGETS_DN	38	30		
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2	50	33		
ZHANG_RESPONSE_TO_CANTHARIDIN_UP	19	17		
HEDENFALK_BREAST_CANCER_BRACX_DN	20	17		
JIANG_AGING_HYPOTHALAMUS_DN	40	39		
CHANG_IMMORTALIZED_BY_HPV31_DN	65	46		
BROWNE_HCMV_INFECTION_24HR_DN	148	120		
MARIADASON_RESPONSE_TO_BUTYRATE_CURCUMIN_SULINDAC_TSA_8	16	12		
CHIBA_RESPONSE_TO_TSA_UP	52	46		
RAMASWAMY_METASTASIS_DN	61	41		
MODY_HIPPOCAMPUS_NEONATAL	35	30		
MCCLUNG_COCAINE_REWARD_5D	79	67		
KAYO_AGING_MUSCLE_UP	244	171		
VISALA_RESPONSE_TO_HEAT_SHOCK_AND_AGING_UP	15	11		
CHUANG_OXIDATIVE_STRESS_RESPONSE_DN	11	10		
BROWNE_HCMV_INFECTION_14HR_DN	298	227		
DELASERNA_MYOD_TARGETS_DN	57	50		
YAMAZAKI_TCEB3_TARGETS_UP	175	152		
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_24HR	55	41		
JIANG_VHL_TARGETS	138	105		
MACLACHLAN_BRCA1_TARGETS_DN	16	14		
LEE_AGING_CEREBELLUM_DN	86	65		
EHRLICH_ICF_SYNDROM_UP	13	10		
BROWNE_INTERFERON_RESPONSIVE_GENES	68	51		
MCCLUNG_DELTA_FOSB_TARGETS_2WK	48	30		
CUI_TCF21_TARGETS_DN	31	25		
SU_THYMUS	20	15		
KANG_FLUOROURACIL_RESISTANCE_DN	16	14		
NIELSEN_LIPOSARCOMA_DN	19	19		
BROWNE_HCMV_INFECTION_8HR_UP	105	82		
MARTINEZ_RESPONSE_TO_TRABECTEDIN_UP	71	59		
JI_RESPONSE_TO_FSH_DN	58	50		
WESTON_VEGFA_TARGETS_12HR	35	34		
KRASNOSELSKAYA_ILF3_TARGETS_UP	38	27		
CHUANG_OXIDATIVE_STRESS_RESPONSE_UP	28	23		
KEEN_RESPONSE_TO_ROSIGLITAZONE_UP	38	32		
NATSUME_RESPONSE_TO_INTERFERON_BETA_DN	52	41		
BAELDE_DIABETIC_NEPHROPATHY_UP	86	66		
LINDVALL_IMMORTALIZED_BY_TERT_UP	78	68		
WU_HBX_TARGETS_3_UP	18	16		
WANG_CISPLATIN_RESPONSE_AND_XPC_DN	228	177		
MURAKAMI_UV_RESPONSE_6HR_UP	37	30		
BROWNE_HCMV_INFECTION_20HR_DN	101	86		
SIMBULAN_PARP1_TARGETS_UP	31	29		
ULE_SPLICING_VIA_NOVA2	43	30		
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_DN	54	39		
IVANOVA_HEMATOPOIESIS_STEM_CELL	254	186		
KUNINGER_IGF1_VS_PDGFB_TARGETS_DN	46	34		
MEDINA_SMARCA4_TARGETS	44	36		
KANG_FLUOROURACIL_RESISTANCE_UP	22	20		
MAHAJAN_RESPONSE_TO_IL1A_DN	76	60		
RUAN_RESPONSE_TO_TNF_DN	84	79		
BLALOCK_ALZHEIMERS_DISEASE_UP	1691		Rejected!	
DELASERNA_MYOD_TARGETS_UP	89	71		
BURTON_ADIPOGENESIS_12	36	20		
LEONARD_HYPOXIA	47	37		
KAYO_AGING_MUSCLE_DN	123	99		
KAAB_FAILED_HEART_ATRIUM_UP	38	26		
NIELSEN_LIPOSARCOMA_UP	18	15		
INGA_TP53_TARGETS	17	15		
MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_UP	83	63		
DASU_IL6_SIGNALING_SCAR_UP	30	27		
LINDVALL_IMMORTALIZED_BY_TERT_DN	80	69		
DAZARD_RESPONSE_TO_UV_SCC_DN	123	98		
CHIBA_RESPONSE_TO_TSA	50	41		
RODWELL_AGING_KIDNEY_DN	145	109		
YIH_RESPONSE_TO_ARSENITE_C2	18	15		
KANG_DOXORUBICIN_RESISTANCE_UP	54	46		
BROWNE_HCMV_INFECTION_48HR_DN	504	385		
BROWNE_HCMV_INFECTION_48HR_UP	180	144		
MA_PITUITARY_FETAL_VS_ADULT_DN	19	13		
BURTON_ADIPOGENESIS_5	126	98		
WESTON_VEGFA_TARGETS	108	91		
CHEN_LVAD_SUPPORT_OF_FAILING_HEART_UP	103	80		
BROWNE_HCMV_INFECTION_8HR_DN	47	32		
APRELIKOVA_BRCA1_TARGETS	49	42		
VERRECCHIA_RESPONSE_TO_TGFB1_C2	25	24		
KIM_GASTRIC_CANCER_CHEMOSENSITIVITY	103	71		
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_DN	33	26		
GENTILE_UV_RESPONSE_CLUSTER_D5	39	28		
BRACHAT_RESPONSE_TO_METHOTREXATE_UP	26	18		
RHODES_UNDIFFERENTIATED_CANCER	69	63		
BROWNE_HCMV_INFECTION_14HR_UP	156	119		
YAMAZAKI_TCEB3_TARGETS_DN	215	166		
LEE_CALORIE_RESTRICTION_MUSCLE_UP	43	32		
MACLACHLAN_BRCA1_TARGETS_UP	21	19		
VERRECCHIA_RESPONSE_TO_TGFB1_C1	19	18		
GAJATE_RESPONSE_TO_TRABECTEDIN_DN	19	18		
LEE_AGING_MUSCLE_DN	46	36		
ZHANG_PROLIFERATING_VS_QUIESCENT	51	48		
GAJATE_RESPONSE_TO_TRABECTEDIN_UP	67	54		
VERRECCHIA_RESPONSE_TO_TGFB1_C5	21	20		
GERHOLD_ADIPOGENESIS_DN	64	52		
LU_AGING_BRAIN_UP	262	215		
BURTON_ADIPOGENESIS_3	101	90		
DAZARD_RESPONSE_TO_UV_NHEK_UP	244	179		
LIAN_LIPA_TARGETS_3M	59	52		
ZHU_CMV_ALL_UP	120	97		
MA_PITUITARY_FETAL_VS_ADULT_UP	29	21		
BURTON_ADIPOGENESIS_8	86	73		
DELLA_RESPONSE_TO_TSA_AND_BUTYRATE	21	21		
RUAN_RESPONSE_TO_TNF_TROGLITAZONE_UP	17	15		
BURTON_ADIPOGENESIS_2	72	66		
VERRECCHIA_EARLY_RESPONSE_TO_TGFB1	58	55		
XU_GH1_EXOGENOUS_TARGETS_UP	85	49		
ZHU_CMV_8_HR_DN	53	43		
ZHU_CMV_24_HR_DN	91	77		
WU_HBX_TARGETS_3_DN	13	11		
SU_KIDNEY	15	6		
GENTILE_UV_RESPONSE_CLUSTER_D2	41	34		
PAL_PRMT5_TARGETS_DN	29	23		
VISALA_AGING_LYMPHOCYTE_DN	19	14		
SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER	49	31		
CHEN_ETV5_TARGETS_SERTOLI	20	13		
BROWNE_HCMV_INFECTION_18HR_DN	178	135		
MOREIRA_RESPONSE_TO_TSA_UP	28	26		
IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM	32	22		
TAKAO_RESPONSE_TO_UVB_RADIATION_DN	98	81		
YIH_RESPONSE_TO_ARSENITE_C4	18	17		
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP	30	23		
MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_4	21	15		
ZHENG_RESPONSE_TO_ARSENITE_UP	18	10		
DAZARD_UV_RESPONSE_CLUSTER_G4	21	13		
GENTILE_UV_RESPONSE_CLUSTER_D7	40	33		
EHRLICH_ICF_SYNDROM_DN	15	12		
KAAB_HEART_ATRIUM_VS_VENTRICLE_DN	261	213		
GENTILE_UV_RESPONSE_CLUSTER_D6	37	25		
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1	39	37		
BROWNE_HCMV_INFECTION_18HR_UP	178	144		
LEE_AGING_NEOCORTEX_UP	89	78		
ZHANG_RESPONSE_TO_CANTHARIDIN_DN	69	59		
BURTON_ADIPOGENESIS_PEAK_AT_24HR	43	35		
SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_UP	34	29		
MULLIGAN_NTF3_SIGNALING_VIA_INSR_AND_IGF1R_UP	23	21		
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_UP	28	22		
GENTILE_UV_HIGH_DOSE_DN	312	249		
GEORGANTAS_HSC_MARKERS	71	51		
HENDRICKS_SMARCA4_TARGETS_DN	53	37		
HAN_JNK_SINGALING_UP	35	31		
KANG_DOXORUBICIN_RESISTANCE_DN	19	15		
SESTO_RESPONSE_TO_UV_C0	107	95		
MCLACHLAN_DENTAL_CARIES_DN	245	167		
BURTON_ADIPOGENESIS_PEAK_AT_2HR	51	46		
CHEN_PDGF_TARGETS	19	15		
MCCLUNG_CREB1_TARGETS_UP	100	70		
LEE_AGING_CEREBELLUM_UP	84	71		
WEIGEL_OXIDATIVE_STRESS_BY_HNE_AND_TBH	60	52		
TSENG_IRS1_TARGETS_DN	135	112		
RODWELL_AGING_KIDNEY_NO_BLOOD_UP	222	164		
RODWELL_AGING_KIDNEY_UP	487	346		
MCCLUNG_COCAIN_REWARD_4WK	75	60		
ZHOU_TNF_SIGNALING_30MIN	54	45		
WELCSH_BRCA1_TARGETS_UP	198	164		
JACKSON_DNMT1_TARGETS_UP	77	72		
CHANG_IMMORTALIZED_BY_HPV31_UP	84	58		
MODY_HIPPOCAMPUS_PRENATAL	42	35		
BURTON_ADIPOGENESIS_4	48	38		
ZHU_CMV_ALL_DN	128	107		
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR	149	103		
GENTILE_UV_HIGH_DOSE_UP	25	20		
SU_LIVER	55	42		
CHIBA_RESPONSE_TO_TSA_DN	23	20		
KUNINGER_IGF1_VS_PDGFB_TARGETS_UP	82	58		
BLALOCK_ALZHEIMERS_DISEASE_INCIPIENT_DN	165	142		
LIANG_SILENCED_BY_METHYLATION_UP	32	21		
SONG_TARGETS_OF_IE86_CMV_PROTEIN	60	56		
LEE_CALORIE_RESTRICTION_NEOCORTEX_DN	88	75		
CUI_TCF21_TARGETS_2_UP	428	338		
SESTO_RESPONSE_TO_UV_C1	72	55		
LY_AGING_MIDDLE_UP	14	9		
WENG_POR_TARGETS_GLOBAL_UP	20	15		
WU_HBX_TARGETS_1_UP	16	12		
GEISS_RESPONSE_TO_DSRNA_UP	38	33		
ABE_VEGFA_TARGETS	20	15		
MMS_MOUSE_LYMPH_HIGH_4HRS_UP	36	31		
BURTON_ADIPOGENESIS_1	33	28		
LIANG_SILENCED_BY_METHYLATION_DN	11	9		
MOREIRA_RESPONSE_TO_TSA_DN	18	17		
WENG_POR_TARGETS_GLOBAL_DN	23	20		
BURTON_ADIPOGENESIS_7	51	45		
KEEN_RESPONSE_TO_ROSIGLITAZONE_DN	106	94		
BROWNE_HCMV_INFECTION_10HR_UP	101	74		
LIU_SMARCA4_TARGETS	64	44		
HEDENFALK_BREAST_CANCER_BRCA1_VS_BRCA2	163	138		
GENTILE_UV_RESPONSE_CLUSTER_D1	18	13		
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN	287	239		
RAMPON_ENRICHED_LEARNING_ENVIRONMENT_EARLY_UP	15	11		
SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_DN	18	16		
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN	51	47		
SCHLINGEMANN_SKIN_CARCINOGENESIS_TPA_DN	29	23		
DELASERNA_TARGETS_OF_MYOD_AND_SMARCA4	11	9		
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN	46	35		
WHITESIDE_CISPLATIN_RESISTANCE_DN	13	11		
BURTON_ADIPOGENESIS_PEAK_AT_0HR	63	54		
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP	49	43		
JACKSON_DNMT1_TARGETS_DN	25	20		
DAZARD_RESPONSE_TO_UV_NHEK_DN	318	244		
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_UP	18	16		
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6	17	14		
KALMA_E2F1_TARGETS	11	11		
VERRECCHIA_RESPONSE_TO_TGFB1_C4	13	12		
ZHU_CMV_24_HR_UP	93	76		
NIELSEN_GIST_AND_SYNOVIAL_SARCOMA_UP	20	14		
BURTON_ADIPOGENESIS_11	57	45		
BROWNE_HCMV_INFECTION_12HR_UP	111	80		
NIELSEN_SCHWANNOMA_UP	18	15		
IVANOVA_HEMATOPOIESIS_STEM_CELL_AND_PROGENITOR	681	474		
RAMASWAMY_METASTASIS_UP	66	50		
DAZARD_RESPONSE_TO_UV_SCC_UP	123	100		
KAYO_CALORIE_RESTRICTION_MUSCLE_UP	95	75		
JIANG_HYPOXIA_NORMAL	311	257		
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_48HR_DN	32	28		
ABE_INNER_EAR	48	35		
MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_5	23	21		
TSENG_IRS1_TARGETS_UP	113	88		
SARTIPY_BLUNTED_BY_INSULIN_RESISTANCE_UP	19	16		
XU_GH1_AUTOCRINE_TARGETS_UP	268	156		
XU_GH1_EXOGENOUS_TARGETS_DN	120	76		
BAELDE_DIABETIC_NEPHROPATHY_DN	434	362		
BROWNE_HCMV_INFECTION_6HR_UP	71	50		
DAZARD_UV_RESPONSE_CLUSTER_G1	67	51		
LY_AGING_OLD_DN	56	49		
WENG_POR_DOSAGE	21	16		
MURAKAMI_UV_RESPONSE_24HR	20	14		
SEMENZA_HIF1_TARGETS	36	30		
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN	60	42		
WANG_CISPLATIN_RESPONSE_AND_XPC_UP	202	156		
VARELA_ZMPSTE24_TARGETS_UP	40	33		
YIH_RESPONSE_TO_ARSENITE_C3	36	33		
SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER	50	29		
CHENG_RESPONSE_TO_NICKEL_ACETATE	45	33		
TSENG_ADIPOGENIC_POTENTIAL_DN	46	42		
DAZARD_UV_RESPONSE_CLUSTER_G6	153	114		
NIELSEN_LEIOMYOSARCOMA_CNN1_UP	19	16		
XU_GH1_AUTOCRINE_TARGETS_DN	142	108		
SESTO_RESPONSE_TO_UV_C7	68	55		
KAAB_FAILED_HEART_VENTRICLE_DN	41	34		
JIANG_HYPOXIA_CANCER	83	64		
ZAMORA_NOS2_TARGETS_DN	96	84		
YIH_RESPONSE_TO_ARSENITE_C1	24	22		
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_DN	161	114		
BURTON_ADIPOGENESIS_PEAK_AT_8HR	39	34		
SIMBULAN_PARP1_TARGETS_DN	17	17		
SAFFORD_T_LYMPHOCYTE_ANERGY	87	75		
WU_HBX_TARGETS_2_UP	23	21		
SESTO_RESPONSE_TO_UV_C5	46	42		
LI_ADIPOGENESIS_BY_ACTIVATED_PPARG	17	16		
NIELSEN_LEIOMYOSARCOMA_UP	18	15		
LY_AGING_MIDDLE_DN	16	16		
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_UP	26	17		
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1	419	285		
WENG_POR_TARGETS_LIVER_UP	41	31		
HU_GENOTOXIC_DAMAGE_4HR	35	32		
MCDOWELL_ACUTE_LUNG_INJURY_DN	48	36		
RAMPON_ENRICHED_LEARNING_ENVIRONMENT_LATE_UP	22	19		
MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_6	52	39		
GENTILE_UV_LOW_DOSE_DN	67	56		
SARTIPY_NORMAL_AT_INSULIN_RESISTANCE_DN	21	16		
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_48HR_UP	18	12		
GENTILE_UV_RESPONSE_CLUSTER_D8	40	34		
BROWNE_HCMV_INFECTION_24HR_UP	148	119		
WANG_SMARCE1_TARGETS_UP	280	214		
SESTO_RESPONSE_TO_UV_C3	20	19		
HAN_JNK_SINGALING_DN	39	33		
KRASNOSELSKAYA_ILF3_TARGETS_DN	46	32		
GENTILE_RESPONSE_CLUSTER_D3	61	53		
JI_RESPONSE_TO_FSH_UP	74	59		
LEE_CALORIE_RESTRICTION_MUSCLE_DN	51	45		
ABE_VEGFA_TARGETS_30MIN	29	19		
BROWNE_HCMV_INFECTION_6HR_DN	160	123		
LEE_AGING_MUSCLE_UP	45	36		
CARDOSO_RESPONSE_TO_GAMMA_RADIATION_AND_3AB	18	14		
MULLIGAN_NTF3_SIGNALING_VIA_INSR_AND_IGF1R_DN	13	9		
SASSON_FSH_RESPONSE	9	6		
CHEN_ETV5_TARGETS_TESTIS	23	15		
ZHU_CMV_8_HR_UP	47	36		
WELCSH_BRCA1_TARGETS_DN	141	116		
DASU_IL6_SIGNALING_SCAR_DN	16	13		
JIANG_AGING_CEREBRAL_CORTEX_DN	54	45		
MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN	271	219		
BURTON_ADIPOGENESIS_9	92	81		
URS_ADIPOCYTE_DIFFERENTIATION_DN	30	26		
TRACEY_RESISTANCE_TO_IFNA2_DN	32	23		
VISALA_RESPONSE_TO_HEAT_SHOCK_AND_AGING_DN	14	12		
BROWNE_HCMV_INFECTION_12HR_DN	101	70		
MAHAJAN_RESPONSE_TO_IL1A_UP	81	63		
JIANG_AGING_HYPOTHALAMUS_UP	47	42		
KYNG_RESPONSE_TO_H2O2	71	59		
DAZARD_UV_RESPONSE_CLUSTER_G2	30	23		
VERRECCHIA_RESPONSE_TO_TGFB1_C3	14	13		
WESTON_VEGFA_TARGETS_3HR	74	60		
TSENG_ADIPOGENIC_POTENTIAL_UP	30	23		
JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP	31	24		
MCLACHLAN_DENTAL_CARIES_UP	253	172		
GERHOLD_ADIPOGENESIS_UP	49	45		
WENG_POR_TARGETS_LIVER_DN	20	18		
SU_PLACENTA	30	15		
BURTON_ADIPOGENESIS_6	189	163		
SUZUKI_RESPONSE_TO_TSA	22	14		
BURTON_ADIPOGENESIS_PEAK_AT_16HR	40	37		
MARCHINI_TRABECTEDIN_RESISTANCE_DN	49	43		
BILD_MYC_ONCOGENIC_SIGNATURE	206	147		
BILD_E2F3_ONCOGENIC_SIGNATURE	246	177		
BILD_HRAS_ONCOGENIC_SIGNATURE	261	198		
BILD_SRC_ONCOGENIC_SIGNATURE	62	50		
BILD_CTNNB1_ONCOGENIC_SIGNATURE	82	57		
DOUGLAS_BMI1_TARGETS_UP	566	433		
DOUGLAS_BMI1_TARGETS_DN	314	233		
KRIGE_AMINO_ACID_DEPRIVATION	29	25		
KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP	953		Rejected!	
KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN	911		Rejected!	
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP	783		Rejected!	
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_DN	1011		Rejected!	
GHO_ATF5_TARGETS_UP	13	9		
GHO_ATF5_TARGETS_DN	16	14		
DURCHDEWALD_SKIN_CARCINOGENESIS_UP	88	61		
DURCHDEWALD_SKIN_CARCINOGENESIS_DN	264	207		
LI_CYTIDINE_ANALOGS_CYCTOTOXICITY	15	13		
LI_CYTIDINE_ANALOG_PATHWAY	17	14		
KIM_LRRC3B_TARGETS	30	17		
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_MACROPHAGE	77	70		
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_ENDOTHELIUM	66	57		
ZHONG_SECRETOME_OF_LUNG_CANCER_AND_FIBROBLAST	132	115		
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_UP	20	19		
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN	36	32		
YANG_MUC2_TARGETS_DUODENUM_3MO_DN	23	17		
YANG_MUC2_TARGETS_DUODENUM_6MO_UP	10	6		
YANG_MUC2_TARGETS_DUODENUM_6MO_DN	21	14		
YANG_MUC2_TARGETS_COLON_3MO_DN	6		Rejected!	
MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP	393	300		
MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN	373	281		
MCCOLLUM_GELDANAMYCIN_RESISTANCE_UP	10	7		
MCCOLLUM_GELDANAMYCIN_RESISTANCE_DN	7	5		
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1	528	369		
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2	473	231		
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3	720		Rejected!	
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4	307	213		
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5	482	344		
MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_UP	10	5		
MILICIC_FAMILIAL_ADENOMATOUS_POLYPOSIS_DN	10		Rejected!	
SINGH_NFE2L2_TARGETS	15	13		
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_UP	64	58		
PELLICCIOTTA_HDAC_IN_ANTIGEN_PRESENTATION_DN	49	44		
LOPES_METHYLATED_IN_COLON_CANCER_UP	27	18		
LOPES_METHYLATED_IN_COLON_CANCER_DN	28	22		
HARRIS_BRAIN_CANCER_PROGENITORS	44	31		
TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_UP	18	10		
TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_DN	17	15		
BAFNA_MUC4_TARGETS_UP	7	6		
BAFNA_MUC4_TARGETS_DN	5		Rejected!	
HOWLIN_CITED1_TARGETS_1_UP	35	22		
HOWLIN_CITED1_TARGETS_1_DN	37	30		
HOWLIN_CITED1_TARGETS_2_UP	17	12		
HOWLIN_CITED1_TARGETS_2_DN	17	15		
HILLION_HMGA1_TARGETS	90	72		
HILLION_HMGA1B_TARGETS	92	80		
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP	77	57		
LEIN_NEURON_MARKERS	69	51		
LEIN_ASTROCYTE_MARKERS	42	33		
LEIN_OLIGODENDROCYTE_MARKERS	74	51		
LEIN_CHOROID_PLEXUS_MARKERS	103	80		
LEIN_MIDBRAIN_MARKERS	82	55		
LEIN_PONS_MARKERS	89	68		
LEIN_MEDULLA_MARKERS	81	58		
LEIN_CEREBELLUM_MARKERS	85	60		
LEIN_LOCALIZED_TO_DISTAL_AND_PROXIMAL_DENDRITES	17	12		
LEIN_LOCALIZED_TO_PROXIMAL_DENDRITES	37	29		
GAVIN_FOXP3_TARGETS_CLUSTER_T4	94	76		
GAVIN_FOXP3_TARGETS_CLUSTER_T7	98	81		
GAVIN_FOXP3_TARGETS_CLUSTER_P2	79	57		
GAVIN_FOXP3_TARGETS_CLUSTER_P3	160	130		
GAVIN_FOXP3_TARGETS_CLUSTER_P4	100	80		
GAVIN_FOXP3_TARGETS_CLUSTER_P6	91	75		
GAVIN_FOXP3_TARGETS_CLUSTER_P7	90	73		
GAVIN_PDE3B_TARGETS	22	19		
GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_UP	19	16		
GAVIN_IL2_RESPONSIVE_FOXP3_TARGETS_DN	5	5		
ZHENG_BOUND_BY_FOXP3	491	376		
MARSON_BOUND_BY_FOXP3_STIMULATED	1022		Rejected!	
MARSON_BOUND_BY_FOXP3_UNSTIMULATED	1229		Rejected!	
MARSON_BOUND_BY_E2F4_UNSTIMULATED	728		Rejected!	
MARSON_FOXP3_TARGETS_STIMULATED_UP	29	23		
MARSON_FOXP3_TARGETS_STIMULATED_DN	11	8		
MARSON_FOXP3_CORE_DIRECT_TARGETS	19	16		
ZHENG_FOXP3_TARGETS_IN_THYMUS_UP	196	153		
ZHENG_FOXP3_TARGETS_IN_THYMUS_DN	12	7		
ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_UP	12	10		
ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN	37	30		
ZHENG_FOXP3_TARGETS_UP	26	21		
ZHENG_FOXP3_TARGETS_DN	5		Rejected!	
SANSOM_APC_TARGETS	212	143		
SANSOM_APC_MYC_TARGETS	217	166		
SANSOM_APC_TARGETS_REQUIRE_MYC	210	157		
SANSOM_WNT_PATHWAY_REQUIRE_MYC	58	52		
YEGNASUBRAMANIAN_PROSTATE_CANCER	128	76		
RIGGINS_TAMOXIFEN_RESISTANCE_UP	66	58		
RIGGINS_TAMOXIFEN_RESISTANCE_DN	220	171		
NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER	22	14		
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP	31	21		
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN	41	36		
STEIN_ESRRA_TARGETS_UP	388	299		
STEIN_ESRRA_TARGETS_DN	105	77		
WANG_LSD1_TARGETS_UP	24	16		
WANG_LSD1_TARGETS_DN	39	30		
FOSTER_TOLERANT_MACROPHAGE_UP	156	132		
FOSTER_TOLERANT_MACROPHAGE_DN	409	335		
TESAR_ALK_TARGETS_EPISC_3D_UP	7		Rejected!	
TESAR_ALK_TARGETS_EPISC_4D_UP	7	5		
TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_UP	5		Rejected!	
TESAR_ALK_AND_JAK_TARGETS_MOUSE_ES_D4_DN	6		Rejected!	
TESAR_JAK_TARGETS_MOUSE_ES_D3_UP	7		Rejected!	
TESAR_JAK_TARGETS_MOUSE_ES_D3_DN	9	6		
JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN	17	16		
JI_CARCINOGENESIS_BY_KRAS_AND_STK11_UP	12	5		
GAZIN_EPIGENETIC_SILENCING_BY_KRAS	26	22		
JEPSEN_SMRT_TARGETS	33	28		
KYNG_DNA_DAMAGE_BY_4NQO	38	30		
KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION	81	66		
KYNG_DNA_DAMAGE_BY_UV	62	55		
KYNG_DNA_DAMAGE_BY_4NQO_OR_GAMMA_RADIATION	15	13		
KYNG_DNA_DAMAGE_BY_4NQO_OR_UV	63	54		
KYNG_DNA_DAMAGE_BY_GAMMA_AND_UV_RADIATION	88	77		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_4NQO_IN_OLD	13	11		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_4NQO_IN_WS	40	30		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_OLD	31	26		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS	33	26		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_UV_IN_OLD	25	20		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_UV_IN_WS	12	9		
KYNG_DNA_DAMAGE_DN	195	165		
KYNG_DNA_DAMAGE_UP	226	190		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_UP	56	48		
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN	21	15		
KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3	97	51		
KONDO_PROSTATE_CANCER_WITH_H3K27ME3	196	79		
KONDO_COLON_CANCER_HCP_WITH_H3K27ME1	26	15		
KONDO_COLON_CANCER_HCP_WITH_H3K27ME3	7		Rejected!	
KONDO_EZH2_TARGETS	245	155		
LEE_LIVER_CANCER	49	34		
ZHANG_GATA6_TARGETS_UP	15	11		
ZHANG_GATA6_TARGETS_DN	64	54		
MCGOWAN_RSP6_TARGETS_UP	18	14		
MCGOWAN_RSP6_TARGETS_DN	5		Rejected!	
KANG_CISPLATIN_RESISTANCE_UP	19	16		
KANG_CISPLATIN_RESISTANCE_DN	8	5		
STEARMAN_TUMOR_FIELD_EFFECT_UP	36	31		
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_UP	125	100		
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN	61	50		
HELLER_SILENCED_BY_METHYLATION_UP	282	195		
HELLER_SILENCED_BY_METHYLATION_DN	105	83		
HELLER_HDAC_TARGETS_UP	317	236		
HELLER_HDAC_TARGETS_DN	292	227		
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP	461	324		
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN	281	218		
CLAUS_PGR_POSITIVE_MENINGIOMA_UP	10	5		
CLAUS_PGR_POSITIVE_MENINGIOMA_DN	12	12		
WONG_MITOCHONDRIA_GENE_MODULE	217	202		
WONG_PROTEASOME_GENE_MODULE	49	43		
AMUNDSON_GAMMA_RADIATION_RESISTANCE	20	13		
AMUNDSON_GAMMA_RADIATION_RESPONSE	40	34		
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_8G	95	84		
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_2G	171	140		
COATES_MACROPHAGE_M1_VS_M2_UP	81	63		
COATES_MACROPHAGE_M1_VS_M2_DN	78	56		
LEE_METASTASIS_AND_RNA_PROCESSING_UP	17	15		
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_UP	74	61		
LEE_METASTASIS_AND_ALTERNATIVE_SPLICING_DN	45	36		
LIN_MELANOMA_COPY_NUMBER_UP	73	51		
LIN_MELANOMA_COPY_NUMBER_DN	41	36		
MARTINEZ_RB1_TARGETS_UP	673		Rejected!	
MARTINEZ_RB1_TARGETS_DN	543	400		
MARTINEZ_TP53_TARGETS_UP	602	475		
MARTINEZ_TP53_TARGETS_DN	593	430		
MARTINEZ_RB1_AND_TP53_TARGETS_UP	601	474		
MARTINEZ_RB1_AND_TP53_TARGETS_DN	591	431		
FINETTI_BREAST_CANCER_KINOME_RED	16	13		
FINETTI_BREAST_CANCER_KINOME_GREEN	16	15		
FINETTI_BREAST_CANCERS_KINOME_BLUE	21	14		
FINETTI_BREAST_CANCERS_KINOME_GRAY	15	13		
MASSARWEH_TAMOXIFEN_RESISTANCE_UP	578	406		
MASSARWEH_TAMOXIFEN_RESISTANCE_DN	258	176		
MASSARWEH_RESPONSE_TO_ESTRADIOL	61	50		
WALLACE_PROSTATE_CANCER_UP	20	18		
WALLACE_PROSTATE_CANCER_DN	6	6		
WALLACE_PROSTATE_CANCER_RACE_UP	299	211		
WALLACE_PROSTATE_CANCER_RACE_DN	88	55		
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP	180	138		
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_DN	154	120		
OUILLETTE_CLL_13Q14_DELETION_UP	74	52		
OUILLETTE_CLL_13Q14_DELETION_DN	60	47		
YOKOE_CANCER_TESTIS_ANTIGENS	38	22		
MARZEC_IL2_SIGNALING_UP	115	100		
MARZEC_IL2_SIGNALING_DN	36	29		
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP	181	129		
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_DN	353	259		
IWANAGA_CARCINOGENESIS_BY_KRAS_UP	170	116		
IWANAGA_CARCINOGENESIS_BY_KRAS_DN	120	88		
DER_IFN_ALPHA_RESPONSE_DN	7		Rejected!	
CAMPS_COLON_CANCER_COPY_NUMBER_UP	92	55		
CAMPS_COLON_CANCER_COPY_NUMBER_DN	74	22		
RIZKI_TUMOR_INVASIVENESS_3D_UP	210	164		
RIZKI_TUMOR_INVASIVENESS_3D_DN	270	208		
RIZKI_TUMOR_INVASIVENESS_2D_UP	69	57		
RIZKI_TUMOR_INVASIVENESS_2D_DN	64	58		
FUJII_YBX1_TARGETS_UP	43	30		
FUJII_YBX1_TARGETS_DN	202	179		
OSADA_ASCL1_TARGETS_UP	46	37		
OSADA_ASCL1_TARGETS_DN	24	20		
CHENG_IMPRINTED_BY_ESTRADIOL	110	68		
DE_YY1_TARGETS_UP	20	10		
DE_YY1_TARGETS_DN	92	82		
BIERIE_INFLAMMATORY_RESPONSE_TGFB1	5		Rejected!	
MCCABE_BOUND_BY_HOXC6	469	240		
POS_RESPONSE_TO_HISTAMINE_UP	13	9		
POS_RESPONSE_TO_HISTAMINE_DN	11	8		
POS_HISTAMINE_RESPONSE_NETWORK	32	28		
DAIRKEE_CANCER_PRONE_RESPONSE_E2	28	24		
DAIRKEE_CANCER_PRONE_RESPONSE_BPA	51	41		
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2	118	100		
YAMASHITA_SILENCED_BY_METHYLATION	7	5		
YAMASHITA_METHYLATED_IN_PROSTATE_CANCER	57	43		
OUYANG_PROSTATE_CANCER_PROGRESSION_UP	20	16		
OUYANG_PROSTATE_CANCER_PROGRESSION_DN	21	18		
OUYANG_PROSTATE_CANCER_MARKERS	19	19		
RIGGI_EWING_SARCOMA_PROGENITOR_UP	430	311		
RIGGI_EWING_SARCOMA_PROGENITOR_DN	191	137		
GAUTSCHI_SRC_SIGNALING	8	8		
VICENT_METASTASIS_UP	14	12		
AMBROSINI_FLAVOPIRIDOL_TREATMENT_TP53	109	83		
HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP	36	19		
HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN	48	33		
ENGELMANN_CANCER_PROGENITORS_UP	48	42		
ENGELMANN_CANCER_PROGENITORS_DN	70	47		
WORSCHECH_TUMOR_REJECTION_UP	56	43		
WORSCHECH_TUMOR_REJECTION_DN	10	10		
HUANG_FOXA2_TARGETS_UP	45	35		
HUANG_FOXA2_TARGETS_DN	36	33		
MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_UP	20	14		
MASRI_RESISTANCE_TO_TAMOXIFEN_AND_AROMATASE_INHIBITORS_DN	20	15		
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_UP	24	18		
MCCABE_HOXC6_TARGETS_UP	10	7		
MCCABE_HOXC6_TARGETS_DN	21	17		
TING_SILENCED_BY_DICER	31	23		
BOYERINAS_ONCOFETAL_TARGETS_OF_LET7A1	12	10		
MCCABE_HOXC6_TARGETS_CANCER_UP	31	21		
MCCABE_HOXC6_TARGETS_CANCER_DN	20	17		
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_UP	67	38		
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN	58	40		
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_UP	174	126		
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN	354	273		
ACEVEDO_LIVER_CANCER_UP	973		Rejected!	
ACEVEDO_LIVER_CANCER_DN	540	410		
ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_UP	863		Rejected!	
ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN	274	202		
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP	295	152		
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN	228	114		
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_UP	141	64		
ACEVEDO_LIVER_CANCER_WITH_H3K9ME3_DN	120	57		
ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN	940	431		
MITSIADES_RESPONSE_TO_APLIDIN_UP	439	321		
MITSIADES_RESPONSE_TO_APLIDIN_DN	249	206		
HOQUE_METHYLATED_IN_CANCER	56	46		
NADELLA_PRKAR1A_TARGETS_UP	9	8		
NADELLA_PRKAR1A_TARGETS_DN	8	7		
SAGIV_CD24_TARGETS_UP	23	21		
SAGIV_CD24_TARGETS_DN	46	39		
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP	39	28		
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN	85	60		
SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP	97	63		
SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN	315	220		
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_UP	21	13		
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN	37	28		
SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP	6	6		
SMID_BREAST_CANCER_RELAPSE_IN_LIVER_DN	10	8		
SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP	6		Rejected!	
SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_DN	27	15		
SMID_BREAST_CANCER_LUMINAL_B_UP	172	111		
SMID_BREAST_CANCER_LUMINAL_B_DN	564	393		
SMID_BREAST_CANCER_LUMINAL_A_UP	84	68		
SMID_BREAST_CANCER_LUMINAL_A_DN	18	14		
SMID_BREAST_CANCER_ERBB2_UP	147	99		
SMID_BREAST_CANCER_ERBB2_DN	5	5		
SMID_BREAST_CANCER_NORMAL_LIKE_UP	476	347		
SMID_BREAST_CANCER_NORMAL_LIKE_DN	6	5		
SMID_BREAST_CANCER_BASAL_UP	648	472		
SMID_BREAST_CANCER_BASAL_DN	701	484		
KUMAMOTO_RESPONSE_TO_NUTLIN_3A_UP	9	8		
KUMAMOTO_RESPONSE_TO_NUTLIN_3A_DN	10	10		
ITO_PTTG1_TARGETS_UP	12	9		
ITO_PTTG1_TARGETS_DN	9	9		
LE_SKI_TARGETS_UP	17	15		
LE_SKI_TARGETS_DN	8	8		
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_UP	31	25		
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN	22	16		
BONOME_OVARIAN_CANCER_SURVIVAL_OPTIMAL_DEBULKING	246	171		
BONOME_OVARIAN_CANCER_SURVIVAL_SUBOPTIMAL_DEBULKING	510	399		
GALI_TP53_TARGETS_APOPTOTIC_UP	8	8		
GALI_TP53_TARGETS_APOPTOTIC_DN	6	5		
MOSERLE_IFNA_RESPONSE	31	19		
MCGARVEY_SILENCED_BY_METHYLATION_IN_COLON_CANCER	42	31		
WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_UP	21	20		
WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_DN	5		Rejected!	
WEBER_METHYLATED_HCP_IN_FIBROBLAST_UP	6		Rejected!	
WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN	42	25		
WEBER_METHYLATED_HCP_IN_SPERM_DN	28	13		
WEBER_METHYLATED_HCP_IN_SPERM_UP	20	15		
BASSO_HAIRY_CELL_LEUKEMIA_UP	6		Rejected!	
BASSO_HAIRY_CELL_LEUKEMIA_DN	80	66		
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C	463	312		
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP	126	87		
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_DN	108	82		
ZHANG_BREAST_CANCER_PROGENITORS_UP	425	325		
ZHANG_BREAST_CANCER_PROGENITORS_DN	145	123		
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN	24	20		
BERNARD_PPAPDC1B_TARGETS_UP	40	31		
BERNARD_PPAPDC1B_TARGETS_DN	58	44		
GAURNIER_PSMD4_TARGETS	73	40		
EHLERS_ANEUPLOIDY_UP	41	31		
EHLERS_ANEUPLOIDY_DN	12	8		
ZHENG_GLIOBLASTOMA_PLASTICITY_UP	250	201		
ZHENG_GLIOBLASTOMA_PLASTICITY_DN	58	51		
BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_UP	24	16		
BUCKANOVICH_T_LYMPHOCYTE_HOMING_ON_TUMOR_DN	24	16		
JONES_TCOF1_TARGETS	5		Rejected!	
AUJLA_IL22_AND_IL17A_SIGNALING	11		Rejected!	
ZHENG_IL22_SIGNALING_UP	56	40		
ZHENG_IL22_SIGNALING_DN	42	30		
BOCHKIS_FOXA2_TARGETS	425	337		
HONMA_DOCETAXEL_RESISTANCE	34	28		
WILENSKY_RESPONSE_TO_DARAPLADIB	29	26		
MATZUK_OVULATION	14	14		
MATZUK_CUMULUS_EXPANSION	9	6		
MATZUK_FERTILIZATION	8	5		
MATZUK_MATERNAL_EFFECT	9	5		
MATZUK_IMPLANTATION_AND_UTERINE	22	13		
MATZUK_POST-IMPLANTATION_AND_POST-PARTUM	14	11		
MATZUK_STEROIDOGENESIS	7	6		
MATZUK_MEIOTIC_AND_DNA_REPAIR	39	31		
MATZUK_CENTRAL_FOR_FEMALE_FERTILITY	29	21		
MATZUK_EMBRYONIC_GERM_CELL	19	18		
MATZUK_EARLY_ANTRAL_FOLLICLE	13	12		
MATZUK_LUTEAL_GENES	8	7		
MATZUK_PREOVULATORY_FOLLICLE	10	9		
MATZUK_MALE_REPRODUCTION_SERTOLI	28	21		
MATZUK_SPERMATOGONIA	24	17		
MATZUK_SPERMATOCYTE	72	54		
MATZUK_SPERMATID_DIFFERENTIATION	37	27		
MATZUK_SPERMATOZOA	114	83		
BONCI_TARGETS_OF_MIR15A_AND_MIR16_1	91	75		
CHUNG_BLISTER_CYTOTOXICITY_UP	134	104		
CHUNG_BLISTER_CYTOTOXICITY_DN	44	31		
WHITEFORD_PEDIATRIC_CANCER_MARKERS	116	98		
GRADE_METASTASIS_DN	45	39		
GRADE_COLON_CANCER_UP	871		Rejected!	
GRADE_COLON_CANCER_DN	33	22		
GRADE_COLON_AND_RECTAL_CANCER_UP	285	230		
GRADE_COLON_AND_RECTAL_CANCER_DN	101	71		
GRADE_COLON_VS_RECTAL_CANCER_UP	38	28		
GRADE_COLON_VS_RECTAL_CANCER_DN	56	39		
BOQUEST_STEM_CELL_UP	260	214		
BOQUEST_STEM_CELL_DN	216	166		
BOQUEST_STEM_CELL_CULTURED_VS_FRESH_UP	425	343		
BOQUEST_STEM_CELL_CULTURED_VS_FRESH_DN	31	24		
LABBE_WNT3A_TARGETS_UP	112	95		
LABBE_WNT3A_TARGETS_DN	97	70		
LABBE_TGFB1_TARGETS_UP	102	81		
LABBE_TGFB1_TARGETS_DN	108	79		
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_UP	111	95		
LABBE_TARGETS_OF_TGFB1_AND_WNT3A_DN	108	84		
NAKAMURA_METASTASIS	47	34		
NAKAMURA_METASTASIS_MODEL_UP	45	33		
NAKAMURA_METASTASIS_MODEL_DN	43	32		
GRATIAS_RETINOBLASTOMA_16Q24	17	13		
WEST_ADRENOCORTICAL_TUMOR_UP	294	244		
WEST_ADRENOCORTICAL_TUMOR_DN	546	432		
WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_UP	21	11		
WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_DN	24	17		
DONATO_CELL_CYCLE_TRETINOIN	6	6		
CHO_NR4A1_TARGETS	33	26		
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP	125	89		
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN	127	93		
CLIMENT_BREAST_CANCER_COPY_NUMBER_UP	23	21		
CLIMENT_BREAST_CANCER_COPY_NUMBER_DN	8	7		
SHARMA_ASTROCYTOMA_WITH_NF1_SYNDROM	5		Rejected!	
SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_UP	25	15		
SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_DN	7		Rejected!	
TSUDA_ALVEOLAR_SOFT_PART_SARCOMA	10	10		
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP	104	81		
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_DN	159	131		
YAGUE_PRETUMOR_DRUG_RESISTANCE_UP	8	5		
YAGUE_PRETUMOR_DRUG_RESISTANCE_DN	13	9		
BRUECKNER_TARGETS_OF_MIRLET7A3_UP	111	92		
BRUECKNER_TARGETS_OF_MIRLET7A3_DN	78	56		
PODAR_RESPONSE_TO_ADAPHOSTIN_UP	147	120		
PODAR_RESPONSE_TO_ADAPHOSTIN_DN	18	14		
LU_TUMOR_ENDOTHELIAL_MARKERS_UP	22	15		
LU_TUMOR_ENDOTHELIAL_MARKERS_DN	5		Rejected!	
LU_TUMOR_ANGIOGENESIS_UP	25	22		
LIN_TUMOR_ESCAPE_FROM_IMMUNE_ATTACK	18	11		
CHEN_HOXA5_TARGETS_6HR_UP	10	8		
CHEN_HOXA5_TARGETS_6HR_DN	6		Rejected!	
CHEN_HOXA5_TARGETS_9HR_UP	223	149		
CHEN_HOXA5_TARGETS_9HR_DN	41	34		
LIN_NPAS4_TARGETS_UP	163	117		
LIN_NPAS4_TARGETS_DN	68	46		
CADWELL_ATG16L1_TARGETS_UP	93	71		
CADWELL_ATG16L1_TARGETS_DN	70	49		
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_UP	62	40		
BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_DN	57	44		
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_UP	49	33		
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_DN	38	31		
CONRAD_STEM_CELL	39	26		
CONRAD_GERMLINE_STEM_CELL	13	9		
THUM_MIR21_TARGETS_HEART_DISEASE_UP	17	14		
THUM_MIR21_TARGETS_HEART_DISEASE_DN	8	7		
KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION	35	15		
HUANG_DASATINIB_RESISTANCE_UP	81	69		
HUANG_DASATINIB_RESISTANCE_DN	69	53		
MATTHEWS_SKIN_CARCINOGENESIS_VIA_JUN	17	12		
MATTHEWS_AP1_TARGETS	17	14		
QI_PLASMACYTOMA_UP	259	230		
QI_PLASMACYTOMA_DN	100	86		
TAYLOR_METHYLATED_IN_ACUTE_LYMPHOBLASTIC_LEUKEMIA	77	53		
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP	52	45		
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_DN	28	27		
HUPER_BREAST_BASAL_VS_LUMINAL_UP	54	30		
HUPER_BREAST_BASAL_VS_LUMINAL_DN	59	46		
MALONEY_RESPONSE_TO_17AAG_UP	41	36		
MALONEY_RESPONSE_TO_17AAG_DN	79	68		
CUI_GLUCOSE_DEPRIVATION	60	52		
BLUM_RESPONSE_TO_SALIRASIB_UP	245	203		
BLUM_RESPONSE_TO_SALIRASIB_DN	342	294		
WINTER_HYPOXIA_METAGENE	242	194		
ALONSO_METASTASIS_EMT_UP	36	27		
ALONSO_METASTASIS_EMT_DN	5		Rejected!	
ALONSO_METASTASIS_NEURAL_UP	18	16		
ALONSO_METASTASIS_UP	198	154		
ALONSO_METASTASIS_DN	26	15		
CROMER_TUMORIGENESIS_UP	63	46		
CROMER_TUMORIGENESIS_DN	51	29		
KRISHNAN_FURIN_TARGETS_UP	12	9		
KRISHNAN_FURIN_TARGETS_DN	13	6		
MUELLER_PLURINET	299	241		
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_UP	149	99		
YAUCH_HEDGEHOG_SIGNALING_PARACRINE_DN	264	151		
FIRESTEIN_CTNNB1_PATHWAY_AND_PROLIFERATION	9	8		
FIRESTEIN_CTNNB1_PATHWAY	33	30		
FIRESTEIN_PROLIFERATION	175	144		
ZHOU_PANCREATIC_EXOCRINE_PROGENITOR	11	7		
ZHOU_PANCREATIC_ENDOCRINE_PROGENITOR	14		Rejected!	
ZHOU_PANCREATIC_BETA_CELL	11		Rejected!	
ISHIKAWA_STING_SIGNALING	8	6		
WANG_TUMOR_INVASIVENESS_UP	374	311		
WANG_TUMOR_INVASIVENESS_DN	210	180		
JIANG_TIP30_TARGETS_UP	46	38		
JIANG_TIP30_TARGETS_DN	24	21		
GRESHOCK_CANCER_COPY_NUMBER_UP	323	278		
WANG_NEOPLASTIC_TRANSFORMATION_BY_CCND1_MYC	21	19		
TSAI_RESPONSE_TO_RADIATION_THERAPY	32	28		
SASAI_TARGETS_OF_CXCR6_AND_PTCH1_UP	13	6		
SASAI_TARGETS_OF_CXCR6_AND_PTCH1_DN	8	5		
MIKI_COEXPRESSED_WITH_CYP19A1	7	6		
BEIER_GLIOMA_STEM_CELL_UP	39	22		
BEIER_GLIOMA_STEM_CELL_DN	66	43		
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_UP	165	137		
VART_KSHV_INFECTION_ANGIOGENIC_MARKERS_DN	138	109		
MOOTHA_HUMAN_MITODB_6_2002	429	388		
MOOTHA_PGC	420	356		
MOOTHA_TCA	16	15		
LEE_LIVER_CANCER_SURVIVAL_DN	175	141		
LEE_LIVER_CANCER_SURVIVAL_UP	185	131		
MOOTHA_MITOCHONDRIA	447	395		
MOOTHA_ROS	7	6		
DAVIES_MULTIPLE_MYELOMA_VS_MGUS_UP	13	12		
DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN	28	22		
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP	38	29		
BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_DN	32	25		
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_UP	27	25		
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN	40	36		
BOYLAN_MULTIPLE_MYELOMA_D_UP	89	70		
BOYLAN_MULTIPLE_MYELOMA_D_DN	78	60		
BOYLAN_MULTIPLE_MYELOMA_C_D_UP	139	105		
BOYLAN_MULTIPLE_MYELOMA_C_D_DN	252	203		
BOYLAN_MULTIPLE_MYELOMA_C_UP	47	36		
BOYLAN_MULTIPLE_MYELOMA_C_DN	59	43		
WU_SILENCED_BY_METHYLATION_IN_BLADDER_CANCER	55	45		
FERRARI_RESPONSE_TO_FENRETINIDE_UP	22	17		
FERRARI_RESPONSE_TO_FENRETINIDE_DN	5	5		
HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS	80	62		
REICHERT_G1S_REGULATORS_AS_PI3K_TARGETS	8	8		
GU_PDEF_TARGETS_UP	71	67		
GU_PDEF_TARGETS_DN	39	22		
TOOKER_GEMCITABINE_RESISTANCE_UP	79	63		
TOOKER_GEMCITABINE_RESISTANCE_DN	122	103		
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP	47	38		
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN	40	36		
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP	53	45		
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_DN	29	16		
VILIMAS_NOTCH1_TARGETS_UP	52	45		
VILIMAS_NOTCH1_TARGETS_DN	20	16		
SPIRA_SMOKERS_LUNG_CANCER_UP	38	29		
SPIRA_SMOKERS_LUNG_CANCER_DN	22	12		
LUDWICZEK_TREATING_IRON_OVERLOAD	7	6		
JU_AGING_TERC_TARGETS_UP	10	9		
JU_AGING_TERC_TARGETS_DN	5		Rejected!	
ZAIDI_OSTEOBLAST_TRANSCRIPTION_FACTORS	14	9		
WAGNER_APO2_SENSITIVITY	25	15		
PALOMERO_GSI_SENSITIVITY_UP	7	7		
PALOMERO_GSI_SENSITIVITY_DN	6		Rejected!	
SOUCEK_MYC_TARGETS	8	7		
SEKI_INFLAMMATORY_RESPONSE_LPS_UP	77	69		
SEKI_INFLAMMATORY_RESPONSE_LPS_DN	23	23		
RAY_ALZHEIMERS_DISEASE	13	7		
HUNSBERGER_EXERCISE_REGULATED_GENES	31	23		
PIONTEK_PKD1_TARGETS_UP	38	29		
PIONTEK_PKD1_TARGETS_DN	18	9		
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP	51	44		
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN	102	86		
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP	24	15		
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN	50	47		
GOLDRATH_ANTIGEN_RESPONSE	346	289		
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP	107	86		
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_DN	40	32		
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP	131	108		
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN	49	40		
LINDSTEDT_DENDRITIC_CELL_MATURATION_A	67	55		
LINDSTEDT_DENDRITIC_CELL_MATURATION_B	53	49		
LINDSTEDT_DENDRITIC_CELL_MATURATION_C	69	56		
LINDSTEDT_DENDRITIC_CELL_MATURATION_D	68	55		
MARSHALL_VIRAL_INFECTION_RESPONSE_UP	7	5		
MARSHALL_VIRAL_INFECTION_RESPONSE_DN	29	25		
MARTINELLI_IMMATURE_NEUTROPHIL_UP	11		Rejected!	
MARTINELLI_IMMATURE_NEUTROPHIL_DN	13	7		
NICK_RESPONSE_TO_PROC_TREATMENT_UP	5	5		
NICK_RESPONSE_TO_PROC_TREATMENT_DN	27	20		
NUTT_GBM_VS_AO_GLIOMA_UP	46	41		
NUTT_GBM_VS_AO_GLIOMA_DN	45	35		
PARK_APL_PATHOGENESIS_UP	14	13		
PARK_APL_PATHOGENESIS_DN	50	37		
PARK_TRETINOIN_RESPONSE	12	12		
PARK_TRETINOIN_RESPONSE_AND_PML_RARA_FUSION	30	30		
PARK_TRETINOIN_RESPONSE_AND_RARA_PLZF_FUSION	22	21		
ZHANG_INTERFERON_RESPONSE	23	17		
WU_ALZHEIMER_DISEASE_UP	14	11		
WU_ALZHEIMER_DISEASE_DN	19	15		
MIZUKAMI_HYPOXIA_UP	12	9		
MIZUKAMI_HYPOXIA_DN	6		Rejected!	
YOSHIMURA_MAPK8_TARGETS_UP	1305		Rejected!	
YOSHIMURA_MAPK8_TARGETS_DN	366	305		
CHAN_INTERFERON_PRODUCING_DENDRITIC_CELL	12	10		
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP	58	37		
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_DN	12	9		
RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP	18	14		
RAY_TARGETS_OF_P210_BCR_ABL_FUSION_DN	16	13		
RUIZ_TNC_TARGETS_UP	153	127		
RUIZ_TNC_TARGETS_DN	142	119		
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP	338	275		
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN	315	236		
RUTELLA_RESPONSE_TO_HGF_UP	418	330		
RUTELLA_RESPONSE_TO_HGF_DN	235	181		
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_UP	408	317		
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN	245	194		
SCHRAETS_MLL_TARGETS_UP	35	28		
SCHRAETS_MLL_TARGETS_DN	33	28		
CHANG_CORE_SERUM_RESPONSE_UP	212	165		
CHANG_CORE_SERUM_RESPONSE_DN	209	152		
CHANG_CYCLING_GENES	148	117		
MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_UP	14	13		
MUELLER_COMMON_TARGETS_OF_AML_FUSIONS_DN	31	21		
ROSS_LEUKEMIA_WITH_MLL_FUSIONS	78	61		
VANASSE_BCL2_TARGETS_UP	40	28		
VANASSE_BCL2_TARGETS_DN	74	59		
VANTVEER_BREAST_CANCER_ESR1_UP	167	123		
VANTVEER_BREAST_CANCER_ESR1_DN	240	188		
VANTVEER_BREAST_CANCER_BRCA1_UP	36	27		
VANTVEER_BREAST_CANCER_BRCA1_DN	44	28		
WALLACE_JAK2_TARGETS_UP	26	19		
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_UP	298	229		
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_DN	238	182		
SWEET_LUNG_CANCER_KRAS_UP	491	388		
SWEET_LUNG_CANCER_KRAS_DN	435	361		
SWEET_KRAS_ONCOGENIC_SIGNATURE	89	74		
HINATA_NFKB_TARGETS_KERATINOCYTE_UP	91	73		
HINATA_NFKB_TARGETS_KERATINOCYTE_DN	23	12		
HINATA_NFKB_TARGETS_FIBROBLAST_UP	84	69		
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_UP	36	28		
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_DN	75	65		
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP	163	133		
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_DN	72	63		
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_UP	70	56		
HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN	50	40		
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_UP	43	35		
HOFFMANN_IMMATURE_TO_MATURE_B_LYMPHOCYTE_DN	50	41		
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP	22	17		
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_DN	30	22		
HOFMANN_MYELODYSPLASTIC_SYNDROM_HIGH_RISK_UP	10	10		
HOFMANN_MYELODYSPLASTIC_SYNDROM_HIGH_RISK_DN	20	12		
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP	24	18		
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_DN	23	18		
LEE_EARLY_T_LYMPHOCYTE_UP	107	73		
LEE_EARLY_T_LYMPHOCYTE_DN	57	33		
LEE_INTRATHYMIC_T_PROGENITOR	21	15		
LEE_DOUBLE_POLAR_THYMOCYTE	27	18		
LEE_SP4_THYMOCYTE	14	11		
LEE_RECENT_THYMIC_EMIGRANT	227	169		
LEE_NAIVE_T_LYMPHOCYTE	19	10		
LEE_DIFFERENTIATING_T_LYMPHOCYTE	200	144		
LI_WILMS_TUMOR	27	16		
FINAK_BREAST_CANCER_SDPP_SIGNATURE	26	20		
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6	456	360		
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4	196	143		
BRUNEAU_SEPTATION_ATRIAL	5		Rejected!	
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A5	70	43		
BRUNEAU_SEPTATION_VENTRICULAR	10	8		
BRUNEAU_HEART_GREAT_VESSELS_AND_VALVULOGENESIS	8	5		
ZHANG_TLX_TARGETS_36HR_UP	221	183		
ZHANG_TLX_TARGETS_36HR_DN	185	145		
ZHANG_TLX_TARGETS_60HR_UP	293	250		
ZHANG_TLX_TARGETS_60HR_DN	277	229		
ZHANG_TLX_TARGETS_DN	108	91		
ZHANG_TLX_TARGETS_UP	89	72		
MELLMAN_TUT1_TARGETS_UP	19	16		
MELLMAN_TUT1_TARGETS_DN	47	42		
HAN_SATB1_TARGETS_UP	395	292		
HAN_SATB1_TARGETS_DN	442	328		
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12	317	189		
COLINA_TARGETS_OF_4EBP1_AND_4EBP2	356	303		
CHEN_METABOLIC_SYNDROM_NETWORK	1210		Rejected!	
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_UP	26	19		
MCMURRAY_TP53_HRAS_COOPERATION_RESPONSE_DN	67	57		
MIKKELSEN_PLURIPOTENT_STATE_UP	11		Rejected!	
MIKKELSEN_PLURIPOTENT_STATE_DN	8	8		
MIKKELSEN_DEDIFFERENTIATED_STATE_UP	8	6		
MIKKELSEN_DEDIFFERENTIATED_STATE_DN	7	5		
MIKKELSEN_PARTIALLY_REPROGRAMMED_TO_PLURIPOTENCY	10	7		
ELLWOOD_MYC_TARGETS_UP	13	11		
ELLWOOD_MYC_TARGETS_DN	40	28		
SHAFFER_IRF4_MULTIPLE_MYELOMA_PROGRAM	36	32		
SHAFFER_IRF4_TARGETS_IN_MYELOMA_VS_MATURE_B_LYMPHOCYTE	101	90		
SHAFFER_IRF4_TARGETS_IN_PLASMA_CELL_VS_MATURE_B_LYMPHOCYTE	67	60		
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_B_LYMPHOCYTE	81	70		
SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL	65	59		
HSIAO_HOUSEKEEPING_GENES	389	350		
MEISSNER_ES_ICP_WITH_H3K4ME3	34	19		
MEISSNER_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3	14	10		
MEISSNER_NPC_HCP_WITH_H3K27ME3	79	26		
MEISSNER_NPC_ICP_WITH_H3K4ME3	20	15		
MEISSNER_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3	142	87		
MEISSNER_NPC_HCP_WITH_H3_UNMETHYLATED	536	329		
MEISSNER_NPC_ICP_WITH_H3_UNMETHYLATED	24	16		
MEISSNER_BRAIN_HCP_WITH_H3K27ME3	269	115		
MEISSNER_BRAIN_ICP_WITH_H3K4ME3	32	19		
MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3	1069		Rejected!	
MEISSNER_BRAIN_HCP_WITH_H3_UNMETHYLATED	37	18		
TAVAZOIE_METASTASIS	108	64		
WENDT_COHESIN_TARGETS_UP	33	26		
FERRANDO_HOX11_NEIGHBORS	23	17		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_HD_MTX_UP	5	5		
CHEOK_RESPONSE_TO_MERCAPTOPURINE_AND_HD_MTX_DN	25	21		
ZHAN_EARLY_DIFFERENTIATION_GENES_UP	7	5		
ZHAN_EARLY_DIFFERENTIATION_GENES_DN	42	37		
MILI_PSEUDOPODIA	43	32		
MILI_PSEUDOPODIA_CHEMOTAXIS_UP	74	51		
MILI_PSEUDOPODIA_CHEMOTAXIS_DN	457	369		
MILI_PSEUDOPODIA_HAPTOTAXIS_UP	518	390		
MILI_PSEUDOPODIA_HAPTOTAXIS_DN	668		Rejected!	
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP	89	71		
LIU_VAV3_PROSTATE_CARCINOGENESIS_DN	17	12		
CROONQUIST_IL6_DEPRIVATION_UP	20	16		
CROONQUIST_IL6_DEPRIVATION_DN	98	88		
CROONQUIST_STROMAL_STIMULATION_UP	60	50		
CROONQUIST_STROMAL_STIMULATION_DN	13	10		
CROONQUIST_NRAS_SIGNALING_UP	41	33		
CROONQUIST_NRAS_SIGNALING_DN	72	67		
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_UP	41	32		
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN	99	81		
IRITANI_MAD1_TARGETS_UP	13	9		
IRITANI_MAD1_TARGETS_DN	47	38		
ZHAN_LATE_DIFFERENTIATION_GENES_UP	33	31		
ZHAN_LATE_DIFFERENTIATION_GENES_DN	16	14		
ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_UP	15	10		
ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_DN	30	28		
ZHAN_V1_LATE_DIFFERENTIATION_GENES_UP	32	29		
ZHAN_V1_LATE_DIFFERENTIATION_GENES_DN	15	15		
ISHIDA_E2F_TARGETS	53	46		
ROME_INSULIN_TARGETS_IN_MUSCLE_UP	442	338		
ROME_INSULIN_TARGETS_IN_MUSCLE_DN	204	117		
VALK_AML_CLUSTER_1	28	23		
VALK_AML_CLUSTER_2	29	20		
VALK_AML_CLUSTER_3	33	27		
VALK_AML_CLUSTER_4	31	20		
VALK_AML_CLUSTER_5	33	20		
VALK_AML_CLUSTER_6	33	24		
VALK_AML_CLUSTER_7	28	21		
VALK_AML_CLUSTER_8	26	22		
VALK_AML_CLUSTER_9	35	27		
VALK_AML_CLUSTER_10	33	25		
VALK_AML_CLUSTER_11	36	34		
VALK_AML_CLUSTER_12	30	27		
VALK_AML_CLUSTER_13	30	20		
VALK_AML_CLUSTER_15	31	24		
VALK_AML_CLUSTER_16	26	16		
VALK_AML_WITH_T_8_21_TRANSLOCATION	5	5		
VALK_AML_WITH_11Q23_REARRANGED	22	11		
VALK_AML_WITH_EVI1	25	16		
VALK_AML_WITH_CEBPA	37	28		
VALK_AML_WITH_FLT3_ITD	40	33		
JISON_SICKLE_CELL_DISEASE_UP	181	147		
JISON_SICKLE_CELL_DISEASE_DN	181	135		
POOLA_INVASIVE_BREAST_CANCER_UP	288	214		
POOLA_INVASIVE_BREAST_CANCER_DN	134	102		
DING_LUNG_CANCER_MUTATED_RECURRENTLY	6	5		
DING_LUNG_CANCER_BY_MUTATION_RATE	20	17		
TCGA_GLIOBLASTOMA_MUTATED	8	7		
CHEN_LIVER_METABOLISM_QTL_CIS	93	77		
BOYAULT_LIVER_CANCER_SUBCLASS_G1_UP	113	89		
BOYAULT_LIVER_CANCER_SUBCLASS_G1_DN	40	30		
BOYAULT_LIVER_CANCER_SUBCLASS_G2	27	24		
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP	188	148		
BOYAULT_LIVER_CANCER_SUBCLASS_G3_DN	51	40		
BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN	27	19		
BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP	65	50		
BOYAULT_LIVER_CANCER_SUBCLASS_G6_DN	19	17		
BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP	39	31		
BOYAULT_LIVER_CANCER_SUBCLASS_G12_DN	15	11		
BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP	52	41		
BOYAULT_LIVER_CANCER_SUBCLASS_G23_DN	10	8		
BOYAULT_LIVER_CANCER_SUBCLASS_G56_UP	12	10		
BOYAULT_LIVER_CANCER_SUBCLASS_G56_DN	17	14		
BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP	45	41		
BOYAULT_LIVER_CANCER_SUBCLASS_G123_DN	51	46		
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP	176	129		
CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_DN	170	135		
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP	178	138		
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_DN	179	139		
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP	26	21		
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN	52	40		
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_UP	79	59		
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7_DN	24	18		
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_UP	85	60		
CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN	193	157		
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP	109	91		
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN	138	111		
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_UP	62	51		
HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN	69	51		
HOSHIDA_LIVER_CANCER_SURVIVAL_UP	73	63		
HOSHIDA_LIVER_CANCER_SURVIVAL_DN	113	89		
KAPOSI_LIVER_CANCER_MET_UP	18	17		
KAPOSI_LIVER_CANCER_MET_DN	6	6		
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP	53	42		
YAMASHITA_LIVER_CANCER_WITH_EPCAM_DN	16	10		
YAMASHITA_LIVER_CANCER_STEM_CELL_UP	47	44		
YAMASHITA_LIVER_CANCER_STEM_CELL_DN	76	62		
BUDHU_LIVER_CANCER_METASTASIS_UP	10	5		
BUDHU_LIVER_CANCER_METASTASIS_DN	7	7		
LEE_LIVER_CANCER_HEPATOBLAST	16	12		
WANG_RECURRENT_LIVER_CANCER_UP	20	18		
WANG_RECURRENT_LIVER_CANCER_DN	16	14		
WOO_LIVER_CANCER_RECURRENCE_UP	105	91		
WOO_LIVER_CANCER_RECURRENCE_DN	80	62		
YAMANAKA_GLIOBLASTOMA_SURVIVAL_UP	11	8		
YAMANAKA_GLIOBLASTOMA_SURVIVAL_DN	9	6		
MONTERO_THYROID_CANCER_POOR_SURVIVAL_UP	12	11		
MONTERO_THYROID_CANCER_POOR_SURVIVAL_DN	11	7		
YAGI_AML_WITH_T_8_21_TRANSLOCATION	368	276		
YAGI_AML_WITH_INV_16_TRANSLOCATION	422	323		
YAGI_AML_WITH_T_9_11_TRANSLOCATION	130	103		
YAGI_AML_WITH_11Q23_REARRANGED	351	289		
MEISSNER_NPC_HCP_WITH_H3K4ME2_AND_H3K27ME3	349	182		
MEISSNER_BRAIN_HCP_WITH_H3K4ME2_AND_H3K27ME3	59	41		
YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_UP	40	24		
YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_DN	65	44		
MEISSNER_NPC_HCP_WITH_H3K4ME2	491	341		
MEISSNER_BRAIN_HCP_WITH_H3K4ME2	17	14		
MIKKELSEN_MCV6_HCP_WITH_H3K27ME3	435	216		
MIKKELSEN_MCV6_ICP_WITH_H3K4ME3_AND_H3K27ME3	34	20		
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3	74	36		
MIKKELSEN_MCV6_LCP_WITH_H3K27ME3	29	13		
MIKKELSEN_MCV6_LCP_WITH_H3K4ME3	162	117		
MIKKELSEN_MEF_ICP_WITH_H3K4ME3_AND_H3K27ME3	38	23		
MIKKELSEN_MEF_ICP_WITH_H3K27ME3	206	97		
MIKKELSEN_MEF_LCP_WITH_H3K27ME3	70	35		
MIKKELSEN_MEF_LCP_WITH_H3K4ME3	128	102		
MIKKELSEN_IPS_WITH_HCP_H3K27ME3	102	39		
MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED	80	39		
MIKKELSEN_IPS_ICP_WITH_H3K4ME3_AND_H327ME3	126	79		
MIKKELSEN_IPS_ICP_WITH_H3K27ME3	54	31		
MIKKELSEN_IPS_LCP_WITH_H3K4ME3_AND_H3K27ME3	5		Rejected!	
MIKKELSEN_IPS_LCP_WITH_H3K27ME3	10	5		
MIKKELSEN_IPS_LCP_WITH_H3K4ME3	174	113		
GLINSKY_CANCER_DEATH_UP	7	5		
KUROKAWA_LIVER_CANCER_EARLY_RECURRENCE_UP	12	8		
KUROKAWA_LIVER_CANCER_EARLY_RECURRENCE_DN	7		Rejected!	
OKAMOTO_LIVER_CANCER_MULTICENTRIC_OCCURRENCE_UP	25	21		
OKAMOTO_LIVER_CANCER_MULTICENTRIC_OCCURRENCE_DN	6	5		
MARSON_FOXP3_TARGETS_UP	66	56		
MARSON_FOXP3_TARGETS_DN	54	44		
ONO_AML1_TARGETS_UP	24	22		
ONO_AML1_TARGETS_DN	41	32		
ONO_FOXP3_TARGETS_UP	23	19		
ONO_FOXP3_TARGETS_DN	42	35		
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_UP	67	57		
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_DN	20	13		
SCHOEN_NFKB_SIGNALING	34	29		
NAKAYAMA_FGF2_TARGETS	29	21		
NGO_MALIGNANT_GLIOMA_1P_LOH	17	16		
YANAGISAWA_LUNG_CANCER_RECURRENCE	9	7		
KESHELAVA_MULTIPLE_DRUG_RESISTANCE	88	62		
SEIKE_LUNG_CANCER_POOR_SURVIVAL	11	9		
WINNEPENNINCKX_MELANOMA_METASTASIS_DN	46	26		
TSAI_DNAJB4_TARGETS_UP	13	11		
TSAI_DNAJB4_TARGETS_DN	6	5		
ASGHARZADEH_NEUROBLASTOMA_POOR_SURVIVAL_DN	46	32		
LI_PROSTATE_CANCER_EPIGENETIC	30	26		
UROSEVIC_RESPONSE_TO_IMIQUIMOD	23	14		
KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS	44	37		
KUROZUMI_RESPONSE_TO_ONCOCYTIC_VIRUS_AND_CYCLIC_RGD	21	15		
FONTAINE_FOLLICULAR_THYROID_ADENOMA_UP	75	55		
FONTAINE_FOLLICULAR_THYROID_ADENOMA_DN	68	53		
FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_UP	36	28		
FONTAINE_THYROID_TUMOR_UNCERTAIN_MALIGNANCY_DN	26	21		
FONTAINE_PAPILLARY_THYROID_CARCINOMA_UP	66	51		
FONTAINE_PAPILLARY_THYROID_CARCINOMA_DN	80	53		
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_QTL	17	12		
WEBER_METHYLATED_LCP_IN_FIBROBLAST_UP	12	7		
WEBER_METHYLATED_LCP_IN_FIBROBLAST_DN	10	7		
WEBER_METHYLATED_ICP_IN_FIBROBLAST	22	10		
WEBER_METHYLATED_ICP_IN_SPERM_UP	8		Rejected!	
WEBER_METHYLATED_ICP_IN_SPERM_DN	14	6		
WEBER_METHYLATED_LCP_IN_SPERM_UP	15	9		
WEBER_METHYLATED_LCP_IN_SPERM_DN	7	5		
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP	56	49		
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_DN	9	6		
GYORFFY_DOXORUBICIN_RESISTANCE	56	36		
GYORFFY_MITOXANTRONE_RESISTANCE	57	40		
SYED_ESTRADIOL_RESPONSE	19	17		
WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_UP	30	26		
WORSCHECH_TUMOR_EVASION_AND_TOLEROGENICITY_DN	14	14		
STEIN_ESR1_TARGETS	85	69		
STEIN_ESRRA_TARGETS	535	404		
STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA	18	14		
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_UP	83	67		
LOPEZ_EPITHELIOID_MESOTHELIOMA	17	13		
LOPEZ_MESOTHELIOMA_SURVIVAL_OVERALL_UP	7		Rejected!	
LOPEZ_MESOTHELIOMA_SURVIVAL_OVERALL_DN	16	13		
LOPEZ_MESOTHELIOMA_SURVIVAL_UP	11	5		
LOPEZ_MESOTHELIOMA_SURVIVAL_DN	12	8		
KORKOLA_CORRELATED_WITH_POU5F1	34	17		
KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_UP	22	13		
KORKOLA_EMBRYONIC_CARCINOMA_VS_SEMINOMA_DN	25	14		
KOBAYASHI_EGFR_SIGNALING_24HR_UP	101	74		
KOBAYASHI_EGFR_SIGNALING_24HR_DN	251	211		
FOURNIER_ACINAR_DEVELOPMENT_LATE_2	277	232		
BOYLAN_MULTIPLE_MYELOMA_PCA1_UP	101	82		
BOYLAN_MULTIPLE_MYELOMA_PCA1_DN	8	8		
BOYLAN_MULTIPLE_MYELOMA_PCA3_UP	80	55		
BOYLAN_MULTIPLE_MYELOMA_PCA3_DN	69	53		
HOSHIDA_LIVER_CANCER_SUBCLASS_S1	237	207		
HOSHIDA_LIVER_CANCER_SUBCLASS_S2	115	103		
HOSHIDA_LIVER_CANCER_SUBCLASS_S3	266	220		
PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP	193	130		
PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_DN	29	9		
CAIRO_HEPATOBLASTOMA_UP	207	167		
CAIRO_HEPATOBLASTOMA_DN	267	212		
CAIRO_HEPATOBLASTOMA_CLASSES_UP	605	497		
CAIRO_HEPATOBLASTOMA_CLASSES_DN	210	163		
CAIRO_LIVER_DEVELOPMENT_UP	166	135		
CAIRO_LIVER_DEVELOPMENT_DN	222	195		
CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL	16	13		
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_UP	12	10		
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN	56	46		
GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_1_UP	9	7		
GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_1_DN	9	7		
GUTIERREZ_MULTIPLE_MYELOMA_DN	35	30		
GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_2	13	5		
WINNEPENNINCKX_MELANOMA_METASTASIS_UP	162	124		
HAHTOLA_CTCL_CUTANEOUS	26	23		
HAHTOLA_CTCL_PATHOGENESIS	16	14		
UZONYI_RESPONSE_TO_LEUKOTRIENE_AND_THROMBIN	37	32		
VANTVEER_BREAST_CANCER_POOR_PROGNOSIS	55	37		
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_UP	93	71		
KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_DN	225	169		
KYNG_NORMAL_AGING_UP	19	9		
KYNG_NORMAL_AGING_DN	30	21		
KYNG_WERNER_SYNDROM_UP	20	13		
KYNG_WERNER_SYNDROM_DN	29	17		
CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY	30	25		
CHIARETTI_T_ALL_RELAPSE_PROGNOSIS	19	16		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_IL3RA	9	6		
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_SCP2_QTL_TRANS	25	19		
ZHAN_MULTIPLE_MYELOMA_CD1_DN	45	34		
ZHAN_MULTIPLE_MYELOMA_CD2_DN	46	37		
ZHAN_MULTIPLE_MYELOMA_LB_DN	44	28		
ZHAN_MULTIPLE_MYELOMA_HP_DN	47	36		
ZHAN_MULTIPLE_MYELOMA_MF_DN	41	26		
ZHAN_MULTIPLE_MYELOMA_MS_DN	46	30		
ZHAN_MULTIPLE_MYELOMA_PR_DN	44	34		
DANG_REGULATED_BY_MYC_UP	72	57		
DANG_REGULATED_BY_MYC_DN	253	225		
DANG_MYC_TARGETS_UP	143	120		
DANG_MYC_TARGETS_DN	31	30		
DANG_BOUND_BY_MYC	1103		Rejected!	
DORN_ADENOVIRUS_INFECTION_12HR_UP	29	25		
DORN_ADENOVIRUS_INFECTION_12HR_DN	33	29		
DORN_ADENOVIRUS_INFECTION_24HR_UP	12	10		
DORN_ADENOVIRUS_INFECTION_24HR_DN	43	37		
DORN_ADENOVIRUS_INFECTION_32HR_UP	11	11		
DORN_ADENOVIRUS_INFECTION_32HR_DN	39	32		
DORN_ADENOVIRUS_INFECTION_48HR_UP	14	14		
DORN_ADENOVIRUS_INFECTION_48HR_DN	40	32		
TIAN_TNF_SIGNALING_VIA_NFKB	28	24		
TIAN_TNF_SIGNALING_NOT_VIA_NFKB	22	21		
WONG_EMBRYONIC_STEM_CELL_CORE	335	282		
WONG_ADULT_TISSUE_STEM_MODULE	721		Rejected!	
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP	76	57		
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_DN	74	54		
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP	87	67		
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN	80	56		
CHANDRAN_METASTASIS_UP	221	146		
CHANDRAN_METASTASIS_DN	306	216		
MIKKELSEN_ES_HCP_WITH_H3K27ME3	41	16		
MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED	63	30		
MIKKELSEN_ES_ICP_WITH_H3K27ME3	42	24		
MIKKELSEN_ES_ICP_WITH_H3K4ME3	718	479		
MIKKELSEN_ES_ICP_WITH_H3K4ME3_AND_H3K27ME3	137	84		
MIKKELSEN_ES_LCP_WITH_H3K27ME3	14	5		
MIKKELSEN_ES_LCP_WITH_H3K4ME3	142	91		
MIKKELSEN_ES_LCP_WITH_H3K4ME3_AND_H3K27ME3	6		Rejected!	
MIKKELSEN_NPC_HCP_WITH_H3K27ME3	341	160		
MIKKELSEN_NPC_HCP_WITH_H3K4ME3_AND_H3K27ME3	210	130		
MIKKELSEN_NPC_ICP_WITH_H3K27ME3	12	5		
MIKKELSEN_NPC_ICP_WITH_H3K4ME3	445	320		
MIKKELSEN_NPC_WITH_LCP_H3K27ME3	7		Rejected!	
MIKKELSEN_NPC_LCP_WITH_H3K4ME3	58	40		
MIKKELSEN_MEF_HCP_WITH_H3K27ME3	590	254		
MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED	228	98		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_0	76	61		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1	68	61		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_2	86	66		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_3	15	13		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_4	15	13		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_5	30	26		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6	75	58		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7	76	63		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_8	49	38		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_9	76	62		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_10	69	54		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_11	103	80		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_12	79	71		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13	172	141		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_14	143	115		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_15	35	29		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_16	79	64		
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17	181	152		
SENGUPTA_EBNA1_ANTICORRELATED	173	106		
YIH_RESPONSE_TO_ARSENITE_C5	10	7		
MOOTHA_PYR	8	6		
MOOTHA_FFA_OXYDATION	22	19		
MOOTHA_GLUCONEOGENESIS	32	28		
MOOTHA_GLYCOGEN_METABOLISM	21	16		
MOOTHA_GLYCOLYSIS	21	19		
LY_AGING_OLD_UP	7	6		
NAKAMURA_ADIPOGENESIS_EARLY_UP	66	45		
NAKAMURA_ADIPOGENESIS_EARLY_DN	38	36		
NAKAMURA_ADIPOGENESIS_LATE_UP	104	85		
NAKAMURA_ADIPOGENESIS_LATE_DN	38	34		
RAMPON_ENRICHED_LEARNING_ENVIRONMENT_EARLY_DN	10	9		
VERRECCHIA_RESPONSE_TO_TGFB1_C6	5	5		
TRACEY_RESISTANCE_TO_IFNA2_UP	6		Rejected!	
BAUS_TFF2_TARGETS_UP	32	27		
BAUS_TFF2_TARGETS_DN	11	9		
KAMMINGA_SENESCENCE	41	29		
HO_LIVER_CANCER_VASCULAR_INVASION	13	9		
GERHOLD_RESPONSE_TO_TZD_UP	6	6		
GERHOLD_RESPONSE_TO_TZD_DN	13	12		
MARIADASON_RESPONSE_TO_BUTYRATE_CURCUMIN_SULINDAC_TSA_1	10	7		
MARIADASON_RESPONSE_TO_BUTYRATE_CURCUMIN_SULINDAC_TSA_2	8	7		
MURAKAMI_UV_RESPONSE_1HR_UP	17	12		
MURAKAMI_UV_RESPONSE_1HR_DN	10	7		
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_UP	40	31		
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_DN	46	37		
VISALA_AGING_LYMPHOCYTE_UP	10	6		
ZEMBUTSU_SENSITIVITY_TO_FLUOROURACIL	17	11		
ZEMBUTSU_SENSITIVITY_TO_CISPLATIN	20	15		
ZEMBUTSU_SENSITIVITY_TO_NIMUSTINE	17	13		
ZEMBUTSU_SENSITIVITY_TO_DOXORUBICIN	17	14		
ZEMBUTSU_SENSITIVITY_TO_CYCLOPHOSPHAMIDE	18	12		
ZEMBUTSU_SENSITIVITY_TO_MITOMYCIN	19	14		
ZEMBUTSU_SENSITIVITY_TO_METHOTREXATE	18	13		
ZEMBUTSU_SENSITIVITY_TO_VINCRISTINE	19	15		
ZEMBUTSU_SENSITIVITY_TO_VINBLASTINE	18	16		
DAZARD_UV_RESPONSE_CLUSTER_G5	12	7		
DAZARD_UV_RESPONSE_CLUSTER_G24	28	19		
DAZARD_UV_RESPONSE_CLUSTER_G28	20	14		
RUAN_RESPONSE_TO_TROGLITAZONE_DN	19	18		
NIELSEN_GIST_VS_SYNOVIAL_SARCOMA_DN	20	14		
NIELSEN_GIST	98	73		
NIELSEN_LEIOMYOSARCOMA_CNN1_DN	20	17		
NIELSEN_LEIOMYOSARCOMA_DN	18	13		
NIELSEN_SYNOVIAL_SARCOMA_UP	18	11		
NIELSEN_SYNOVIAL_SARCOMA_DN	20	16		
NIELSEN_MALIGNAT_FIBROUS_HISTIOCYTOMA_DN	18	15		
NIELSEN_SCHWANNOMA_DN	18	13		
DASU_IL6_SIGNALING_UP	59	47		
DASU_IL6_SIGNALING_DN	7	6		
BANDRES_RESPONSE_TO_CARMUSTIN_WITHOUT_MGMT_24HR_DN	9	8		
BANDRES_RESPONSE_TO_CARMUSTIN_MGMT_24HR_UP	9	8		
HOFFMAN_CLOCK_TARGETS_UP	11	8		
HOFFMAN_CLOCK_TARGETS_DN	10	6		
WHITFIELD_CELL_CYCLE_LITERATURE	44	40		
JIANG_HYPOXIA_VIA_VHL	34	29		
WU_APOPTOSIS_BY_CDKN1A_VIA_TP53	55	42		
WU_APOPTOSIS_BY_CDKN1A_NOT_VIA_TP53	12	9		
ONGUSAHA_BRCA1_TARGETS_UP	13	12		
ONGUSAHA_BRCA1_TARGETS_DN	14	11		
SASSON_RESPONSE_TO_GONADOTROPHINS_UP	91	75		
SASSON_RESPONSE_TO_GONADOTROPHINS_DN	87	77		
SASSON_RESPONSE_TO_FORSKOLIN_UP	90	75		
SASSON_RESPONSE_TO_FORSKOLIN_DN	88	78		
BAE_BRCA1_TARGETS_UP	75	68		
BAE_BRCA1_TARGETS_DN	32	28		
BROWNE_HCMV_INFECTION_30MIN_UP	56	40		
BROWNE_HCMV_INFECTION_30MIN_DN	150	94		
BROWNE_HCMV_INFECTION_1HR_UP	61	41		
BROWNE_HCMV_INFECTION_1HR_DN	222	165		
BROWNE_HCMV_INFECTION_2HR_UP	39	28		
BROWNE_HCMV_INFECTION_2HR_DN	49	43		
BROWNE_HCMV_INFECTION_4HR_UP	55	43		
BROWNE_HCMV_INFECTION_4HR_DN	254	181		
WHITFIELD_CELL_CYCLE_G1_S	147	102		
WHITFIELD_CELL_CYCLE_S	162	115		
WHITFIELD_CELL_CYCLE_G2	182	131		
WHITFIELD_CELL_CYCLE_G2_M	216	171		
WHITFIELD_CELL_CYCLE_M_G1	148	111		
RAGHAVACHARI_PLATELET_SPECIFIC_GENES	70	59		
KARLSSON_TGFB1_TARGETS_UP	127	97		
KARLSSON_TGFB1_TARGETS_DN	207	175		
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP	22	17		
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_DN	30	19		
WANG_METASTASIS_OF_BREAST_CANCER	15	8		
LI_INDUCED_T_TO_NATURAL_KILLER_UP	307	244		
LI_INDUCED_T_TO_NATURAL_KILLER_DN	116	96		
NOUSHMEHR_GBM_SOMATIC_MUTATED	9	8		
NOUSHMEHR_GBM_GERMLINE_MUTATED	8		Rejected!	
NOUSHMEHR_GBM_SILENCED_BY_METHYLATION	50	32		
KAMIKUBO_MYELOID_CEBPA_NETWORK	28	25		
KAMIKUBO_MYELOID_MN1_NETWORK	19	18		
MARTENS_BOUND_BY_PML_RARA_FUSION	456	359		
MARTENS_TRETINOIN_RESPONSE_UP	857	441		
MARTENS_TRETINOIN_RESPONSE_DN	841		Rejected!	
STAMBOLSKY_BOUND_BY_MUTATED_TP53	18	12		
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_UP	49	31		
STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN	50	33		
STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP	84	53		
STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_DN	26	15		
KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_UP	756		Rejected!	
KIM_ALL_DISORDERS_OLIGODENDROCYTE_NUMBER_CORR_DN	36	19		
KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_UP	682		Rejected!	
KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_DN	88	52		
KIM_ALL_DISORDERS_CALB1_CORR_UP	548	426		
KIM_ALL_DISORDERS_CALB1_CORR_DN	37	21		
KIM_ALL_DISORDERS_DURATION_CORR_UP	9	5		
KIM_ALL_DISORDERS_DURATION_CORR_DN	146	122		
VERHAAK_GLIOBLASTOMA_PRONEURAL	177	111		
VERHAAK_GLIOBLASTOMA_NEURAL	129	91		
VERHAAK_GLIOBLASTOMA_CLASSICAL	162	126		
VERHAAK_GLIOBLASTOMA_MESENCHYMAL	216	178		
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_UP	242	195		
HIRSCH_CELLULAR_TRANSFORMATION_SIGNATURE_DN	103	78		
CHICAS_RB1_TARGETS_SENESCENT	572	429		
CHICAS_RB1_TARGETS_LOW_SERUM	100	62		
CHICAS_RB1_TARGETS_GROWING	243	197		
CHICAS_RB1_TARGETS_CONFLUENT	567	436		
WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_UP	397	237		
WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN	374	284		
QI_HYPOXIA	140	115		
QI_HYPOXIA_TARGETS_OF_HIF1A_AND_FOXA2	37	32		
GREGORY_SYNTHETIC_LETHAL_WITH_IMATINIB	145	101		
LU_EZH2_TARGETS_UP	295	190		
LU_EZH2_TARGETS_DN	414	278		
HOELZEL_NF1_TARGETS_UP	139	101		
HOELZEL_NF1_TARGETS_DN	115	71		
DEMAGALHAES_AGING_UP	55	42		
DEMAGALHAES_AGING_DN	16	13		
DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP	229	193		
DUTERTRE_ESTRADIOL_RESPONSE_6HR_DN	91	71		
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP	324	268		
DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN	505	391		
FIGUEROA_AML_METHYLATION_CLUSTER_1_UP	125	70		
FIGUEROA_AML_METHYLATION_CLUSTER_1_DN	48	29		
FIGUEROA_AML_METHYLATION_CLUSTER_2_UP	54	30		
FIGUEROA_AML_METHYLATION_CLUSTER_2_DN	9	5		
FIGUEROA_AML_METHYLATION_CLUSTER_3_UP	170	107		
FIGUEROA_AML_METHYLATION_CLUSTER_3_DN	42	25		
FIGUEROA_AML_METHYLATION_CLUSTER_4_UP	112	75		
FIGUEROA_AML_METHYLATION_CLUSTER_4_DN	15	9		
FIGUEROA_AML_METHYLATION_CLUSTER_5_UP	12	7		
FIGUEROA_AML_METHYLATION_CLUSTER_5_DN	50	29		
FIGUEROA_AML_METHYLATION_CLUSTER_6_UP	140	91		
FIGUEROA_AML_METHYLATION_CLUSTER_6_DN	38	18		
FIGUEROA_AML_METHYLATION_CLUSTER_7_UP	118	73		
FIGUEROA_AML_METHYLATION_CLUSTER_7_DN	5		Rejected!	
WANG_CLASSIC_ADIPOGENIC_TARGETS_OF_PPARG	26	24		
WANG_ADIPOGENIC_GENES_REPRESSED_BY_SIRT1	28	23		
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP	134	106		
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_DN	157	114		
TSUTSUMI_FBXW8_TARGETS	9	8		
LI_DCP2_BOUND_MRNA	89	76		
WAGSCHAL_EHMT2_TARGETS_UP	13	5		
SUBTIL_PROGESTIN_TARGETS	36	32		
OHGUCHI_LIVER_HNF4A_TARGETS_UP	44	37		
OHGUCHI_LIVER_HNF4A_TARGETS_DN	149	118		
GABRIELY_MIR21_TARGETS	289	238		
THILLAINADESAN_ZNF217_TARGETS_UP	44	33		
THILLAINADESAN_ZNF217_TARGETS_DN	9	6		
PHESSE_TARGETS_OF_APC_AND_MBD2_UP	20	11		
PHESSE_TARGETS_OF_APC_AND_MBD2_DN	13	10		
CHYLA_CBFA2T3_TARGETS_UP	387	298		
CHYLA_CBFA2T3_TARGETS_DN	242	162		
FUKUSHIMA_TNFSF11_TARGETS	16	13		
CARD_MIR302A_TARGETS	77	64		
WIERENGA_STAT5A_TARGETS_UP	217	152		
WIERENGA_STAT5A_TARGETS_DN	213	149		
WIERENGA_STAT5A_TARGETS_GROUP1	136	95		
WIERENGA_STAT5A_TARGETS_GROUP2	60	43		
WIERENGA_PML_INTERACTOME	42	35		
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_UP	84	68		
ACOSTA_PROLIFERATION_INDEPENDENT_MYC_TARGETS_DN	116	93		
KANG_AR_TARGETS_UP	17	15		
KANG_AR_TARGETS_DN	19	14		
PILON_KLF1_TARGETS_UP	504	404		
PILON_KLF1_TARGETS_DN	1972		Rejected!	
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP	211	165		
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN	88	76		
BHAT_ESR1_TARGETS_VIA_AKT1_UP	281	210		
BHAT_ESR1_TARGETS_VIA_AKT1_DN	82	67		
JOHNSTONE_PARVB_TARGETS_1_UP	7		Rejected!	
JOHNSTONE_PARVB_TARGETS_1_DN	63	37		
JOHNSTONE_PARVB_TARGETS_2_UP	140	116		
JOHNSTONE_PARVB_TARGETS_2_DN	336	265		
JOHNSTONE_PARVB_TARGETS_3_UP	430	338		
JOHNSTONE_PARVB_TARGETS_3_DN	918		Rejected!	
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A	898		Rejected!	
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_B	549	408		
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_C	92	56		
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_D	280	191		
BRUINS_UVC_RESPONSE_LATE	1137		Rejected!	
BRUINS_UVC_RESPONSE_EARLY_LATE	317	230		
BRUINS_UVC_RESPONSE_MIDDLE	98	70		
CERIBELLI_PROMOTERS_INACTIVE_AND_BOUND_BY_NFY	44	20		
CERIBELLI_GENES_INACTIVE_AND_BOUND_BY_NFY	45	18		
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP	259	199		
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN	229	158		
IVANOVSKA_MIR106B_TARGETS	90	74		
KIM_GLIS2_TARGETS_UP	84	73		
KIM_GLIS2_TARGETS_DN	6	5		
MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_UP	7	6		
MIKHAYLOVA_OXIDATIVE_STRESS_RESPONSE_VIA_VHL_DN	6	5		
STEGER_ADIPOGENESIS_UP	21	20		
STEGER_ADIPOGENESIS_DN	25	23		
ZHU_SKIL_TARGETS_UP	20	19		
ZHU_SKIL_TARGETS_DN	9	8		
KIM_PTEN_TARGETS_UP	18	14		
KIM_PTEN_TARGETS_DN	6		Rejected!	
ISHIDA_TARGETS_OF_SYT_SSX_FUSIONS	6	6		
MAEKAWA_ATF2_TARGETS	24	16		
ISSAEVA_MLL2_TARGETS	62	50		
LINSLEY_MIR16_TARGETS	206	169		
CHENG_TAF7L_TARGETS	6		Rejected!	
CHANGOLKAR_H2AFY_TARGETS_UP	48	38		
CHANGOLKAR_H2AFY_TARGETS_DN	40	31		
PASINI_SUZ12_TARGETS_UP	112	74		
PASINI_SUZ12_TARGETS_DN	315	281		
BAKKER_FOXO3_TARGETS_UP	61	49		
BAKKER_FOXO3_TARGETS_DN	187	130		
BERGER_MBD2_TARGETS	7		Rejected!	
VANDESLUIS_COMMD1_TARGETS_GROUP_2_UP	15	11		
VANDESLUIS_COMMD1_TARGETS_GROUP_3_UP	89	73		
VANDESLUIS_COMMD1_TARGETS_GROUP_3_DN	39	25		
VANDESLUIS_COMMD1_TARGETS_GROUP_4_UP	19	16		
VANDESLUIS_COMMD1_TARGETS_GROUP_4_DN	16	10		
VANDESLUIS_NORMAL_EMBRYOS_UP	5		Rejected!	
VANDESLUIS_NORMAL_EMBRYOS_DN	25	16		
SUMI_HNF4A_TARGETS	34	22		
WANG_NFKB_TARGETS	25	17		
WANG_TNF_TARGETS	24	16		
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_UP	121	86		
AZARE_NEOPLASTIC_TRANSFORMATION_BY_STAT3_DN	17	13		
AZARE_STAT3_TARGETS	24	18		
DELPUECH_FOXO3_TARGETS_UP	68	59		
DELPUECH_FOXO3_TARGETS_DN	41	35		
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2	57	48		
KASLER_HDAC7_TARGETS_1_UP	194	161		
KASLER_HDAC7_TARGETS_1_DN	17	16		
KASLER_HDAC7_TARGETS_2_UP	6		Rejected!	
KASLER_HDAC7_TARGETS_2_DN	32	26		
DORMOY_ELAVL1_TARGETS	17	14		
LEE_BMP2_TARGETS_UP	745		Rejected!	
LEE_BMP2_TARGETS_DN	882		Rejected!	
BILANGES_SERUM_SENSITIVE_GENES	90	69		
BILANGES_SERUM_AND_RAPAMYCIN_SENSITIVE_GENES	68	60		
BILANGES_RAPAMYCIN_SENSITIVE_GENES	39	32		
BILANGES_RAPAMYCIN_SENSITIVE_VIA_TSC1_AND_TSC2	73	56		
BILANGES_SERUM_SENSITIVE_VIA_TSC1	23	16		
BILANGES_SERUM_SENSITIVE_VIA_TSC2	39	31		
BILANGES_SERUM_RESPONSE_TRANSLATION	37	31		
KIM_TIAL1_TARGETS	32	28		
DUAN_PRDM5_TARGETS	79	53		
DALESSIO_TSA_RESPONSE	29	18		
FEVR_CTNNB1_TARGETS_UP	682	498		
FEVR_CTNNB1_TARGETS_DN	553	428		
FARDIN_HYPOXIA_9	7		Rejected!	
FARDIN_HYPOXIA_11	32	25		
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_TOP20_UP	20	15		
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_TOP20_DN	18	16		
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_UP	271	207		
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN	321	253		
WINZEN_DEGRADED_VIA_KHSRP	100	77		
VANLOO_SP3_TARGETS_UP	9		Rejected!	
VANLOO_SP3_TARGETS_DN	89	71		
YUAN_ZNF143_PARTNERS	22	18		
KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3	824		Rejected!	
RAFFEL_VEGFA_TARGETS_UP	9	9		
RAFFEL_VEGFA_TARGETS_DN	5		Rejected!	
TERAO_AOX4_TARGETS_HG_UP	28	21		
TERAO_AOX4_TARGETS_HG_DN	6	5		
TERAO_AOX4_TARGETS_SKIN_UP	38	33		
TERAO_AOX4_TARGETS_SKIN_DN	27	13		
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_UP	87	62		
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_DN	180	135		
PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_UP	344	244		
PURBEY_TARGETS_OF_CTBP1_NOT_SATB1_DN	448	322		
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP	570	438		
GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	1080		Rejected!	
GOBERT_CORE_OLIGODENDROCYTE_DIFFERENTIATION	40	32		
WACKER_HYPOXIA_TARGETS_OF_VHL	13	11		
IKEDA_MIR1_TARGETS_UP	53	49		
IKEDA_MIR1_TARGETS_DN	7	6		
IKEDA_MIR133_TARGETS_UP	43	41		
IKEDA_MIR133_TARGETS_DN	8	7		
IKEDA_MIR30_TARGETS_UP	116	106		
IKEDA_MIR30_TARGETS_DN	27	21		
KUWANO_RNA_STABILIZED_BY_NO	7	7		
LIU_TOPBP1_TARGETS	16	9		
SCHMIDT_POR_TARGETS_IN_LIMB_BUD_UP	26	22		
SCHMIDT_POR_TARGETS_IN_LIMB_BUD_DN	8		Rejected!	
KATSANOU_ELAVL1_TARGETS_UP	169	133		
KATSANOU_ELAVL1_TARGETS_DN	148	106		
WANG_THOC1_TARGETS_UP	5	5		
WANG_THOC1_TARGETS_DN	20	14		
JUBAN_TARGETS_OF_SPI1_AND_FLI1_UP	115	91		
JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN	92	71		
SERVITJA_ISLET_HNF1A_TARGETS_UP	163	132		
SERVITJA_ISLET_HNF1A_TARGETS_DN	109	92		
SERVITJA_LIVER_HNF1A_TARGETS_UP	135	121		
SERVITJA_LIVER_HNF1A_TARGETS_DN	157	132		
MADAN_DPPA4_TARGETS	46	26		
KOHOUTEK_CCNT1_TARGETS	50	41		
KOHOUTEK_CCNT2_TARGETS	58	35		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1	46	36		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_3	20	12		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4	110	74		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5	11	9		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_6	29	21		
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7	403	291		
PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2	76	59		
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_36HR	152	114		
WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_36HR	29	25		
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D	882		Rejected!	
WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D	658		Rejected!	
WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK	145	114		
PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP	13	10		
PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_DN	6	5		
YANG_BCL3_TARGETS_UP	364	290		
YANG_BCL3_TARGETS_DN	8	5		
LOPEZ_TRANSLATION_VIA_FN1_SIGNALING	35	34		
VERNOCHET_ADIPOGENESIS	19	17		
IM_SREBF1A_TARGETS	5	5		
GUO_TARGETS_OF_IRS1_AND_IRS2	98	84		
HUANG_GATA2_TARGETS_UP	149	120		
HUANG_GATA2_TARGETS_DN	72	63		
LE_NEURONAL_DIFFERENTIATION_UP	18	13		
LE_NEURONAL_DIFFERENTIATION_DN	19	19		
STEINER_ERYTHROCYTE_MEMBRANE_GENES	15	10		
PLASARI_TGFB1_TARGETS_1HR_UP	34	30		
PLASARI_TGFB1_TARGETS_1HR_DN	6	6		
PLASARI_TGFB1_TARGETS_10HR_UP	199	167		
PLASARI_TGFB1_TARGETS_10HR_DN	244	204		
PLASARI_NFIC_TARGETS_BASAL_UP	27	21		
PLASARI_NFIC_TARGETS_BASAL_DN	18	18		
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_UP	33	26		
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_DN	106	82		
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_UP	54	36		
PLASARI_TGFB1_SIGNALING_VIA_NFIC_10HR_DN	30	24		
WANG_MLL_TARGETS	289	219		
SANDERSON_PPARA_TARGETS	15	14		
ROLEF_GLIS3_TARGETS	37	19		
DELACROIX_RARG_BOUND_MEF	367	288		
DELACROIX_RAR_TARGETS_UP	48	39		
DELACROIX_RAR_TARGETS_DN	24	22		
DELACROIX_RAR_BOUND_ES	462	328		
KRIEG_HYPOXIA_VIA_KDM3A	53	43		
KRIEG_KDM3A_TARGETS_NOT_HYPOXIA	208	146		
KRIEG_HYPOXIA_NOT_VIA_KDM3A	770		Rejected!	
MALIK_REPRESSED_BY_ESTROGEN	12	11		
TIAN_BHLHA15_TARGETS	16	14		
LIU_IL13_MEMORY_MODEL_UP	17	14		
LIU_IL13_MEMORY_MODEL_DN	5	5		
LIU_IL13_PRIMING_MODEL	15	11		
ALFANO_MYC_TARGETS	239	198		
FU_INTERACT_WITH_ALKBH8	13	12		
SUZUKI_CTCFL_TARGETS_UP	12	7		
REICHERT_MITOSIS_LIN9_TARGETS	28	26		
GUILLAUMOND_KLF10_TARGETS_UP	51	41		
GUILLAUMOND_KLF10_TARGETS_DN	30	24		
FORTSCHEGGER_PHF8_TARGETS_UP	279	199		
FORTSCHEGGER_PHF8_TARGETS_DN	784		Rejected!	
BRIDEAU_IMPRINTED_GENES	63	46		
PEDRIOLI_MIR31_TARGETS_UP	221	120		
PEDRIOLI_MIR31_TARGETS_DN	418	282		
PHONG_TNF_TARGETS_UP	63	54		
PHONG_TNF_TARGETS_DN	8	6		
PHONG_TNF_RESPONSE_VIA_P38_COMPLETE	227	180		
PHONG_TNF_RESPONSE_VIA_P38_PARTIAL	160	137		
PHONG_TNF_RESPONSE_NOT_VIA_P38	337	282		
RATTENBACHER_BOUND_BY_CELF1	467	292		
KINNEY_DNMT1_METHYLATION_TARGETS	14		Rejected!	
ABDELMOHSEN_ELAVL4_TARGETS	16	15		
ZHANG_ADIPOGENESIS_BY_BMP7	14	13		
FOSTER_KDM1A_TARGETS_UP	266	163		
FOSTER_KDM1A_TARGETS_DN	211	160		
YU_BAP1_TARGETS	29	23		
RAO_BOUND_BY_SALL4_ISOFORM_A	182	113		
RAO_BOUND_BY_SALL4_ISOFORM_B	517	380		
RAO_BOUND_BY_SALL4	227	155		
VANOEVELEN_MYOGENESIS_SIN3A_TARGETS	220	166		
BOUDOUKHA_BOUND_BY_IGF2BP2	111	85		
BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE	151	119		
BOSCO_TH1_CYTOTOXIC_MODULE	114	80		
BOSCO_INTERFERON_INDUCED_ANTIVIRAL_MODULE	78	56		
BOSCO_EPITHELIAL_DIFFERENTIATION_MODULE	69	31		
PECE_MAMMARY_STEM_CELL_UP	146	108		
PECE_MAMMARY_STEM_CELL_DN	146	104		
ABRAMSON_INTERACT_WITH_AIRE	45	38		
MIZUSHIMA_AUTOPHAGOSOME_FORMATION	19	15		
KUMAR_PATHOGEN_LOAD_BY_MACROPHAGES	275	155		
KUMAR_AUTOPHAGY_NETWORK	71	42		
GENTLES_LEUKEMIC_STEM_CELL_UP	29	22		
GENTLES_LEUKEMIC_STEM_CELL_DN	19	7		
ROESSLER_LIVER_CANCER_METASTASIS_UP	107	91		
ROESSLER_LIVER_CANCER_METASTASIS_DN	53	40		
HOLLEMAN_PREDNISOLONE_RESISTANCE_B_ALL_UP	22	17		
HOLLEMAN_PREDNISOLONE_RESISTANCE_B_ALL_DN	12	7		
HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_UP	38	30		
HOLLEMAN_VINCRISTINE_RESISTANCE_B_ALL_DN	15	14		
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP	26	22		
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_DN	15	10		
HOLLEMAN_DAUNORUBICIN_B_ALL_UP	10	9		
HOLLEMAN_DAUNORUBICIN_B_ALL_DN	12	10		
HOLLEMAN_PREDNISOLONE_RESISTANCE_ALL_UP	19	15		
HOLLEMAN_PREDNISOLONE_RESISTANCE_ALL_DN	11	8		
HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_UP	27	20		
HOLLEMAN_VINCRISTINE_RESISTANCE_ALL_DN	19	18		
HOLLEMAN_DAUNORUBICIN_ALL_UP	7	7		
HOLLEMAN_DAUNORUBICIN_ALL_DN	8	6		
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_UP	22	19		
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_DN	25	19		
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION	128	103		
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP	289	228		
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN	308	229		
ANASTASSIOU_CANCER_MESENCHYMAL_TRANSITION_SIGNATURE	64	55		
LIM_MAMMARY_STEM_CELL_UP	489	395		
LIM_MAMMARY_STEM_CELL_DN	428	352		
LIM_MAMMARY_LUMINAL_PROGENITOR_UP	58	43		
LIM_MAMMARY_LUMINAL_PROGENITOR_DN	14	11		
LIM_MAMMARY_LUMINAL_MATURE_UP	116	92		
LIM_MAMMARY_LUMINAL_MATURE_DN	99	86		
DURAND_STROMA_S_UP	297	229		
DURAND_STROMA_NS_UP	162	120		
SMIRNOV_RESPONSE_TO_IR_2HR_UP	53	42		
SMIRNOV_RESPONSE_TO_IR_2HR_DN	55	42		
SMIRNOV_RESPONSE_TO_IR_6HR_UP	166	116		
SMIRNOV_RESPONSE_TO_IR_6HR_DN	114	89		
GHANDHI_DIRECT_IRRADIATION_UP	110	69		
GHANDHI_DIRECT_IRRADIATION_DN	33	21		
GHANDHI_BYSTANDER_IRRADIATION_UP	86	58		
GHANDHI_BYSTANDER_IRRADIATION_DN	12	9		
WARTERS_RESPONSE_TO_IR_SKIN	83	51		
WARTERS_IR_RESPONSE_5GY	47	34		
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_2HR	8	6		
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR	85	68		
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR	128	102		
ZWANG_EGF_PERSISTENTLY_UP	32	20		
ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF	516	353		
ZWANG_CLASS_2_TRANSIENTLY_INDUCED_BY_EGF	51	34		
ZWANG_CLASS_3_TRANSIENTLY_INDUCED_BY_EGF	222	173		
ZWANG_DOWN_BY_2ND_EGF_PULSE	293	106		
ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY	1725		Rejected!	
ZWANG_TRANSIENTLY_UP_BY_1ST_EGF_PULSE_ONLY	1839		Rejected!	
ZWANG_EGF_INTERVAL_UP	105	45		
ZWANG_EGF_INTERVAL_DN	214	152		
ZWANG_EGF_PERSISTENTLY_DN	61	39		
CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_UP	35	23		
CHEMELLO_SOLEUS_VS_EDL_MYOFIBERS_DN	19	12		
HORTON_SREBF_TARGETS	25	23		
HECKER_IFNB1_TARGETS	95	64		
